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Epstein-Barr virus (EBV) establishes a lifelong latent infection in host B cells and 
is associated with the development of various lymphoid and epithelial 
malignancies. Approximately half of Hodgkin's lymphomas (HL) are EBV 
positive where LMP2 is highly expressed. However, the contribution of LMP2 to 
the pathogenesis of HL remains largely unknown. In this study, HL cell lines 
stably expressing LMP2A and LMP2B HL were generated. The impact of global 
gene expression in KMH2 cells expressing LMP2A and LMP2B was performed 
using Gene expression microarrays; this identified a number of potentially 
important transcriptional targets of LMP2A and LMP2B which may be of 
relevance to the development of HL, but also highlighted important difference in 
the effect of these proteins on cellular gene expression that were dependant on 
their expression levels. 
In addition, to identify cellular proteins that interact with LMP2, His-tagged 
versions of LMP2A and LMP2B were stably expressed in HEK 293 cells. The 
expression of LMP2 in these cells was confirmed. A new approach stable isotope 
labelling amino acid in cell culture (SILAC) to identify interacting proteins which 
combined with LC-MS/MS analysis was performed and 10 novel LMP2A 
interactors and 20 novel LMP2B interactors were identified. All these potential 
interactions require validation but of particular interest is the possible interaction 
of DNA methyl transferase 1 (DNMT1) with LMP2A and OB-cadherin with 
LMP2B. 
Overall, the studies described in this thesis demonstrate that LMP2A and LMP2B 
have profound effects on the behaviour of HL cells and SILAC combined with 
LC-MS/MS is a useful and reliable approach to identify interacting proteins. 
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CHAPTER ONE: INTRODUCTION 
Introduction 
1 Introduction 
1.1 Epstein-Barr virus (EBV) 
The Epstein-Barr virus (EBV), also called Human herpesvirus 4 (HHV-4), is a 
virus of the herpes family and was identified as the first candidate human tumour 
virus due to its consistent association with African Burkitt's lymphoma (Epstein 
et al., 1964, Epstein et al., 1965; Henle and Henle, 1966). It is named after 
Epstein and Barr, who, along with B. G. Achong, discovered the virus in 1964 in a 
cultured Burkitt's lymphoma cell line (Epstein et al., 1964). EBV is widespread in 
more than 90% of all human populations (Henle et al., 1969; Henle et al., 1976; 
Henle and Henle, 1979); most people carry EBV asymptomatically. EBV persists 
in the infected host as a latent infection in B lymphocytes and as probably a lytic 
infection in the oropharynx (Nilsson et al., 1971; Gerber et al., 1982). EBV was 
shown to transform resting B lymphocytes in vitro leading to the outgrowth of B 
lymphoblastoid cell lines (LCLs), thus establishing EBV as B lymphotropic 
transforming virus (Henle et al., 1967). EBV is associated with certain 
haematopoietic cancers, such as Burkitt's lymphoma (BL), Hodgkin's lymphoma 
(HL) and T-cell and NK-cell lymphomas (Rickinson and Kieff, 2001). It is also 
associated with two epithelial origin diseases, nasopharyngeal carcinoma (NPC), 
oral hairy leukoplakia and post-transplant lymphoproliferative disease (PTLD) 
(Rickinson and Kieff, 2001). All these EBV related diseases will be detailed later. 
1.2 EBV classification 
EBV is a member of the Herpesviridae. This family of viruses can be further 
divided into three subfamilies: alpha, beta and gamma. The subdivision was 
originally made according to biological properties such as host range, duration of 
14 
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reproductive cycle, cytopathology and characteristics of latent infection but is 
now at the level of genome organisation and homology. The gamma herpesvirus 
subfamily is subdivided into two genera, gamma 1 or lymphocryptovirus (LCV), 
and gamma 2 or rhadinovirus (RDV). EBV is the prototype LCV and the only 
human virus in the genus. Many Old World primate species and some New World 
primate species have their own LCVs but such viruses are not found in non- 
primate hosts. LCV are predominantly B lymphotropic and although latent in B 
cells in vivo they can also reactivate to produce lytic infection. Whether there is a 
non-B cell type, which is naturally fully permissive for LCVs in vivo remains in 
doubt, but it is possible that an epithelial cell of this kind exists in the oropharynx 
and is the source of chronic viral shedding. 
1.3 EBV structure 
EBV has a 172 kilobase pair (kb) linear, double-stranded DNA genome wrapped 
around a toroid-shaped protein core, encased by a nucleocapsid and surrounded by 
a glycoprotein (gp)-rich envelope (Epstein et al., 1965). Initially the genome was 
divided into short and long unique domains, (US and UL), either side of the 
reiterated 3kbp internal repeats, IR1 (Hayward et al., 1982). UL is further 
subdivided by repeats IR2-4 into US2-5. The ends of the linear genome are 
flanked by 4-12 copies of tandem, reiterated, 500bp direct repeats, termed 
terminal repeats (TRs), (Hayward and Kieff, 1976; Kintner and Sugden, 1979), 
which mediate circularisation of the viral DNA into episomes. This feature 
enables the cell clonality of viral episomes to be establised, as latently infected 
progeny cells will retain the same number of TRs as the parental cell (Raab- 
Trauband and Flynn, 1986), although a recent study reported that TR number 
15 
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varied inversely to the quantity of LMP2A transcripts for both lymphoid and 
epithelial cell types in vitro (Moody et al., 2003). 
EBV was the first herpesvirus to have its complete genome cloned and sequenced 
(Dambaugh et al., 1980; Arrand et al., 1981; Biggin et al., 1984). This was done 
using BamHI restriction fragments from the B95.8 EBV strain and consequently 
the nomenclature was changed to reflect this cloning strategy (Biggin et al., 
1984). Every cell in an LCL carries multiple copies of the viral episome and 
constitutively expresses a limited set of viral gene products, the so-called latent 
proteins, consisting of six nuclear antigens (EBNAs1,2,3A, 3B, 3C and -LP) and 
three latent membrane proteins (LMPsI, 2A and 2B) (Kieff and Rickinson, 2001). 
EBNA-LP is transcribed from a variable number of repetitive exons. LMP2A and 
LMP2B are composed of multiple exons, which are located on either side of the 
terminal repeat (TR) region, which is formed during the circularization of the 
linear DNA to produce the viral episome. EBER1 and EBER2 are highly 
transcribed non-polyadenylated RNAs and their transcription is a consistent 
feature of latent EBV infection. All the EBNAs are transcribed from either the Cp 
or Wp promoter; the different EBNAs are encoded by individual mRNAs that are 
generated by differential splicing of the same long primary transcript. The BamHI 
restriction-endonuclease map of the prototype B95.8 genome shows that the 
BamHI fragments are named according to size, with A being the largest and 
lowercase letters being the smallest fragments. Figure 1.1 shows a schematic of 
the EBV genome. 
Open reading frames (ORFs) are stated relative to their BamHI fragment, 
direction of transcription and position relative to other ORFs located on the same 
fragment. For example, BHRF 1 is the first rightward ORF located in the BamHI 
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H fragment. All EBV strains have essentially the same genome organisation and 
the sequences are highly conserved overall. However, sequence analysis of 
different geographic EBV isolates had revealed two types, type 1 and 2, which 
differ primarily in the latent genes encoding EBV nuclear antigens (EBNAs)-LP, 
2,3A, 3B and 3C (Sixbey et al., 1989; Sample et al., 1990). EBV strains of the 
same type can be further classified according to local changes at polymorphic 
sites, such as the number of repeat sequences in several of the latent genes, the 
presence or absence of a 30bp region within the LMP 1 gene, as well as single 
nucleotide changes particularly in the genes encoding EBNA1, EBNA2 and 
LMP 1 (Lung et al., 1994; Miller et al., 1994; Falk et al., 1995; Khanim et al., 
1996; Sandvej et al., 1997). Many of these local polymorphisms distinguish EBV 
strains of different geographic origins, consistent with a slow evolutionary drift of 
the virus over thousands of years in physically separate human populations. 
However, the origins of the two different EBV types, where EBNA2,3A, 3B and 
3C alleles with 47%, 16%, 20% and 28% nucleotide homology at the respective 
loci are found within genomes that are otherwise highly homologous, remains a 
mystery. Epidemiologically, type 1 virus strains are dominant in most populations 
but in equatorial Africa and New Guinea, areas where BL is endemic, type 2 
strain are nearly as prevalent as type 1 viruses (Young et al., 1987; khanim et al., 
1996; Yao et al., 1998; Habeshaw et al., 1999). 
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Figure 1-1 Schematic of the Epstein-Barr virus 
A: Electron micrograph of the Epstein-Barr virus (EBV) virion. 
B: Diagram showing the location and transcription of the EBV latent genes on the 
double-stranded viral DNA episome. The origin of plasmid replication (OriP) is 
shown in orange. The large green solid arrows represent exons encoding each of 
the latent proteins, and the arrows indicate the direction in which the genes 
encoding these proteins are transcribed. LMP2A and LMP2B are composed of 
multiple exons, which are located on either side of the terminal repeat (TR) region. 
The blue arrows at the top represent the highly transcribed non-polyadenylated 
RNAs EBERI and EBER. The long outer green arrow represents EBV 
transcription during a form of latency known as latency III, in which all the 
EBNAs are transcribed from either the Cp or Wp promote. The inner, shorter red 
arrow represents the EBNA1 transcript, which originates from the Qp promoter 
during Lat I and Lat II. The locations of the BARFO and BARF1 coding regions 
are shown here. 
C: Location of open reading frames for the EBV latent proteins on the BamHI 
restriction-endonuclease map of the prototype B95.8 genome. 
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1.4 EBV tissue tropism 
When tested on human target cells in vitro, efficient EBV infection is restricted to 
B lymphocytes and results in their transformation to continuously proliferating B 
LCLs (Henle et al., 1967). Such LCLs express a small subset of viral genes, now 
called the latent genes, a pattern of expression termed Latency III. In addition a 
small percentage of cells in many LCLs spontaneously activate into lytic cycle. 
The ability of EBV to infect target B cells efficiently is determined by expression 
of the C3d complement component receptor, CD21, which serves as the major 
virus receptor (Fingeroth et al., 1984; Nemerow et al., 1986; Ahearn et al., 1988; 
Nemerow et al., 1990); this is expressed widely on mature B cells but is lost on 
terminal differentiation. Thus EBV can infect B cells at most stages of 
development, with the exception of plasma cells. The CD21 ligand is the EBV 
outer envelope protein gp350/220 (Nemerow et al., 1987, Tanner et al., 1988). 
The initial events of viral infection involve adsorption to CD21, internalisation, 
and circularisation of the viral episome within the infected cell nucleus. Three 
additional EBV envelope glycoproteins, gp85, gp25 and gp42 also play a role in B 
cell infection acting as a heterotrimeric complex; gp85/gp25 are involved in 
envelope fusion with the target cell membrane (Miller and Hutt-Fletcher, 1992; 
Haddad and Hutt-Fletcher, 1989) and gp42 in co-receptor interactions by 
engaging human leukocyte antigen (HLA) class II molecules that are naturally 
expressed on the B cell surface (Wang and Hutte-Fletcher, 1998; Molesworth et 
aL, 2000; Ressing et al., 2005). 
EBV can also establish infections in other cell types, as shown by the association 
between EBV and epithelial or T cell malignancies. However, it is not known 
what mode of entry EBV utilises to infect these cell types. Certainly in vitro 
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infection of primary epithelial and T cells, where possible, is very inefficient 
(Groux et al., 1997) and does not result in transformation (Yoshiyama et al., 
1997; Imai et al., 1998; Fingeroth et al., 1999). Immature T cell populations 
transiently express very low levels of CD21 during thymic development and in 
vitro infection of these cells has been claimed (Tsoukas and Lambris, 1993). 
However, reports of in vitro infection of CD21-negative T cells first suggested the 
possibility of a gp350/CD21-independent route (Hedrick et al., 1992). This is now 
confirmed by the fact that recombinant gp350-knockout viruses can infect a 
variety of cell types; infection is nevertheless much less efficient than that seen by 
wild-type virus in B cells. It is thought that gp85/gp25 complexes may be 
important in CD2 1 -independent infection (Molesworth et al., 2000; Oda et al., 
2000) as well as gpl10 (Neuhierl et al., 2002); the ligand for gpl10 is as yet 
unknown. 
1.5 Patterns of latent infection 
1.5.1 Latency I 
Burkitt's lymphoma (BL) is characterised by a Latency I pattern (Gregory et al, 
1990). In latency I infected cells the EBNA promoters Cp and Wp, and the LMP 
promoters are silent, but there is activation of an alternative EBNA promoter, 
termed Qp, located downstream in the BamHI Q fragment (Schaefer et al., 1995; 
Nonkwelo et al., 1996). EBNA1 is the only latent protein to be expressed from Qp 
and is encoded by a novel Q-U-K spliced transcript. The non-coding EBER RNAs 
and BamHI A transcripts are also detectable in Latency I cells (Table 1.1, Figure. 
1.2) (Rowe et al., 1987; Brooks et al., 1993). 
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Table 1-1 Pattern of EBV-latent gene expression and the cell types in which 
these patterns occur 
Type of Latency Latent genes expressed Cell types 
Latency 0 EBERs, LMP2A BamHI A, Resting B cells in vivo 
EBNA1? 
Latency I EBNA1, EBERs, BamHI A BL tumour cells, most early passage BL 
cell lines. 
Latency II EBNAI, LMP1, LMP2, EBERs, Epithelial cells from NPC and Reed- 
BamHI A Sternberg cells in HL 
Latency III EBNAs 1,2,3a, 3b, 3c, -LP, LCLs in vitro, IM and PTLD tumour cells 
LMPI, LMP2, EBERs, BamHI A in vivo. Some unstable BL cell lines may 
also drift towards this phenotype. 
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Figure 1-2 Pattern of EBV-latent gene transcription in three different forms 
of latency 
Transcripts are drawn in correct orientation relative to one another, with promoter 
(pennants) and splicing patterns as shown; exons are illustrated for non-coding 
RNAs (white) and for mRNA (black). The actual genomic positions of those 
exons are shown (top) on a linear map of the viral genome. Burkitt's lymphoma 
(BL) is characterised as Latency I (Gregory et al, 1990). Hodgkin's lymphoma 
(HL) and Nasopharyngeal Carcinoma (NPC) both exhibit the Latency II pattern of 
gene expression (Young and Murray, 2003) while Post-Transplant 
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1.5.1 Latency II 
Another restricted form of latency, termed latency II, is observed in the Reed- 
Sternberg cells of EBV-positive Hodgkin's lymphoma (HL), and in the epithelial 
cell tumour nasopharyngeal carcinoma (NPC) (Young and Murray, 2003; Pallesen 
et al., 1991). In Latency II infected cells, Cp and Wp are silent and selective 
expression of EBNA 1 initiates from Qp, as in BL cells. However, in contrast to 
Latency I, there is variable expression of LMP1 and LMP2 proteins, in addition to 
BamHI A and EBER transcripts (Table 1.1; Fig. 1.2) (Brooks et al., 1992; Kerr et 
al., 1992; Deacon et al., 1993). 
1.5.2 Latency III 
The pattern of Latency III was observed in vitro transformed LCLs, which is 
characterised by expression of all six nuclear antigens, EBNAs 1,2, -LP, 3A, 3B 
and 3C from Cp or Wp and the membrane proteins LMPs 1,2A and 2B from their 
own promoters along with spliced BamHI A transcripts and EBERs (Table 1.1; 
Fig. 1.2 taken from (Rickison and Kieff, 2001)) (Alfieri et al., 1991; Brooks et al., 
1993). Latency III infection induces a' lymphoblastoid' phenotype similar to that 
observed in B cells following by mitogenic/antigenic stimuli in vitro; this is 
associated with high level expression of activation and adhesion markers, HLA 
molecules and the acquisition of efficient antigen-processing function (Peng and 
Lundgten, 1993; Rowe et al., 1995). 
Latency III transcripts are also detectable in peripheral blood mononuclear cells 
(PBMCs) and tonsils of infectious mononucleosis (IM) patients, indicating a 
similar growth transforming program is induced during primary infection in vivo 
(Tierney et al., 1994; Niedobitek et al., 1997). However, in immunocompetent 
individuals this form of latency elicits a strong CD8+ cytotoxic T cell (CTL) 
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immune response such that Latency III transcripts are no longer detectable in the 
blood of healthy virus carriers, although they may be detected in tonsillar B cell 
preparations as a result of new EBV infections initiated from lytically-infected 
cells releasing progeny virus in the oropharynx (Babcock et al., 2000). The 
importance of the immune system in controlling EBV infections is underlined in 
the case of immunocompromised transplant patients where Latency III infected 
cells are often detected in the proliferating tumour cells of EBV-positive post- 
transplant lymphoproliferative disease (PTLD) (Young and Murray, 2003; Young 
et al., 1989). 
1.5.3 Latency 0 
A fourth form of latency, termed Latency 0 has been proposed to account for EBV 
persistence in resting memory B cells in vivo (Babcock et al., 1999); this would be 
analogous to that seen in latent alpha herpesvirus infections of neuronal cells in 
vivo. In Latency 0, viral transcription is limited to EBER, LMP2A and possibly 
the EBNA1 and BamHI A transcripts (Miyashita et al. 1995; Miyashita et al. 
1997) (Table 1.1; Fig. 1.2). 
1.6 EBV latent antigens 
1.6.1 EBNA1 
EBV-infected cells express a group of nuclear proteins that influence both viral 
and cellular transcription. EBNA1 is expressed in all virus-infected cells, in which 
its role is the maintenance and replication of the episomal EBV genome, achieved 
through sequence-specific binding to the plasmid origin of viral replication, OriP 
(Kieff and Rickinson, 2001) (Figure 1.1 b, c). EBNA1 can also interact with 
certain viral promoters, thereby contributing to the transcriptional regulation of 
the EBNAs (including EBNA1 itself) and of LMP1. EBNA1 is separated into 
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amino- and carboxy-terminal domains by a Gly-Ala repeat sequence, the main 
function of which seems to be to stabilize the mature protein - preventing its 
proteasomal breakdown (Levitskaya et al., 1995) - rather than functioning in its 
originally suggested role as an immune-evasion domain (Voo et al., 2004; Lee et 
al., 2004; Tellam et al., 2004). Gene-knockout studies indicate that EBNA1 does 
not have a crucial function in in vitro B-cell transformation beyond the 
maintenance of the viral genome (Humme et al., 2003); on the other hand, a more 
direct involvement in oncogenesis is indicated by the ability of B-cell-directed 
EBNA1 expression to produce B-cell lymphomas in transgenic mice (Wilson et 
al., 1996), and by its possible contribution to the survival of Hodgkin's lymphoma 
cells (Hammerschmidt and Sugden, 2004). 
EBNA1 is the only viral protein that is consistently expressed in all EBV- 
associated malignancies, as well as in chronic active EBV infection (Yoshioka et 
al., 2003), and is essential for viral DNA replication and maintenance of the viral 
episomes in infected cells. EBNA1 binds the symmetrical sequences of the origin 
of replication of the viral DNA and together with cellular proteins co-ordinates 
replication of viral episomes with cellular DNA (Yates et al., 1985). Both LMP1 
and EBNA1 are regulated by the JAK-STAT (Janus kinase-signal transducers and 
activators of transcription) signalling transduction pathways, suggesting that 
dysregulation of the JAK-STAT pathway may precede the development of EBV- 
associated tumorigenesis (Chen et al., 2001). 
1.6.2 EBNA2 
EBNA2 is a transcriptional transactivator that is one of the first viral genes 
expressed after EBV infection of B cells and is essential for EBV immortalization 
of B cells in vitro (Cohen et al., 1989; Hammerschmidt et al., 1989). The inability 
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of the P3HR-1 EBV, which has deletion encompassing EBNA2 and the last two 
exons of EBNA-LP, to transform B cells in vitro was the first indication of the 
crucial role of EBNA2 in the transformation process (Kieff and Rickinson, 2001). 
Restoration of the EBNA2 gene in P3HR-1 cells has unequivocally confirmed the 
importance of EBNA2 in B-cell transformation and has allowed the functionally 
relevant domains of EBNA2 to be identified (Hammerschmidt and Sugden, 1989; 
Cohen et al., 1989). EBNA2 interacts with a sequence-specific DNA-binding 
protein, JK-recombination-binding protein (RBP-JK), to transcriptionally activate 
cellular genes such as CD23 and the key viral genes LMPI and LMP2A (Kieff and 
Rickinson, 2001; Grossman et al., 1997; Hsieh et al., 1995). EBNA2 is a mimic of 
NotchlC (Zhang et al., 2001; Zimber-Strobl et al., 2001). Although the role of 
Notch in the B cell compartment remains incompletely understood, recent 
observations allow speculation on the ways in which the EBNA2 usurping of 
Notch function may sustain a life-long EBV infection in the host (Zimber-Strobl 
et al., 2001; Izon et al., 2002; Radtke et al., 2002). The c-MYC oncogene also 
appears to be an important target of EBNA2 and this effect deems to be important 
for EBV-induced B cell proliferation (Kaiser et al. 1999). 
1.6.3 The EBNA3 Family 
An essential role for EBNA3A and EBNA3C in B-cell transformation in vitro has 
been shown using EBV recombinants, whereas EBNA3B is dispensable 
(Tomkinson et al., 1993). EBNA3C can cooperate with RAS in rodent-fibroblast 
transformation assays and disrupt cell-cycle checkpoints (Parker et al., 1996; 
Parker et al., 2000). These effects are partly explained by the interaction of 
EBNA3C with factors that modulate transcription (for example, histone 
deacetylase 1, nonmetastatic protein 23-homologue 1 and C-terminal binding 
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protein) or influence cell-cycle progression (for example, cyclin A) (Radkov et 
al., 1999). EBNA3C can induce the up-regulation of both cellular (CD21) and 
viral (LMP 1) gene expression can repress the Cp promoter (Allday and Farrell, 
1997; Radkov et al., 1997) and might interact with the retinoblastoma protein pRb 
to promote transformation (Parker et al., 1996). EBNA3B has been shown to 
induce expression of vimentin and CD40 (Silins and Sculley, 1994) 
1.6.4 EBNA-LP 
EBNA-LP interacts with EBNA2 and is required for the efficient outgrowth of 
virus-transformed B cells in vitro (Mannick et al., 1991; Sinclair et al., 1994). The 
transcriptional activation, which is mediated by EBNA2 in conjunction with 
EBNA-LP is modulated by the EBNA3 family of proteins, which repress 
transactivation (Robertson et al., 1996; Zhao et al., 1996). EBNA-LP and EBNA2 
were transfected transiently into primary B cells and induced transition from Go to 
G1 as measured by the up-regulation of cyclin D2 expression (Yokoyama et al., 
2001). EBNA-LP can also cooperate with EBNA2 in upregulating transcriptional 
targets of EBNA2, including LMP 1 (Nitsche et al., 1997, MacCann et al., 2001). 
1.6.5 LMP 1 
LMP 1 is a 66kDa integral membrane protein encoded by the BNLF 1 ORF, and 
consists of a short N-terminal cytoplasmic tail of 17 amino acid residues, six 
hydrophobic transmembrane segments and a long C- terminal cytoplasmic region 
of 200 amino acid residues (Fennewald et al., 1984). After translation, LMP1 
inserts into the plasma membrane, where it aggregates in tight plasma membrane 
patches (Liebowitz et al., 1986). Aggregation is essential for LMP1 signalling 
and is dependent upon the presence of the transmembrane domains (Baichwal and 
Sugden, 1989; Liebowitz et al., 1992). Vimentin co-localises with LMP 1 and is 
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drawn into the patch by LMP 1 but once associated can redirect LMP 1 to other 
sites (Liebowitz et al., 1987). However, the functional significance of this 
association is unclear as LMP 1 can still transduce signals in B cell lines that lack 
vimentin (Liebowitz and Kieff, 1989). Approximately 30% of LMP1 assembles in 
glycosphingolipid (GSL) rafts and this localisation may be important for its 
function (Clausse et al., 1997; Ardila-Osorio et al., 1999). LMP1 has a relatively 
short half-life of 30 minutes, extending to 2-3 hours when phosphorylated on 
serine and threonine residues (Mann and Thorley-Lawson, 1987; Moorthy and 
Thorley-Lawson, 1990). 
LMP1 is essential for primary B cell transformation (Baichwal and Sugden, 1988; 
Kaye et al., 1993) and the sustained growth of LCLs (Kaye et al., 1993; Kilger et 
al., 1998). Indeed, it is the best example of an EBV protein that is active on its 
own in conventional assays of transforming function. The expression of LMP 1 in 
the B lymphocytes of transgenic mice predisposes them to develop lymphoma late 
in life (Kulwichit et al., 1998). LMP1 is also capable of transforming Rat-1 
fibroblasts in vitro, inducing morphology changes, anchorage independent 
growth, loss of contact inhibition and tumourigenicity in nude mice (Baichwal and 
Sugden, 1989). For these reasons, LMP 1 is generally considered to be an 
oncogenic protein. 
In addition to the transmembrane domains, two regions spanning amino acid 
residues 185-231. and amino acid residues 351-386, within the C-terminal 
cytoplasmic domain, termed (carboxy terminus activating regions) CTARI and 
CTAR2 respectively, play critical roles in the transforming phenotype of LMP1 
(Izumi and Kieff, 1997; Kaye et al., 1999). Deletion of CTARI shows it is 
essential for primary B cell transformation (Izumi et al., 1997; Kaye et al., 1999); 
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deletion of CTAR2 did not fully abrogate transformation but severely impaired 
growth of the resulting LCLs (Izumi and Kieff, 1997). 
LMP1 mediates cellular phenotypic changes by stimulating signal transduction 
pathways that lead ultimately to the activation of transcription factors, such as 
nuclear factor kappaB (NF-kB) and activating protein-i (AP-1) (Eliopoulos and 
Young, 1998; Hatzivassiliou et al., 1998). LMP1 expression in EBV-negative B 
cells results in the upregulation of activation markers CD21, CD23, CD30, CD39, 
CD40 and CD44 and of cell adhesion molecules ICAM 1, LFA 1 and LFA3 and 
can even restore antigen processing function to BL cells (Peng and Lundgren, 
1993; Huen et al., 1995; Rowe et al., 1995). LMP1 expression in epithelial cells 
induces epidermal growth factor receptor (EGFR) expression (Miller et al., 
1995b). In B cells and epithelial cells LMP 1 can induce anti-apoptotic factors, 
A20 and Bc12 (Laherty et al., 1992; Rowe et al., 1994). 
As the cytoplasmic tail of LMP1 does not possess intrinsic kinase activity istself, 
it is thought to exert its effects through association with tumour necrosis factor 
(TNF) receptor associated factors (TRAFs). LMP1 resembles members of the 
TNF receptor family and can in part functionally substitute for CD40 in in vitro 
assays of CD40 signalling (Eliopoulos et al., 1997; Floettmann et al., 1998; 
Hatzivassiliou et al., 1998; Kilger et al., 1998) and can even mimic some (but not 
all) of CD40 functions in vivo in a transgenic mouse model (Uchida et al., 1999). 
There are two recognized NF-kB pathways: the canonical pathway which mainly 
utilizes IKK-ß to phosphorylate IKB-a resulting in the generation of p50/p65 
dimer; and the non-canonical pathway, which involves IKK-a leading to the 
processing of p100 (NF-kB-2) and generation of p52/ReIB dimers. Recently, it 
has been shown that the CTAR1 domain of LMP1 activates NF-kB mainly though 
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the non-canonical pathway (TRAF3/NIK/IKK-a) (Brodeur et al., 1997; Sandberg 
et al., 1997; Eliopoulos et al., 1999; Lufitig et al., 2003). In contrast, CTAR2 
appears to activate the canonical pathway by utilizing TRAF6 and TAK1 to 
activate IKK-ß (Wu et al., 2006). It also appears that much of LMP1-induced NF- 
kB activation is TRADD-independent (Wu et al., 2006). CTAR2 is also important 
in LMP 1 activation of the c-Jun N-terminal kinase (JNK) pathway leading to 
activation of AP-1 (Eliopoulos and Young, 1998; Hatzivassiliou et al., 1998; 
Eliopoulos et al., 1999a). CTAR1 and CTAR2 can both induce p38 MAPK 
activation in HEK 293 and Rat-cells leading to activation of the transcription 
factor ATF2 (Eliopoulos et al., 1999b). 
The region of LMP1 lying between CTAR1 and CTAR2, sometimes referred to as 
CTAR3, is not required for EBV immortalisation of B lymphocytes (Izumi et al., 
1999a) but has been implicated in activating the janus kinase/signalling transducer 
and activator of transcription (JAK/STAT) pathway via JAK3 binding (Gires et 
al., 1999). However, mutation of this site does not affect JAK signalling implying 
some redundancy of function. LMP 1 has also been shown to signal through 
GTPases such as Cdc42, inducing reorganisation of the cytoskeleton in serum- 
starved mouse fibroblasts (Puls et al., 1999). The expression of LMP 1 in NPC is 
associated with increased metastatic spread, an effect that is also reflected in the 
ability of LMP 1 to induce increased cell motility and invasive growth when 
expressed in epithelial cells in vitro (Kim et al., 2000; Horikawa et al., 2000; 
Horikawa et al., 2001). LMP1 can activate the PI3K/Akt pathway and this effect 
is responsible for LMP 1-induced actin polymerization, morphological 




1.6.6.1 The structure of LMP2A and LMP2B 
There are two LMP2 proteins, LMP2A and LMP2B which are encoded by 2.0kb 
and 1.7kb mRNAs messages respectively, which initiate from promoters 3kb apart 
in the EBV genome and splice across the TRs (Hudson et al., 1985; Laux et al., 
1988; Laux et al., 1989; Sample et al., 1989). Each of the transcripts has a unique 
first exon but 8 shared common exons. The first exon of LMP2A encodes a 119- 
amino-acid N-teminal cytoplasmic domain unique to this protein. The first exon 
of LMP2B is non-coding and translation of LMP2B initiates at a methionine 
codon at the beginning of the common second exon (Sample et al., 1989). The 
remaining LMP2A and LMP2B exons encode 12 hydrophobic integral 
membrane-spanning domains and a 27-amino-acid hydrophilic cytoplasmic C 
terminal tail (Figurel. 3) (Longnecker, 2000). Thus, the predicted molecular 
weights of LMP2A and LMP2B are 54kDa and 40kDa, respectively. The 
hydrophobic domains led to speculation that the LMP2 is a membrane associated 
protein, and this has been confirmed. However the exact subcellular localisation 
remains controversial. It was reported that LMP2A localised to the same patch of 
the plasma membrane as LMP 1 in latently infected B cells (Longnecker and 
Kieff, 1990). LMP2A localized to the same site in the plasma membrane of 13- 
lymphoma cells whether or not LMP 1 was expressed in the same cell 
(Longnecker and Kieff, 1990). However, other studies reported a distinct 
intracytosolic pattern of LMP2 distribution (Lynch et al., 2002). In non-B-cells, 
LMP2A and LMP2B localise to perinuclear vesicles, the ER (Endoplasmic 
reticulum) and Golgi network indicating that LMP2 may localise to different 
regions in a cell type dependent manner (Lynch et al 2002; Dawson et al, 2001). 
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The cytosolic amino terminal tail of LMP2A contains 8 tyrosine (Y) residues, 2 of 
which (Y74 and Y85) form an immunoreceptor tyrosine-based activation motif 
(ITAM) (Fruehling et al., 1996; Fruehling and Longnecker, 1997; Fruehling et al., 
1998; Longnecker, 2000). When phosphorylated the ITAM present in the B cell 
receptor (BCR), it plays a central role in mediating lymphocyte proliferation and 
differentiation by the recruitment and activation of the Src family of protein 
tyrosine kinases (PTKs) and the Syk PTK by sequestering these tyrosine kinases 
and blocking the translocation of the BCR into lipid rafts (Dykstra et al., 2001). 
Thus, the LMP2A ITAM has been shown to be responsible for blocking BCR- 
stimulated calcium mobilisation, tyrosine phosphorylation and activation of the 
EBV lytic cycle in B cells (Miller et al., 1995). Another tyrosine residue in the 
LMP2A amino terminal domain (Y112) is also required for efficient binding of 
Src family PTKs, particular Lyn (Longnecker et al., 1991; Burkhardt et al., 1992; 
Longnecker, 2000). LMP2A inhibits BCR signal transduction cascades initiated 
by cross-linking of surface immunoglobulin (sIg), CD19 or MHC class II 
molecules (Miller et al., 1993; Miller et al., 1995a). The N terminal tail also has 
multiple serine (Ser)/threonine (Thr) residues, which may bind Ser/Thr Kinases, 
and proline rich regions. It has already been confirmed that S 15 and S 102 are 
phosphorylated by MAPK in vitro, and MAPK was demonstrated to associate 
with LMP2A in vitro (Panousis and Rowe, 1997). LMP2B, lacking the receptor- 
like amino terminal domain of LMP2A, might downregulate the activity of 
LMP2A by increasing the spacing between the receptor-like tail domains of 




The proline rich regions have been postulated to recruit proteins containing either 
Src Homology 3 (SH3) domains (Pawson and Gish, 1992) or WW domains 
(Sudol, 1996). SH3 domains are similar to SH2 domains in being non-catalytic 
regions that recruit kinases and adaptor proteins that are important in linking 
receptors to their signalling pathways. WW domains consist of paired tryptophan 
residues separated by 20-22 amino acids. LMP2A has been shown to contain two 
such regions in the amino terminal tail, which bind ubiquitin ligases (Ikeda et al., 
2000; Ikeda et al., 2001). More specifically, it was demonstrated that members of 
the Nedd 4 ubiquitin ligase family associate with LMP2A (Winberg et al., 2000; 
Ikeda et al., 2003); this may decrease LMP2A activity. The structure and function 
of LMP2 is shown in Figure 1.3. 
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Figure 1-3 Overview of LMP2 structure and function 
LMP2A and LMP2B share the C terminal region and the 12 transmembrane 
spanning domains (Laux et al., 1989; Sample et al, 1989). LMP2A has an 
additional hydrophilic 119 amino acid N terminal domain (Longnecker, 2000). 
This N terminal region contains multiple tyrosine residues (Y) which can interact 
with Src family tyrosine kinases Syk and Lyn. The latter interaction sequesters 
Lyn from the BCR complex, resulting in inhibition of B-cell signalling pathways. 
The P13-K and Akt pathways are also activated, leading to cell survival (Damania, 
2004). LMP2A also recruits NEDD4-like ubiquitin protein ligases through 
phosphotyrosine (PY) motifs, and these promote the degradation of Lyn by an 
ubiquitin-dependent mechanism (Ikeda et al., 2000). LMP2A interacts with the 
ERK1, MAPK and this results in the phosphorylation of two serine residues 
(Serl5 and Ser102) in LMP2A, and might contribute to LMP2A-induced 
activation of JUN (Chen et al., 2002). No function has yet been ascribed to 
LMP2B; however the C terminal tail has been demonstrated to contain a 
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1.6.6.2 Function of LMP2A and LMP2B in B cells 
LMP2A blocks normal B-cell signal transduction by mimicking an activated B- 
cell receptor (BCR) (Miller et al., 1995, Portis et al., 2002). This function is 
dependent upon the LMP2A cytoplasmic amino terminal domain and was 
subsequently shown to map to critical tyrosine residues within motifs that interact 
with Lyn and Syk (Longnecker et al., 1991; Burkhardt et al., 1992). LMP2 also 
provides a survival signal to primary B lymphocytes (Caldwell et al., 1998; Portis 
and Longnecker, 2004; Fukuda and Longnecker, 2004). Expression of LMP2A in 
the B cells of transgenic mice abrogates normal B cell development allowing 
immunoglobulin-negative cells to colonise peripheral lymphoid organs suggesting 
that LMP2A can drive the proliferation and survival of B cells in the absence of 
signalling through the B cell receptor (BCR) (Caldwell et al., 1998). Furthermore, 
bone marrow cells from LMP2A TgE transgenics in both wild-type and 
recombinase-activating gene (RAG)-deficient backgrounds form colonies in IL-7- 
containing methylcellulose, indicating that LMP2A bypasses the requirement for 
Ig rearrangement and allows for IL-7-driven B-cell proliferation (Caldwell et al., 
2000). The LMP2A-mediated effects on B-cell development and survival in vivo 
have also been shown to require the signalling component Syk, BLNK (SLP-65) 
and Bruton's tyrosine kinase (Btk) (Merchant et al., 2000; Engels et al., 2001; 
Merchant and Longnecker, 2001). LMP2A activates the phosphatidylinositol 3- 
kinase (PI3K)/Akt pathway, which normally provides a survival signal in 
response to BCR signalling (Scholle et al., 2000; Swart et al., 2000; Fukuda and 
Longnecker, 2004). A recent study showed that LMP2A mediates the survival of 
primary, BCR-negative B cells by constitutively activating the Ras/PI3K/Akt 
pathway (Portis and Longnecker, 2004; Fukuda and Longnecker, 2004). DNA 
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microarrays also demonstrate that expression of LMP2A in murine B cells 
interferes with global transcription factor regulation for proper B-cell development 
when expressed during B lymphopoiesis (Portis and Longnecker, 2003; Portis et 
al., 2003). Taken together these data support a role for LMP2 in modifying the 
normal B cell development program to favour the maintenance of EBV latency in 
the bone marrow and to prevent inappropriate activation of the EBV lytic cycle. 
LMP2A uses ubiquitination to regulate its own activity and might also utilize 
ubiquitination to modulate cellular signalling pathways, which regulate cell 
survival and differentiation (Ikeda et al., 2003; Portis et al., 2004). LMP2A 
signalling appears to be regulated in B cells by association of LMP2A with 
members of the HECT-domain containing Nedd4-family ubiquitin protein ligases, 
including AIP4/Itchy, WWP2, Nedd4 and KIAA0439/Nedd4-2 (Ikeda et al., 
2000; Winberg et al., 2000). Nedd4-family members bind specifically to PY 
motifs present in the cytoplasmic domain of LMP2A, resulting in the 
ubiquitination and degradation of LMP2A and its associated proteins, such as the 
PTK Lyn (Winberg et al., 2000; Ikeda et al., 2001; Ikeda et al., 2002). Although 
most proteins are specifically ubiquitinated at lysine residues, LMP2A is 
ubiquitinated at its N-terminal methionine residue (Ikeda et al., 2002). This 
uncommon N-terminal ubiquitination is also observed in LMP1 (Aviel et al., 
2000), indicating that EBV might specifically utilize this type of host cell 
modification during viral latency. Experiments crossing LMP2A transgenic mice 
with mice deficient for Itchy, the mouse homologue of human AIP4, demonstrate 
that Itchy negatively regulates LMP2A function in vivo (Ikeda et al., 2003). 
Interestingly, the extent of LMP2A expression and its emanating signal strength 
has been shown to influence B-cell differentiation during development. Low 
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LMP2A expression does not inhibit immunoglobulin (Ig) rearrangement, BCR 
expression or normal B-cell differentiation into follicular and marginal zone B 
cells (Casola et al., 2004; Caldwell et al., 2000). By contrast, high LMP2A 
expression inhibits BCR expression and results in exclusive B-1 differentiation in 
the bone marrow and peripheral lymphoid organs (Casola et al., 2004; Ikeda et 
al., 2004). It is therefore likely that LMP2A utilizes ubiquitin-mediated 
degradation through the proteasome complex to regulate the strength of its own 
signal, which might allow LMP2A to modulate B-cell processes, such as 
differentiation, activation or survival. 
Several reports have demonstrated that neither LMP2A and nor LMP2B are 
essential for the immortalisation of B cells; they do not affect the ability of EBV 
to transform primary B lymphocytes into LCLs or LCL survival (Longnecker et 
al., 1992; Kim and Yates, 1993; Longnecker et al., 1993a; Longnecker et al., 
1993b; Speck et al., 1999; Konishi et al., 2001), but there is disagreement over the 
possible influence of LMP2 as an enhancer of transformation efficiency 
(Brielmeier et al., 1996; Dawson et al., 2001). LMP2A and LMP2B are controlled 
by two separate promoters and may be differentially expressed depending on the 
environment of the latently infected lymphocyte (Longnecker and Miller 1996). 
Thus, the differential expression may cause either lytic activation or maintenance 
of latent infection. 
1.6.6.3 LMP2A and LMP2B in epithelial cells 
NPC tumours show consistent expression of LMP2A at the mRNA level with 
variable levels of LMP 1 expression. LMP2A was detectable in over 90% of NPC 
biopsies whereas LMP2B could only be detected in 39% (Brooks et al., 1992; 
Busson et al., 1992). Recently, the expression of LMP2A protein was reported in 
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50% of NPC biopsies by immunohistochemical staining (Heussinger et al, 2004). 
LMP2A can indirectly interact with LMP 1 to enhance LMP 1 signalling in 
epithelial cells, especially through the ITAM motif (Dawson et al, 2001). The 
half-life of LMP 1 was almost doubled in the presence of LMP2A (Dawson et al, 
2001). Another study demonstrated that LMP2A has other novel effects on 
epithelial cell signalling; the expression of LMP2A in HEK293 cells led to the 
phosphorylation of ERK and JNK, which are components of the MAPK signalling 
pathway (Chen et al, 2002). The phosphorylation of LMP2A in epithelial cells is 
triggered by cell adhesion, but this does not appear to be mediated via Src kinases 
(Scholle et al., 1999). It was speculated that this phosphorylation is due to C- 
terminal c-Src kinase (Csk, a negative regulator of Src kinases). Csk has been 
shown to regulate the activity of focal adhesion kinase (FAK) and paxillin, 
providing a mechanism whereby LMP2A may influence cell spreading (Tremblay 
et al., 1996). Whereas LMP2A and LMP2B are not essential for B cell 
transformation, LMP2A can transform epithelial cells and enhance their adhesion 
and motility; effects that might be mediated by the activation of the 
phosphatidylinositol-3-kinase-Akt pathway (Scholle et al., 2000). Recently, it 
was demonstrated that expression of LMP2A and LMP2B had no effect on the 
morphology of squamous epithelial cells in monolayer culture, but their 
expression was associated with an increased capacity to spread and migrate on 
extracellular matrix (Allen et al., 2005). The use of selective pharmacological 
inhibitors has established a role for tyrosine kinases in this phenotype but ruled 
out contributions of P13k, ERK/MAPK and protein kinase C. LMP2B may 
directly engage signalling pathways to influence epithelial cell behaviour such as 
cell adhesion and motility (Allen et al., 2005). All the evidence points towards an 
41 
Introduction 
important role for LMP2A in NPC tumour development, but the mechanism is 
unclear. 
Less than 10% of gastric carcinomas are EBV positive, and these tumours display 
a restricted pattern of EBV latent-gene expression which includes the EBERs, 
EBNA1, LMP2A, BARTs and BARF1, similar to that seen in NPC (Imai et al., 
1994; Burgess et al, 2002; Karim and Pallesen, 2003; Alipov et al., 2005). The 
role of LMP2 in the pathogenesis of gastric carcinoma remains to be determined. 
1.6.6.4 LMP2A and LMP2B in Hodgkin's lymphoma 
Appoxmately 50% of HL contains EBV DNA and viral gene expression is limited 
to EBNA1, LMP1 and LMP2 (Thorley-Lawson, 2001; Khan and Coates, 1994; 
Oallesen et al., 1994; Wu et al., 1990). LMP2A transcripts and protein are 
consistently detected in all the EBV positive HL tumour cells (Murray et al., 
2000, Kieff and Rickinson, 2000). HRS cells are presumed to be derived from 
germinal centre B cells that have lost Ig expression and should have undergone 
apoptosis (Kuppers et al., 2002; Marafioti et al., 2000). A recent study using DNA 
microarrays reports that LMP2A induces a global down-regulation of B-cell- 
specific transcription factors and signalling molecules, many of which are also 
significantly down-regulated in HRS cells (Portis and Longnecker, 2003; Portis et 
al., 2003). Although many studies have used LMP2 as a target for immunotherapy 
of HL (Rooney et al., 1998; Dukers et al., 2000; Bollarol et al., 2004), the exact 
role of LMP2 in the pathogenesis of HL remains unknown. 
1.6.7 EBERs 
The EBV encoded small non-polyadenylated RNAs, EBERs1 and 2, which are166 
and 172 nucleotides in length, respectively and the most abundantly expressed 
EBV RNAs in latently infected cells (Arrand and Rymo, 1982). The genes 
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encoding the EBERs are situated adjacent to one another in the right hand 1 kb of 
the BamHI fragment. EBER1 is transcribed by RNA polymerase II and III, 
whereas EBER2 is transcribed by RNA polymerase III (Howe and Shu, 1989; 
Howe and She, 1993). While EBERs 1 and 2 share only 54% sequence similarity 
in their primary sequences, they are predicted to have similar secondary 
structures, displaying base paired structures containing a number of short-stem 
loops. Once transcribed, the EBERs localise to the nucleus where they are found 
in ribonucleoprotein (RNP) particles complexed to cellular protein La (Lerner et 
al., 1981) and to EBER-associated protein (EAP), better known as the ribosomal 
protein L22 that has been implicated as a potential oncoprotein in another context 
(Toczyski and Steitz, 1991; Nucifora et al., 1993; Toczyski et al., 1994). The 
EBER sequences are highly conserved between types 1 and 2 EBV; this and their 
consistent expression in all known forms of EBV latency may be indicative of a 
critical role for these RNAs in EBV biology. However, EBER-knockout EBV 
recombinants are not impaired for primary B cell transformation (Swaminathan et 
al., 1991). Furthermore, no differences were detected in the growth of the 
resulting LCLs or in the permissivity of these cells for lytic replication following 
induction. 
1.6.8 Other latent transcripts 
1.6.8.1 BamHIA transcripts 
In addition to the latent antigens, a family of differentially spliced 
complementary-strand BamHI A rightward transcripts (CSTs, BARTs or 
BARFOs) have been detected in BL cells, NPC tumours, HL tumours, latently 
infected lymphocytes from peripheral blood and primary infected B lymphocytes 
in culture (Gilligan et al., 1990; Chen et al., 1992a; Karran et al., 1992; Brooks et 
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al., 1993; Chen et al., 1999; Smith et al., 2000; Deacon et al., 1993). Several 
putative ORFs have been identified in the BamHI A family of transcripts which 
may encode proteins in latently infected cells; these include BARFO, encoded in 
the 3' ORF in exon 7; an extension of BARFO, RK-BARFO; RPMS 1 encoded by 
an ORF spanning exon 4 and part of exon 5 of some BamHI A transcripts; and 
A73 encoded by an ORF from components of exons 6 and 7 (Sadler and Raab- 
Teaub, 1995; Fries et al., 1997; Kienzle et al., 1999; Smith et al., 2000). BARF 1 
is another transcript from the BamHI A region, which encodes 31kDa protein. It 
has been detected in NPC and gastric carcinoma as a latent secreted protein (De 
Jesus et al., 2003; Smith et al., 2000), which can activate cell cycle as a growth 
factor (Sall et al., 2004). Although the function and protein coding capacity of the 
BamHI A transcripts has not been fully elucidated, the finding that they are 
consistently expressed in all EBV-associated epithelial and B cell tumours and in 
tightly latent peripheral lymphocytes suggests they may have an important, as yet 
undiscovered, function in viral persistence. However, from recombinant virus 
experiments, the BamHI A transcripts are not essential for transformation of 
primary B cells in vitro, LCL outgrowth or survival (Robertson et al., 1994; 
Kempkes et al., 1995). 
1.6.8.2 BHRF1 
The BHRF 1 coding sequence is found at the 3' end of some Cp/Wp-initiated 
EBNA transcripts in latently infected cells. However, while the BHRF1 protein, a 
homologue of cellular Bc12 may normally function to promote productive EBV 
infection, it might also contribute to the development of EBV-associated tumours 
(Dawson et al., 1995). BHRF1 is not essential for the transformation of primary B 
lymphocytes, or for outgrowth or survival of LCLs, or for EBV replication 
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(Marchini et al., 1991; Lee and Yates, 1992). The role of BHRF1 in EBV infected 
cells has yet to be elucidated but it has been confirmed as a functional Bcl-2 
homologue and has antiapoptotic effects when expressed in EBV-negative B cell 
lines (Henderson et al., 1993; Homer et al., 1995). Its physiological role could be 
to maintain the viability of EBV-infected cells following entry into lytic cycle, 
thereby extending the time over which viral progeny can be produced. 
1.7 Lytic cycle 
There is no naturally permissive system in which to study replication. In EBV 
latently infected cells, only a small percentage of cells spontaneously enter lytic 
cycle, so it is not easy to analyse the EBV lytic cycle. Lytic cycle can be induced 
in latently infected cells by treatment with phorbol ester, calcium ionophore 
treatment, 5'-azacytidine, sodium butyrate, vector-mediated BZLF 1 expression 
and sometimes by slg cross-linking or superinfection with P3HR1 virus (Luka et 
al., 1979; Zur Hausen and Fresen; 1978; Ben-Sasson and Klein, 1981). In the 
best-characterised system involving anti-Ig induction of the Latency I Akata-BL 
cell line, EBV lytic cycle takes 48-72 hours (Takada and Ono, 1989). The first 
proteins to be expressed are the products of the immediate early genes, BZLF1 
and BRLF1, classified as such because their transcription post-induction is 
independent of protein synthesis (Flemington and Speck, 1990). 
Some latency-associated proteins are expressed during lytic cycle. For example, 
EBNA1 continues to be expressed in lytic cycle but now transcription initiates 
from the lytic Fp promoter, located in the BamHI F fragment (Lear et al., 1992; 
Schaefer et al., 1995a). The other EBNAs appear to be downregulated if lytic 
cycle is induced in a latency III background, possibly reflecting the reported 
ability of BZLF1 to repress Cp activity (Kenney et al., 1989). In at least some, the 
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LMP promoters are also active in lytic cycle, with expression of LMP 1 as an early 
lytic cycle protein (Rowe et al., 1992). 
1.8 Primary EBV infection in vivo and. viral persistence 
EBV is naturally transmitted via the salivary route and infection results in life- 
long EBV persistence. Primary EBV infection may occur within cells of the 
oropharynx. It was initially believed that EBV infected the epithelial cells of the 
oropharynx and subsequently spread to infiltrating B lymphocytes, since EBV 
replication was detected within epithelial cells shed in the throat of IM patients 
(Sixbey et al., 1984; Yao et al., 1985). However, doubt was cast on this 
hypothesis when examination of IM tonsils in tissue sections failed to detect 
infected epithelial cells (Niedobitek et al., 1997). Instead replicating virus could 
be found in B cells situated near epithelial crypts and it is now thought that initial 
EBV infection requires virus replication in B lymphocytes infiltrating the 
oropharynx (Tao et al., 1996; Karajannis et al., 1997). A model of EBV infection 
is shown in Figure 1.4. 
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Figure 1-4 A model of primary EBV infection 
In the oropharynx, EBV infects naive B cells and expresses the full spectrum of 
latent proteins (latency III programme: EBNA1, LMPs 1 and 2A, EBNA3s and 
LP). The virus can thereby drive the activation and proliferation of these B cells, 
which then migrate to lymphoid follicles and form germinal centres. Many of 
these proliferating cells are removed by the emerging latent-antigen-specific 
primary-T-cell response. Concomitantly, expression of EBNA3s and LP are 
downregulated, leaving EBNA1 and the LMPs expressed (latency II programme), 
some which establish a stable reservoir of resting viral-genome-positive memory 
B cells, in which viral antigen expression is mostly suppressed (latency 0), but to 
evade a host immune response. An alternative view therefore envisages infection 
of pre-existing memory cells as a direct route into memory B cell. 
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Analysis showed that EBV-infected tonsillar B cells are heterogeneous both in 
morphology and viral antigen expression in IM (Niedobitek et al., 1997; Kurth et 
al., 2003). While there is clearly a proliferating compartment of LCL-like cells 
expressing both EBNA2 and LMP 1, there are also smaller cells expressing 
EBNA2 by staining and a number of very large cells with Hodgkin's lymphoma- 
like morphology that are EBNA2-negative and LMP1 positive. Cells with these 
different morphologies and apparently different latency patterns can even exist 
within the same expanding clone (Kurth et al., 2000). 
EBV-infected B cells are also detectable in the blood of IM patients, usually at 
levels between 0.1-1% of all circulating B cells (Klein et al., 1976; Katsuki et al., 
1979), but occasionally reaching 10% (Robinson et al., 1980). As a result of virus 
replication in the oropharynx, virus-driven proliferation and expansion of the B 
cell pool; aT cell response is initiated and EBV-specific CD8+ CTLs proliferate 
rapidly to give the diagnostic atypical numbers of mononuclear cells in the blood 
(Callan et al., 1998). Some of these CTLs are responsive to latent antigens, but the 
majority are reactive to lytic antigen epitopes (Steven et al., 1997). As IM patients 
convalesce, virus replication in the oropharynx falls and the numbers of infected 
peripheral B cells reduces. However, despite the strong CTL response the virus 
establishes a lifelong persistence and remains detectable at very low levels both as 
infectious virus in throat washings and as a latent infection of the B cell pool (Yao 
et al., 1985). The relationship between these two sites of virus persistence remains 
ill-defined and, while the balance of evidence favours the B cell pool as the 
essential reservoir of EBV persistence, there remains the possibility of a separate 
oropharyngeal reservoir of persistence, perhaps involving chronic replication 
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rather than true latency (Sixbey et al., 1984). A model of EBV persistence is 
shown in Figure 1.5. 
Evidence favouring B cells as the site of EBV persistence includes i) total body 
irradiation destroying the lymphoid system but leaving epithelium intact, can clear 
EBV from a virus carrier (Gratama et at., 1988); ii) treating patients with 
acyclovir eradicated EBV replication in the oropharynx but did not affect EBV 
residing in the peripheral blood (Yao et at., 1989); and iii) patients with X-linked 
agammaglobulinaemia (XLA), and therefore incapable of producing mature B 
cells remain EBV negative (Faulkner et al., 1999). In the blood the site of EBV 
persistence had now been identified as the CD19+, CD23', CD80' (BT), CD27' 
resting memory B cell population (Miyashita et al., 1997; Babcock et al., 1998; 
Malbran et at., 2004), but how EBV preferentially colonises this cell compartment 
is widely debated. Downregulation of EBV latent gene expression from the initial 
Latency III infection is a crucial step in viral persistence in the immunocompetent 
host and so another possibility is that both naive and memory B cell are 
susceptible to Latency III infection but only pre-existing memory cells have the 
capacity to switch latency type in vivo; therefore only these cells can survive in 
the immunocompetent host. RT-PCR analyses of latent gene transcripts expressed 
in peripheral B cells isolated from healthy virus carries have detected EBER 
RNAs, BamHI A transcripts, LMP2A transcripts and trace levels of Qp-initiated 
EBNA1 transcripts (Qu and Rowe, 1992; Tierney et al., 1994; Miyashita et al., 
1997; Chen et at., 1999). However, another report showed the major infected 
population in the blood of immunosuppressed patients may not express the known 
latent proteins (Babcock et al., 1999). 
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EBV can presumably be reactivated from memory B cells into lytic cycle in vivo 
(as well as in vitro immediately following the culture of circulating B cells from 
virus carriers). And this reactivation may serve to establish new transformation 
events that replenish the infected B cell pool (Babcock and Thorley-Lawson, 
2000). Infection by EBV is controlled by both cellular and humoral immune 
mechanisms (Hochberg et al., 2004a; Hochberg et al., 2004b). However, the 
immune system is unable to eliminate the virus completely, and as a consequence, 
viral shedding and virus-infected cells persist at a low level in memory B cells 
(Laichalk et al., 2002). 
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Figure 1-5 A model of EBV persistence 
As B cells recirculate to the oropharynx, a switch into the EBV lytic cycle might 
occur, possibly triggered by maturation of B cells into plasma cells, allowing for 
virus replication, shedding into saliva and transmission both to new hosts and to 
previously uninfected B cells within the same host. This might initiate new 
growth-transforming latency III infections of naive and/or memory B cells and 
might possibly replenish the B-cell reservoir, but are more likely to be efficiently 
removed by the now well-established memory-T-cell response. 
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1.9 EBV associated malignancies 
1.9.1 Burkitt's lymphoma (BL) 
EBV is present in all cases of 'endemic' Burkitt's lymphoma (BL)-the high- 
incidence form of the tumour that affects children in areas of Africa and New 
Guinea in which malaria is holoendemic. EBV is also present in up to 85% of 
cases in areas of intermediate incidence such as Brazil and North Africa, but in 
only 15% of the low-incidence 'sporadic' tumours that are seen in children in the 
developed world. BL is also common among adult human immunodeficiency 
virus (HIV) carriers in the developed world and often arises as the first AIDS- 
defining illness in relatively immunocompetent patients, of which 30-40% 
tumours are EBV-associated (Kieff and Rickinson, 2001). The vast majority of 
EBV-positive BL tumours show a highly restricted latency I form of infection, 
with viral antigen expression limited to that of EBNA1 (Rowe et al., 1987; Kelly 
et al., 2002). So, how EBV contributes to the pathogenesis of BL remains a 
matter of speculation. The virus might have an initiating role in which growth- 
transforming B-cell infections establish a pool of target cells that are at risk of a 
subsequent MYC translocation, a process that has been successfully modelled in 
vitro (Polack et al., 1996). EBV might contribute to the BL phenotype through the 
latency-I-associated genes themselves. EBNA1 is an candidate, but report about its 
oncogenicity remains controversial (Wilson, 1996), and its contribution to virus- 
induced B-cell transformation in vitro might be limited to maintenance of the viral 
genome (Humme et al., 2003; Kang et al., 2001); however, another recent report 
showed EBNA1 promoted cell survival (Kennedy, 2003). Irrespective of their 
EBV status, the phenotype of BL cells is similar to that of germinal centroblasts, 
and the detection of ongoing Ig-gene mutation in tumour cells supports the 
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suggestion that they originate in germinal centres (Chapman 1995; Harris et al., 
2001). 
1.9.2 Hodgkin's lymphoma (HL) 
Hodgkin's lymphoma (HL) is an unusual tumour, characterized by atypical, large 
tumour cells known as Hodgkin (mononucleated) and Reed-Sternberg 
(multinucleated) (HRS) cells (Weiss, 2000). HRS cells usually represent less than 
1% of the cells in the HL tumour tissue, the vast majority of cells are non- 
malignant T cells, B cells, macrophages, eosinophils, plasma cells and others 
(Weiss et al., 2000). The incidence of HL in the Western world is about 2.5-3 
new cases per 100,000 people per year and it is more common among people 15 
to 35 and 50 to 70 years old (Glaser et al, 1997). In EBV positive HL, young 
patients under 15 years have better prognosis than older patients with subtype NS 
(nodular sclerosis) (Keegan et al., 2005). HL is has a high cure rate, about 90% of 
patients achieve a long-term remission following treatment. 
In 1832 Thomas Hodgkin first described the case of lymphoid lesion that was 
later named Hodgkin's disease (HD), and in 1902 and 1898, Dorothy Reed and 
Carl Sternberg described a peculiar cell type in HD tissues which was referred to 
as the Reed-Sternberg (RS) cell (Hodgkin, 1832; Reed, 1902; Sternberg, 1898). 
Based on the differences in the cellular composition and the histology of lesions, 
HL is divided into lymphocyte predominance and classical Hodgkin lymphoma 
(LPHL and cHL). In LPHL, the Hodgkin cells are also called L&H cells 
(lymphocytic and histocytic). cHL is further distinguished into four subsets of 
classical HL, nodular sclerosis (NS), mixed cellularity (MC), lymphocyte 
depletion (LD), lymphocyte rich (LR). NS and MC are the most common types, 
which together comprise 80% to 90% of all HL. NS is more common in adults in 
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their 20's and 30's, particularly females. HRS cells of HL are large cells that can 
be more than 501im in diameter and have a moderate amount of cytoplasm and a 
clearly visible nucleolus in each nucleus (Weiss, 2000). 
The origin of these cells was finally clarified by using microdissection to isolate 
single HRS cells from frozen tissue sections following by analysis of the 
rearranged immunoglobulin (Ig) genes. In nearly all the cases, the HRS cells 
carried a rearranged Ig heavy and light chain gene, and by this these cells were 
identified as B cells (Brauninger et al., 1999; Kuppers et al., 1994). Moreover, by 
the detection of the identical Ig V gene rearrangements in the HRS cells of a given 
case, their monoclonality was demonstrated (Kuppers et al., 1994; Marafioti et al., 
2000). It was reported recently that all cases of HL with crippling mutations that 
prevent BCR expression are EBV positive (Brauninger et al., 2006). 
Approximately half of HL cases have EBV DNA within HRS cells and express at 
least four viral products, the so-called latency II programme (Deacon et al., 1993): 
EBERs, EBNA1, LMP1, LMP2 and BamHI A transcripts. Type-1 EBV has been 
detected in most HL tissues and type-2 virus is found in a small proportion of 
cases. The presence of EBV in HL depends on a number of factors, including the 
patent's country of residence, histological subtype, sex, ethnicity and age. EBV- 
positive HL is less common than EBV-negative HL in well-developed populations 
compared with poorly developed communities (Glaser et al., 1997). EBV is more 
commonly associated with the mixed-cellularity subtype of HL and less 
frequently with the other forms of this disease (Glaser et al., 1997). The 
association of EBV with HL has been intensely investigated over the last few 
years; however, the contribution of EBV to the pathogenesis of HL remains 
unknown. A recent report showed that EBV infection in HL cells induces the 
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expression of autotoxin (a secreted tumour-associated factor) and proliferates HL 
cells; this indicates that EBV infection has a contribution to the pathogenesis of 
HL. Furthermore, in addition to the role of EBV in the aetiology of HL, the 
function of EBV-latent antigens, such as LMP1 and LMP2, in the malignant HL 
cells requires investigation. 
The expression pattern of EBV-encoded genes in HRS cells indicates a role for 
EBV in the rescue and transformation of pre-apoptotic germinal-centre B cells 
(Kuppers and Hansmann, 2005). Two of the main survival signals for germinal- 
centre B cells are mediated through the BCR and through stimulation of CD40 
(Liu et al., 1989). These signals can presumably be replaced by LMP2A and 
LMP 1, respectively, both of which are expressed in the EBV-positive HRS cells 
(Herbst et al., 1991; Niedobitek et al., 1997; Pallesen et al., 1991). Therefore, it 
might be the expression of LMP1 and LMP2A in the EBV-infected germinal- 
centre B cells that allows them to survive despite the presence of crippling 
mutations (Kuppers and Hansmann, 2005; Brauninger et al., 2006). 
Recently it was reported that LMP2A might contribute significantly to the HL 
phenotype by altering cellular gene transcription; these included downregulation 
of the specific gene expression for B cell development (KÜppers et al., 2002, 
Portis et al., 2003; Portis and Longnecker, 2003). The ability of LMP2A to 
substitute for a functional BCR was clearly demonstrated in EBV infected B cells, 
even if in cells that failed to hypermutate their BCR successfully (Casola et al., 
2004). Therefore, the rescue of pre-apoptotic germinal centre B cells by LMP2A 
might be a crucial step in their transformation. However, LMP2A might have few, 
if any, functions in the established HRS tumour clone: It was reported that HRS 
cells have lost the expression of most B-cell-specific genes, including the kinases 
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Syk and Lyn and the adaptor molecule B-cell linker (BLNK, also known as 
SLP65) (Schwering et al., 2003). These molecules are not only crucial for BCR 
signalling, but are also essential components of the signalling pathway used by 
LMP2A (Engels et al., 2001). Therefore, LMP2A might not be able to mimic the 
presence of a BCR in HRS cells, at least through the known signalling pathways. 
1.9.3 Post transplant lymphoproliferative disease (PTLD) 
Immunosupressed transplant patients have been shown to be at increased risk of 
developing a particular spectrum of EBV-associated B lymphoproliferative 
lesions/lymphomas termed PTLD (Penn, 2000). The disease normally arises 
within the first two years after transplantation and presents as multifocal lesions 
within the lymphoid tissues, the central nervous system (CNS), the liver or the 
transplanted organ (Nalesnik et al., 1988). There is a high association with EBV 
(Nalesnik, et al., 1988. Weiss and Movahed, 1989; Nalesnik, 1998). Patients 
EBV-negative at the time of transplantation are at a 20-fold increased risk of 
developing the disease, since they frequently suffer primary infection post- 
transplant and have no pre-existing EBV immunity upon which to call (Ho et al., 
1985). Measuring and monitoring increased EBV loads in the PBMCs of 
transplant patients may serve as a useful diagnostic tool to predict the likelihood 
of PTLD onset (Rowe et al., 1997; Baldanti et al., 2000). Most early onset PTLD 
tumours display a type III latency pattern of EBV gene expression, with 
detectable EBNA1, EBNA2 and LMP1 expression, consistent with in vitro LCL 
outgrowth in the absence of CTL responses (Young et al., 1989; Rea et al., 1994; 
Delecluse et al., 1995). Interestingly, even within these largely LCL-like PTLD 
lesions, antibody staining reveals subpopulations of EBNA2-positive LMP1- 
negative and EBNA2 negative LMP1-positive cells; analogous to the 
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heterogeneity seen in EBV-expanding cell lines in IM tonsils. The full 
significance of this heterogeneity remains to be determined. However, other 
PTLDs clearly show a more restricted pattern of gene expression, with only 
EBNA1 protein detectable (Delecluse et al., 1995; Oudejans et al., 1995). 
1.9.4 Nasopharyngeal carcinoma (NPC) 
The EBV-associated, undifferentiated form of nasopharyngeal carcinoma (NPC) 
shows the most consistent worldwide association with EBV and is particularly 
common in areas of China and south-east Asia, reaching a peak incidence of 
around 20-30 cases per 100,000 (Yu and Yuan, 2002). However, NPC is 
uncommon disease in the west; where the incidence is less than 1 per 100,000 
among Caucasians from North American and other Western countries. Incidence 
rates are high in individuals of Chinese descent, irrespective of where they live, 
and particularly in Cantonese males. In addition to this genetic predisposition, 
environmental cofactors such as dietary components (for example, salted fish) are 
thought to be important in the aetiology of NPC (Yu et al., 1986). NPC tumours 
are characterized by the presence of undifferentiated carcinoma cells and a 
prominent lymphocytic infiltrate, and an interaction between tumour cells and 
lymphocytes seems to be crucial for the continued propagation of the malignant 
component. 
EBV latent-gene expression in NPC is predominantly restricted to EBNA1 
LMP2A, LMP2B, EBERs and the BamHIA transcripts, with -20% of tumours 
also expressing the oncogenic LMP1 protein (Raab-Traub, 2002). Southern-blot 
hybridization of DNA from NPC tissues demonstrates the monoclonality of the 
resident viral genomes, indicating that EBV infection takes place before the clonal 
expansion of the population of malignant cells (Raab-Traub and Flynn, 1986). 
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Studies of normal nasopharyngeal tissue and pre-malignant biopsies indicate that 
genetic events occur early in the pathogenesis of NPC, and that these might 
predispose to subsequent EBV infection. Higher frequencies of deletions on 
chromosomes 3p and 9p are found in histologically normal nasoharyngeal 
epithelia from southern Chinese, as well as in low- and high-grade dysplastic 
lesions (Chan et al., 2000; Chan et al., 2002). Extensive serological screening has 
identified increased EBV-specific antibody titres in high-incidence areas; in 
particular, IgA antibodies to the EBV capsid antigen and early antigens have 
proved useful in diagnosis and in monitoring the effectiveness of therapy (Zeng, 
1985). More recent studies using real-time quantitative PCR to measure 
circulating tumour-derived EBV DNA in the blood of patients with NPC have 
shown that the level of pre-treatment EBV DNA is strongly associated with 
overall survival, and that post-treatment EBV DNA levels predict progression-free 
and overall survival (Chan, 2002). Association of EBV with the other more 
differentiated forms of NPC (WHO types I and II) has been shown, particularly in 
those geographical regions with a high incidence of undifferentiated NPC 
(Pathmanathan et al., 1995). However, the precise role of virus infection in 
carcinogenesis and the contribution of epithelial cell infection to EBV persistence 
and replication remain unknown. 
1.9.5 Gastric carcinoma 
EBV is also found in -10% of typical gastric adenocarcinomas, accounting for up 
to 75,000 new cases per year (Shibata and Weiss, 1992; Burgess et al, 2002; 
Tokunaga et al., 1993). These tumours display a restricted pattern of EBV latent- 
gene expression (expression of EBERs, EBNAI, LMP2A, BARTs and BARF1), 
similar to that seen in NPC (Imai et al., 1994). There is significant geographical 
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variation in the association of EBV with gastric carcinoma, which might be due to 
ethnic and genetic differences. EBV-positive gastric carcinomas have distinct 
phenotypic and clinical characteristics compared with EBV-negative tumours, 
including loss of expression of INK4A (also known as p16) and improved patient 
survival (Schneider et al., 2000; Lee et al., 2004). As in NPC, the precise role of 
EBV in the pathogenesis of gastric carcinoma remains to be determined, but the 
absence of EBV infection in pre-malignant gastric lesions supports the suggestion 
that viral infection is a relatively late event in gastric carcinogenesis (Zur Hausen 
et al., 2004). 
1.9.6 Virus-associated T-cell and NK-cell lymphomas 
EBV has been linked to a proportion of peripheral T cell non-Hodgkin's 
lymphomas, in which 5-50% of the tumour cells are EBV detectable. The EBV 
infection was documented occurring subsequent to tumour development. This 
suggests that EBV infection might provide an additional growth/survival signal to 
the transformed T cells (Anagnostopoulos et al., 1992; Anagnostopoulos et al., 
1995; Ho et al., 1998; Niedobitec et al., 1997; Tao et al., 1995). Nasal or nasal- 
type NK-cell lymphoma presents a distinctive clinicophathologic entity, almost 
always associated with EBV. These NK-cell lymphomas, more common in Asia 
and especially in China (Jaffe et al., 1996), characteristically present as a nasal 
destructive disease. The nasal lymphoma tissues display a latency II pattern of 
EBV gene expression characterized by expression of EBNA-1, LMP-1 and LMP- 
2A, but not EBNA-2 and LMP-2B (Chiang et al, 1996). EBV is B-lymphotropic, 
but how the virus accesses T cell lineages in vivo is still remain unknown. Most 




1.10 Aims and objectives 
The contribution of LMP2 to the pathogenesis of virus-associated tumours is 
poorly understood. Therefore, this project seeks to address the contribution of 
LMP2A and LMP2B to the phenotype of HL and epithelial tumours. 
The first objective of this work is to develop an in vitro system for the stable 
expression of LMP2 in an EBV-negative HL cells. Such cells will be used to 
examine the influence of LMP2 in cellular survival and proliferation and then to 
study the impact of LMP2A and LMP2B on cellular gene expression. 
Finally, HEK293 cells will be used to generate cell lines expressing His-tagged 
LMP2A and LMP2B proteins. These will then be subjective to a novel 
methodology, stable isotope labelling amino acid in cell culture for the detection 
of LMP2A and LMP2B-interacting proteins. 
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Materials and Methods 
2 Materials and methods 
2.1 Cell culture 
2.1.1 Maintenance of cells 
2.1.1.1 Hodgkin's lymphoma cells 
KMH2, L428, L591 and L591-SD3 are Hodgkin's lymphoma derived cell lines 
(American Type Culture Collection, Rockville, MD). KMH2 was established from 
the pleural effusion of a patient with mixed cellularity HL (Kamesaki, et al., 
1986). L428 was derived from a pleural effusion that was histologically 
confirmed as HL (Schaadt et al., 1980). L591 is a cell line established from 
pleural effusion of a female patient with histologically confirmed nodular 
sclerosis HL (Diehl et al., 1982). L591-SD3 is a EBV-negative HL cell line 
generated by a series dilution of L591 (Baumforth et al., 2005). All cell lines 
were maintained in exponential growth at 37°C, 5% CO2 in 75 cm2 flasks in RPMI 
1640 medium (Gibco) supplemented with 10% v/v selected B cell serum*, 2mM 
glutamine (Gibco) and 1% penicillin and strepmycin (Sigma). KMH2 and L428 
cells stably infected with EBV or stably expressing LMP2 were maintained under 
lmg/ml G418 selection. 
*B cell Serum: a number of batches of Foetal Calf Serum (FCS) were obtained 
from several sources and tested for their ability to support B cell growth as 
measured by the efficiency of colony formation when plated out at clonal density. 
The batch that gave the most efficient colony formation was selected as the FCS 
for use in all B culture. FCS was sterilised by pressure filtration, tested for 
virus/mycoplasma and stored in 20m1 aliquots at -20°C. 
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2.1.1.2 HEK 293 cells 
HEK 293 cell line is an immortalised cell line derived from primary human 
embryonal kidney cells transformed by sheared human adenovirus type 5 DNA 
(Graham et al., 1977). 293 cells were grown at 37°C, 5% CO2 in 75 cm2 flasks in 
DME/HEPES medium (Gibco) supplemented with 10% v/v FCS, 2mM glutamine 
(Gibco) and 1% penicillin and streptomycin (Sigma). Cells were trypsinised with 
1% w/v trypsin in diaminothanetetra-acetic acid disodium salt (EDTA) (Gibco) at 
37°C for 5 minutes, pelleted by centrifugation at 1500rpm for 5 minutes and 
resuspended at an appropriate concentration in complete DME/HEPES medium as 
above. 293 cells stably expressing LMP2 were maintained under 400ug/ml Zeocin 
(Invitrogen) selection. 
2.1.2 Cryopreservation of cells 
Typically, aliquots of 5-10 x 106 cells were pelleted by centrifugation at 1500rpm 
for 5 minutes and resuspended in lml freezing mix (50% v/v complete medium, 
40% v/v FCS and 10% v/v dimethyl sulphoxide (DMSO). Cells were transferred 
to a cryopreservation tube in a freezing box (container surrounded by sponge 
soaked in isopropanol) and stored at -70°C for short-term storage, before being 
transferred to the vapour phase of a -180°C liquid nitrogen freezer for long-term 
storage. 
2.1.3 Recovery of cells from liquid nitrogen 
The cells were thawed quickly at 37°C to minimise to DMSO damage and 
transferred to a 15 ml centrifuge tube. Corresponding pre-warmed medium at 
37°C was added to the cells dropwise to dilute out the DMSO and allow the cells 
to recover slowly. Cells were pelleted by centrifugation at 1500rpm for 5 minutes, 
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resuspended in corresponding cell medium and grown in a 25cm3 flask at 37°C, 
5% CO2. 
2.2 Infection of KMH2 and L428 cells with retrovirus carrying LMP2A, 
LMP2B and Neomycin resistance cassette 
2.2.1 Generation of Retrovirus carrying LMP2A, LMP2B and Neo 
A13 packaging cells were stably transfected with the pLNSX-LMP2A, pLNSX- 
LMP2B plasmids or empty vector pLNSX (Neo) (a kind gift from Dr. CW. 
Dawson, CRUK Institute, University of Birmingham). These stably transfected 
packaging cells were seeded into 6cm petri dishes and the recombinant 
retroviruses produced by these cells were shed into the surrounding media. The 
conditioned media containing retrovirus pLNSX-LMP2A, pLNSX-LMP2B or 
pLNSX only were collected after 48 hours incubation, which were then used to 
transduce KMH2 and L428 cells as described below. 
2.2.2 Infection of KMH2 and L428 cells with retrovirus carrying LMP2A, 
LMP2B and Neomycin resistance cassette 
Cells were counted and their viability was checked. The cells were pelleted and 
resuspended in fresh medium (5x104 cells/ml). 1 ml of each cell suspension was 
put into 6 well plates. 2m1 of supernatant with retrovirus carrying LMP2A, 
LMP2B or Neomycin resistance gene were added to each corresponding well. 4µl 
polybrene (Sigma, IOµg/ml) was added to each well and mixed. 2ml medium was 
topped up to each well after the plates were incubated for 4 hours at 37°C. 48 
hours post-infection, the growth medium was changed to medium containing 
G418 (lmg/ml, Sigma). After 10 days of drug selection, drug-resistant polyclonal 
populations were screened for expression of LMP2A and LMP2B by RT-PCR and 
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immunofluorescence staining. Drug-resistant, polyclonal populations were then 
expanded in the presence of G418 (1mg/ml). 
2.3 DNA/RNA detection 
2.3.1 Reverse Transcription (RT) 
2.3.1.1 RNA extraction 
Total RNA was extracted from cell lines (1-5x106 cells) using the Nucleospin® 
RNA II kit (MACHERY-NAGEL), following the instructions provided by the 
manufacturer. Cell suspension was centrifuged at 1500rpm for 5 minutes and 
supernatant was removed from the pellets. Cells were lysed in a solution 
containing beta-mercaptoethanol, which enables adsorption of RNA to a silica 
membrane and inactivates any RNase enzymes. The lysate was then loaded onto a 
silica membrane. Any trace of DNA was removed by adding extra DNAse 
solution. Membrane was washed using buffers provided from the kit to remove 
any contaminants such as salts, metabolites and cellular components. RNA was 
eluted in RNase-free water in a volume of 6Oµ1 to ensure maximal yield. The yield 
and quality of each RNA sample was determined using an UV-spectrophotometer 
assuming 1 A260 unit=40µg RNA. 
2.3.1.2 cDNA reaction 
LMP2-specific cDNA was made using AMV kit (Roche) and LMP2 reverse 
oligonucleotide primer (see Appendix 8.1.1). 200ng of total RNA was put into a 
0.5 ml microfuge tube to perform the reverse transcription in a final 20µl volume 
containing 4 µl 5xRT buffer (50mM KCI, 10mM Tris-HCI, pH 8.3), 5.5 mM 
MgCl2,0.5 mM each of dATP, dCTP, dGTP and dTTP, 2.0 µM LMP2A 
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oligonucleotide reverse primer, 1 unit RNase inhibitor and 20 units reverse 
transcriptase. These cDNA synthesis reactions were incubated at 42°C for 1 hour, 
followed by heating at 95°C for 5 minutes to inactivate the reverse transcriptase 
enzyme. Positive and negative controls were included in each run. 
2.3.1.3 LMP2 PCR 
Red Hot DNA polymerase kit (ABgene) was used for conventional PCR. 2µl gene 
specific primed cDNA was aliquoted into 0.5 ml microfuge tubes and a reaction 
mix was added to give a final reaction concentration of lx reaction buffer (50mM 
KCI, 10mM Tris-HCI, pH 8.3), 5.5 mM MgC12i 0.25 mM each of dATP, dCTP, 
dGTP and dTTP, 1.0 gM of each forward and reverse LMP2A oligonucleotide 
primers (See Appendix 8.1.1) and 5 units of Red Hot DNA polymerase in a total 
reaction volume of 50ul. Samples were placed in a PCR machine, heated to 94°C 
for 5 minutes, then subjected to 40 cycles of denaturation at 94°C for 30 seconds, 
annealing at 58°C for 1 minute and extension at 72°C for 30 seconds with a final 
extension phase at 72°C for 10 minutes. LMP2-positive cell line (X-50-7) was 
used as positive control. 
2.3.1.4 Semi-quantitiative PCR 
1 µg of RNA from each sample was used to make cDNA in 20 µl volume. PCR 
was run as described above with 2 [il cDNA for 20,25,30 and 35 cycles. 
Annealing temperature was determined for each set of primers. 5µ1 of each PCR 
product was run on 1.2% Argarose gels. At the same time PCR for GAPDH was 
run alone side as a loading control. 
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2.3.1.5 Electrophoresis 
The 10 µl PCR reactions were mixed with 5x gel loading buffer (0.25%w/v 
xylene cyanol, 0.25% w/v bromophenol blue, 30%w/v glycerol) and subjected to 
electrophoresis (110 volts) through 1.2% agarose gel containing 0.5 pg/ml 
ethidium bromide in 1xTBE running buffer (90mM Tris-borate, 2 mM EDTA). A 
1 kbp DNA ladder (Roche) was also loaded alongside the samples so that the size 
of the PCR products could be determined. After electrophoresis, the PCR 
products, as stained by the ethidium bromide, were visualised with UV light on a 
transilluminator and Polaroid photographs taken. 
2.4 Protein detection and analysis 
2.4.1 Immunofluorescence Staining (IF) 
2.4.1.1 Two-Step immunofluorescence 
Size 12 Teflon-coated slides (Hendley-Essex) were autoclaved, 50 µ1 of 
fibronectin (Sigma, 10µg/ml in PBS) was added to each well; then slides were 
kept in a sterile petridish at 4°C overnight. On the next day, the fibronectin was 
washed off carefully with PBS 2-3 times for 5 minutes. Cell suspension with 
approximately 5x104 to 1x105 cells in 50ul of medium was loaded to each well 
and incubated at 37°C overnight. Slides were fixed with 4% PFA 
(Paraformaldehyde) for 10 minutes, washed with PBS twice for 5 minutes and 
permeabilized with 0.1% (vol/vol) TritonX-100 for 2 minutes. Antibodies were 
diluted to the appropriate concentration in 20% HINGS. Primary and secondary 
antibody incubations were Ih each, and the slides were washed twice with PBS 
after each incubation. The slides were covered with DEBCO (2.5 mg in 90 ml 
DEBCO and 10 ml PBS) and coverslips added. Slides were imaged by UV 
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microscopy. The primary and secondary antibodies were used as described in 
Table 2.1 and Table 2.2. 
Table 2-1 Primary antibodies used for IF 
Primary Ab Specificity Nature Dilution Supplier 
Bala serum LMP2 EBV-positive 1: 50 NPC patient 
human serum 
Anti-His Ab His epitope Mouse 1: 100 Upstate 
monoclonal 
Anti-IF127 Ab IFI27 epitope Mouse 1: 100 Abcam 
monoclonal 
Anti-AICDA Ab AICDA epitope Rat monoclonal 1: 100 Gift from Professor 
Niedobitek 
(Germany) 
Table 2-2 Secondary antibodies used for IF 
Secondary Ab Conjugate Dilution Supplier 
Goat anti-human IgG FITC 1: 200 Sigma 
Goat anti-mouse IgG AlexaFluor 594 1: 200 Molecular Probes 
Goat anti- mouse IgG AlexaFluor 488 1: 200 Molecular Probes 
Goat anti-Rat IgG AlexaFluor 488 1: 200 Molecular Probes 
Goat anti- Rat IgG AlexaFluor 594 1: 200 Molecular Probes 
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2.4.1.2 Dual Staining 
For dual staining with two separate antibodies, the primary antibodies were 
derived from different animals and the secondary antibody to each was conjugated 
to a different fluorescent marker, e. g. one FITC or AlexaFluor 488 and the other 
TRITC or AlexaFluor 594. At each stage, both antibodies were diluted together in 
20% HINGS to the appropriate concentration. The subsequent steps are the same 
as described above. Staining was viewed under two filters by UV microscope. 
2.4.2 Western blotting 
Cells were washed with PBS, pelleted, and then lysed with the cell lysis buffer 
(see Appendix 8.2.3) on ice for 30 minutes. The cell lysate was spun down at 
13,000 rpm for 10 minutes at 4°C. Proteins were quantified using the BioRad DC 
protein Assay Kit (500-0120 BioRad, UK). The GSB gel sample buffer (50mM 
Tris pH6.8,100mM dithiothreitol, 2% SDS, 10% glycerol, 0.05% bromophenol 
blue) was added to the protein samples and these were boiled for 5 minutes. 
Soluble proteins were separated by SDS-polyacrylamide gel electrophoresis and 
transferred to BioTrace NT membrane (VWR internatonal, UK) for 
immunoblotting. The membrane was blocked with 5% milk PBS-Tween buffer 
for 1 hour; then incubated overnight at 4°C with primary antibody. The membrane 
was washed for 5 minutes twice with PBST buffer and incubated for 1 hour with a 
1: 2000 dilution of HRP-conjugated secondary antibody. Specific antibody-protein 
complexes were detected using the Enhanced Chemiluminescence (ECL) kit 
(RPN2106; Amersham Pharmacia Biotech, UK). The primary and secondary 
antibodies used are listed see Table 2.3 and Table 2.4. 
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Table 2-3 Primary antibodies were used for western blotting 
Primary Ab Specificity Nature Dilution Supplier 
B-Actin Ab Actin Mouse monoclonal 1: 20000 Sigma 
Anti-HA Ab Hemagglutinin Rabbit polyclonal 1: 1000 Santa Cruz 
Anti-His Ab Histidine Mouse monoclonal 1: 1000 Upstate 
Anti-IFI27 Ab IF127 Mouse monoclonal 1: 100-1: 2000 Abcam 
Anti-AICDA Ab AICDA Rat monoclonal 1: 100: 1: 1000 Gift from Professor 
Niedobitek (Germany) 
Table 2-4 Secondary antibodies were used for western blotting 
Secondary Conjugate Dilution Supplier 
Goat anti-mouse IgG Peroxidase 1: 1000 Dako 
Goat anti-rabbit IgG Peroxidase 1: 1000 Dako 
Goat anti-rat IgG Peroxidase 1: 1000 Dako 
2.5 Cell proliferation and viability assays 
2.5.1 Cell proliferation assay 
5x 104 cells from each cell line were pelleted at 1500 rpm for 5 minutes and 
resuspended in 5 ml PBS. Cells were washed three times with PBS to remove any 
trace of serum. Finally, cells were resuspended in 2 ml of growth medium 
RPMI1640 containing glutamine, penicillin/streptomycin solution and 10%, 5%, 
or 1% B cell serum without G418 presence. 100 µl of cell suspension from each 
concentration of serum was pipetted in triplicate to 5 separate 96-well plates. The 
plates were labelled Day 0,2,4,6 and 8 and incubated at 37°C in 5% CO2 for up 
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to 8 days without changing the medium. Every 2 days (starting at Day 0), a plate 
was removed for WST-1 assay. Assessment of cell proliferation was carried out 
every two days (starting at Day 0) for serum concentration. Briefly 20 µl of WST- 
1 reagent (Roche) was added to each well and plates incubated for 1 hour at 37°C. 
Absorbances were read at 450 nm on a Microplate Autoreader (Model EL311; 
Bio-tek Instruments, Vermont, USA). Mean results were taken from triplicate 
wells and plotted as a graph showing standard error of mean, and subjected to 
statistical analysis in MicrosoftTM Excel using a two-tailed student's T-test 
assuming the two samples displayed unequal variance. The p-values indicated a 
significant difference between the data sets when the p-value was <0.05. 
2.5.2 Cell viability assay 
1.2 x 106 cells from each cell line were pelleted at 1500 rpm for 5 minutes and 
resuspended in 5 ml PBS. Cells were washed three times to remove any trace of 
serum. Finally, cells were resuspended in 4 ml cell maintenance medium, 
RPMI1640 containing glutamine, penicillin/streptomycin solution and 10%, 5%, 
or 1% B cell serum without G418 presence. 200 µl of each cell suspension at each 
of the different serum concentrations was pipetted in triplicate into 5 separate 48- 
well plates. Plates were labelled Day 0,2,4,6 and 8 and incubated at 37° C in 5% 
CO2 for up to 8 days without changing the medium. Every 2 days (starting at Day 
0), a trypan blue viability assay was carried out with trypan blue reagent (Sigma). 
80 µl of cell suspension was mixed with 20 µl trypan blue reagent for 2 minutes 
and the cell viability was evaluated by direct counting of unstained cells under a 
microscope. Mean results were taken from triplicate wells and plotted as a graph 
showing standard error of mean, and subjected to statistical analysis in 
Microsoft" Excel using a two-tailed student's T-test assuming the two samples 
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displayed unequal variance. The p-values indicated a significant difference 
between the data sets when the p-value was <0.05. 
2.6 Gene expression microarray 
2.6.1 RNA extraction 
5-10x106 of KMH2-LMP2A, -LMP2B and -Neo cells were washed with PBS and 
pelleted. 1 ml TRIZOL Reagent was added to lyse the cells by repetitive pipetting. 
After 5 minutes incubation at room temperature (RT), 200µ1 chloroform was 
added and shaken vigorously for 15 seconds by hand. The mixture was incubated 
at RT for another 2-3 minutes then centrifuged at full speed for 15 minutes at 4°C. 
The aqueous phase was transferred into a fresh tube and 500µ1 of isopropyl 
alcohol was added to each sample. Samples were incubated for 10 minutes at RT, 
and then spun down at full speed at 4°C for 10 minutes. The supernatant was 
carefully removed and l ml of 70% ethanol was added and mixed. The sample was 
centrifuged at 8000rpm for 5 minutes at 4°C and the supernatant was taken off. 
The RNA pellet was air dried for 10 minutes and dissolved in RNase-free water at 
55°C for 10 minutes. RNA was stored at -80°C. 
2.6.2 First strand cDNA synthesis 
Reactions were made up in RNase free tubes and contained 10µg total RNA from 
KMH2-LMP2A, -LMP2B or-Neo, 2µl diluted poly-A control (Affymetrix), 1µl 
(I OOpmol/µl) T7 (dT) 24 primer (Proligo, 
5'-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)24-3'), 
plus DEPC treated dH2O (Ambion) to a final volume of 11 pl. The sample was 
mixed by pipetting and given a short spin, then incubated at 65-70°C for 10 
minutes and put on ice. To each reaction was added 7µl of a master mix prepared 
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on ice with 4i1 (5x) First Strand Buffer (Invitrogen), 2µl DTT (0.1M, Invitrogen), 
1µl dNTPs (10mM, Invitrogen). After 2 minutes incubation, 1µl Superscript II 
Reverse Transcriptase (200U/ µl, Invitrogen) was added and incubated at 42°C for 
1 hour. Samples were then ready to proceed to "Second Strand Synthesis" or 
stored at -80°C. 
2.6.3 Second strand cDNA synthesis 
A master mix was prepared on ice in a new RNase free microfuge tube with 91µ1 
DEPC treated dH2O, 30µl (5x) Second Strand Buffer, 3µl dNTPs (10mM, 
Invitrogen), 11il E. coli DNA Ligase (IOU/µl, Invitrogen), 4p. 1 E. coli DNA 
Polymerase I (IOU/µl, Invitrogen), lµ1 E. coli RNAse H (2U/µl, Invitrogen) for 
each reaction. 130µ1 master mix was added to each "First Strand cDNA" reaction 
and incubated at 16°C for 2 hours. 2 µd T4 DNA Polymerase (5U/µl, Invitrogen) 
was added to each reaction and incubated at 16°C for 5 minutes. Finally, 10µl 
0.5M EDTA (Invitrogen) was added to each reaction after which the samples were 
ready to proceed to "Clean-up of double stranded cDNA" or were stored at -80°C. 
2.6.4 Clean-up of double stranded cDNA 
The Affymetrix Sample Cleanup Module was used to clean up cDNA following 
the instructions of the manufacturer. cDNA reaction mix was transferred to a 
1.5m1 tube and 600µ1 cDNA binding buffer was added. 500µ1 of the mixture was 
loaded to a cDNA cleanup spin column and spun for 1 min at full speed and the 
flow-through was discarded. The remainder of the mixture was loaded and spun 
as before. The column was transferred to a new collection tube and 750µ1 of wash 
buffer was applied to the column, which was spun at full speed and the flow- 
through was discarded. The column was centrifuged for 5min at maximum speed 
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with the cap opened. The column was transferred to a new 1.5m1 collection tube. 
14µl cDNA Elution buffer was directly loaded onto the spin column membrane 
and incubated for 1 min at room temperature, then spun for 1 min at full speed. 
Cleaned cDNA was ready for the in vitro transcription reaction or store at -80 ° C. 
2.6.5 Synthesis of cRNA by in vitro transcription 
An Affymetrix in vitro transcription (IVT) labelling kit was used for this step. All 
reagents and double stranded cDNA were thawed at room temperature. A master 
mix was prepared at room temperature containing, per reaction, 14µl DEPC 
treated dH2O, 4µl lOx IVT labelling Buffer, 12µ1 IVT labelling NTP mix, 4µl 
IVT labelling enzyme mix. 34µl of the master mix was added into each 6µl of 
previously prepared cDNA from KMH2-LMP2A, -LMP2B or -Neo and incubated 
at 37°C overnight. Samples were then ready to proceed to "Clean-up of cRNA" or 
were stored at -80°C. 
2.6.6 Clean-up of cRNA 
The Affymetrix Sample Cleanup Module was used to clean up the cRNA 
following the instructions of the manufacturer. 60µl RNase-free water was added 
to the IVT reaction and mixed. 350µl cRNA binding buffer was added, mixed, 
and then topped up to 250µl 100% ethanol. The mixture was loaded to the IVT 
cRNA cleanup column and spun at full speed for 15 seconds. Flow-through was 
discarded and the spin column was transferred to a fresh 2m1 collection tube. The 
column was washed with 500µ1 cRNA wash buffer and spun for 15 seconds at full 
speed. 500µl of 80% ethanol was applied to the column and spun for 15 seconds 
at full speed. The column was spun for 5minutes at maximum speed. 11 µl of 
RNase-free water was loaded directly onto the column membrane and after I 
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minute incubation was spun down for 1 minute at full speed. cRNA was measured 
using the Nanodrop spectrophotometer. cRNA was ready for the fragmentation 
step or stored at -80 ° C. 
2.6.7 cRNA fragmentation 
A 50µl reaction mix was made up in a PCR tube with 10µ1 (5x) Fragmentation 
buffer (200mM Tris-acetate, pH 8.1,500mM KOAc, 150mM MgOAc), 25µg 
cRNA and DEPC treated dH2O. The samples were incubated in a PCR machine at 
94°C for 35 minutes and put on ice immediately after the incubation. The samples 
were then ready to proceed to hybridization or stored at -80°C. An aliquot of the 
RNA, cRNA and fragmented cRNA of KMH2-LMP2A, -LMP2B or-Neo was run 
on a gel to check the RNA quality. 
2.6.8 Hybridisation 
Stocks of GeneChip Eukaryotic Hybridisation Controls, B2 oligo (provided with 
the GeneChip Eukaryotic Hybridisation Control kit, Affymetrix) were heated to 
65 °C for 5 minutes before aliquoting and use. 4Oµ1 (20µg) of fragmented cRNA 
from KMH2-LMP2A, -LMP2B or -Neo was added to 360µl of hybridization 
cocktail containing 7µl of B2 Oligo, 20x Hybridisation Cocktail (Affymetrix), 4µl 
of Herring Sperm DNA (10mg/ml, Promega), 4µl of Acetylated BSA (50mg/ml, 
Invitrogen), 2x Hybridisation Buffer, 4Oµ1 DMSO (Sigma-Aldrich), and 85µ1 of 
DEPC treated dH2O. 
U133 plus2 chips (Affymetrix) were warmed to room temperature before use. 
They were then filled with 250 µl of lx Hybridisation Buffer (see appendix 8.2.6) 
and incubated in the oven at 45°C for 10 with rotation at 60rpm. 
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The hybridisation cocktail was heated in a heating block at 99°C for 5 minutes 
then moved to a 45°C block for another 5 minutes. The samples were then spun at 
maximum speed in a microcentrifuge for 5 minutes. The buffer was removed from 
the pre-hybridised chips and replaced with 200µl of clarified hybridisation 
cocktail of KMH2-LMP2A, -LMP2B or-Neo. Arrays were incubated at 45°C for 
16 hrs with rotation at 60rpm. 
2.6.9 Washing and staining in the Fluidics station and scanning 
The washing, staining and scanning procedures were controlled using Affymetrix 
Gene Chip Operating Software (GCOS). The washing and staining process used 
an antibody amplification protocol and comprised 3 staining steps: 1St: SAPE 
(Streptavidin Phycoerythrin), 2nd: Antibody (biotinylated a-streptavidin) and 3`d: 
SAPE. SAPE was the fluorescent stain used and was stored in the dark at 4°C (in 
an amber tube). The SAPE stain solution was prepared fresh immediately before 
use. 
2.6.9.1 Preparation of the SAPE stain and antibody stain solutions 
1St and 3rd stain solution were the same. 600µ1 of SAPE stain was prepared for 
each array containing 300µl of 2x MES Stain buffer (Sigma, see Appendix 8.2.6), 
24µl of Acetylated BSA (50mg/ml, Invitrogen), 6 t1 of SAPE (1mg/ml, 
Cambridge biosciences) and 27Oµ1 of DEPC dH2O. 
600 µl of antibody solution for each array contained 300µ1 of 2x MES stain 
buffer, 24µl of Acetylated BSA (50mg/ml), 6µ1 of Normal goat IgG (10mg/ml, 
sigma), 3.6µl of a-streptavidin biotinylated antibody (goat, 0.5mg/ml, Vector 
Labs) and 266.4µl of DEPC H2O. 
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2.6.9.2 Washing and staining 
After16 hrs incubation, the hybridisation cocktail was removed from the chips and 
stored at -80°C for long-term storage. The array was filled with 250µ1 of Non- 
Stringent Wash Buffer A (See Appendix 8.2.6) (The array can be stored at 4°C for 
3 hrs at this step if necessary). Arrays were washed and stained on an Affymetrix 
FS400 fluidics station using protocol EukGE_WS2v5. 
2.6.9.3 Scanning 
Arrays were scanned using an Affymetrix Gene Chip Scanner 3000. GCOS 
software generates the primary scan intensity data (dat) files which are then 
automatically converted into "smoothed" cel files that can be further analysed by 
GCOS or other array analysis packages. 
2.6.10 Statistical significance of differential expression 
The Affymetrix system of gene expression quantification was used. Three 
biological replicate experiments comparing KMH2-Neo gene transcription with 
either KMH2-2A or KMH2-2B cells were performed. Following hybridisation 
and scanning of arrays, scanned image of microarray chips were analysed using 
the GCOS (GeneChip Operating Software) from Affymetrix, Inc. (Santa Clara, 
California, USA) with the target signal set to 100. Probe level quantile 
normalisation (Bolstad et al., 2003) and RMA (robust multi-array analysis) 
(Irizarry et al., 2003) were preformed using the affymetrix package of the 
Bioconductor project (http: //www. bioconductor. ora). Differentially expressed 
probe sets were identified using the rank products method (Breitling et al., 2004; 
Breitling and Herzyk 2005) of the RankProd package in Bioconductor following 
RMA with the PFP (percentage of false-positives) threshold set to 10%. Gene 
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expression heat maps were generated using dChip (http: //www. dchip. org) with the 
default settings. Genes with changes in differential expression values of two fold 
or greater, probability values less than 0.05, and Affymetrix calls other than no 
change were considered statistically significant. 
2.7 Cloning of DNA in bacterial plasmids 
2.7.1 Design primers using software Prophet 
Expression vector pCDNA4His/maxA (Invitrogen), containing a polyhistidine 
tag, CMV promoter, ZeocinTM resistance gene, Enterokinase recognition site, 
Multiple cloning sites, Ampicillin resistance gene, SV40 promoter and origin, was 
used for making LMP2 plasmids. LMP2A, LMP2A-N and LMP2B primers were 
designed using software Prophet including the two cloning site sequences of the 
vector. Two restriction sites, KpnI and Xbal were selected and the sequence of 
KpnI (GGTACC) was added to forward primers and Xbal (TCTAGA) to reverse 
primers. The map of the vector used for making the plasmids is given in Figure 
2.1. 
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Figure 2-1 Map pcDNA4/HisMax A vector 
The expression vector, pcDNA4/HisMax A, was used to make all three LMP2 
constructs, LMP2A, LMP2B and LMP2A-N. 6-polyhistidine tag is circled in red 
as are restriction sites for Kpn I and Xba I in the map of the vector. 
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Comments for pcDNA4/HisMax© A: 
5258 nucleotides 
CMV promoter: bases 232-819 
T7 promoter/priming site: bases 863-882 
QBI SP163 translational enhancer: bases 917-1079 
ATG initiation codon: bases 1080-1082 
Polyhistidine tag: bases 1092-1109 
XpressTM epitope: bases 1149-1172 
Enterokinase recognition site: bases 1158-1172 
Multiple cloning site: bases 1172-1245 
BGH reverse priming site: bases 1265-1282 
BGH polyadenylation sequence: bases 1268-1495 
fl origin: bases 1541-1969 
SV40 promoter and origin: bases 1996-2305 
EM-7 promoter: bases 2353-2408 
ZeocinTM resistance gene: bases 2427-2801 
SV40 polyadenylation sequence: bases 2931-3061 
pUC origin: bases 3444-4117 
Ampicillin resistance gene: bases 4262-5122 
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2.7.2 PCR for LMP2A, LMP2B and LMP2A-N 
ing of pSG5-LMP2A plasmid DNA (kindly provided by Professor Richard 
Longnecker, North Western University, Chicago) was used as a template for PCR 
amplification of LMP2A, LMP2B and LMP2A-N. Different concentrations of 
MgC12,1.0 mM, 1.5 mM, 2.0 mM, and 2.5 mM were used to optimise the PCR 
condition. 5µl of lOx reaction buffer (50mM KCI, 10mM Tris-HC1, pH 8.3), 0.25 
mM each of dATP, dCTP, dGTP and dTTP, 1.0 µM each of forward and reverse 
LMP2 primers and 5 units of Red Hot DNA polymerase were added in a 5011 
reaction volume. Samples were subjected to 5 cycles of denaturing at 94°C for 30 
seconds, annealing at 50°C for 30 seconds and extension at 72°C for 2 minutes, 
then 35 cycles of denaturation at 94°C for 30 seconds, annealing at 65°C for 30 
seconds and extension at 72°C for 2 minutes with a final extension phase at 72°C 
for 10 minutes. 
2.7.3 Purification of PCR products 
100µ1 of PCR products were purified using PCR purification Kit (Qiagen); 
following the protocol provided by the manufacturer. DNA was eluted in 50111 
elution buffer, and then measured using a UV-spectrophotometer. 
2.7.4 Restriction of vector and LMP2 DNA 
3x 3µg of pCDNA4His/maxA vector DNA and 3µg of each of LMP2A, LMP2B 
or LMP2A-N DNA were aliquoted to labelled 0.5ml tubes. The restriction 
reaction contained 4p1 of 10x restriction buffer, 20 units of each enzyme, KpnI 
and Xbal and dH2O to 4Oµ1. The samples were incubated at RT overnight. Results 
were checked by running 1.5% agarose gels and visualised under UV light. 
Correctly size bands of DNA were cut for purification. 
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2.7.5 Purification of restricted DNA 
Sterile empty eppendorfs were weighed and labelled. Bands were cut under UV 
light and placeed into the corresponding tubes. DNA was purified using a gel 
purification kit (Qiagen) according to the protocol provided by the manufacturer. 
DNA was eluted in 25µl elution buffer, measured using a spectrophotometer and 
prepared for dephosphorylation and ligation. 
2.7.6 Dephosphorylation of vector DNA using Shrimp Alkaline Phosphatase 
(SAP) 
15µl of purified vector DNA was added to a 0.5 ml eppendorf tube on ice with 2.7 
µl SAP (Roche), 2.7µl of 10 x buffer and 6µl of sterile dH2O to make a total 
volume of 27µl. After mixing and a short centrifugation, the reaction mixture was 
incubated at 37°C for 1 hour, followed by 65°C for 15minutes to denature the 
enzyme. The vector was ready for ligation. 
2.7.7 Ligation 
50ng of dephosphorylated vector was used for each reaction. The volume of 
purified DNA from LMP2A, LMP2B and LMP2A-N calculated according to their 
molecular weight and the equation below were placed into the corresponding 
0.5m1 tubes on ice. l011 of 2x buffer plus water were added to each 20gl reaction. 
The reactions were incubated at RT for 15 minutes, and then at 4°C overnight. 
Equation 2-1 inserted DNA is required: 
(ng) vector x (Kb) insert / (Kb) vector x3 
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2.7.8 Transformation 
DH5a bacteria were thawed and the ligated DNA chilled on ice. PUC19 plasmid 
DNA (Invitrogen, working concentration 50ng/µl) was used as a positive control. 
50µl of bacteria were added to each tube together with 20µ1 of ligated DNA. 
Samples were mixed and chilled on ice, then incubated at 42°C water bath for 90 
seconds and put back on ice immediately. 500µ1 L-broth solution (10g L-Broth 
powder in 500 ml distilled H2O, autoclaved) was added to each tube; mixed and 
incubated at 37°C for 1 hour (vortexed 2-3 times). LB plates (IOg L-Broth powder 
and 7.5g of Nutrient Agar in 500 ml distilled H2O, autoclaved) with Ampicillin 
(100µg/ml) were put into a 37°C incubator (the lids were left slightly open to 
allow dissipation of steam). 2O0µ1 of each reaction solution was plated onto its 
corresponding plate under flame with a sterile glass rod. All the plates were 
incubated upside down in a 37°C incubator overnight. 
2.7.9 Cloning 
Clones were checked and selected the next day. 3ml of LB solution containing 
Ampicillin was added to 15m1 tubes and labelled. Big, round single clones were 
picked under flame with sterile pipette tips and put into the tubes. All tubes were 
put into a 37°C shaker and left overnight. 
2.8 Amplification and purification of plasmid DNA 
2.8.1 Small scale preparation of plasmid DNA 
1.5m1 of each of the bacteria culture solution was poured into an eppendorf and 
centrifuged at full speed for 2 minutes at 4°C. Supernatant was removed by 
aspiration and the bacterial pellet was left as dry as possible. The bacterial pellet 
was resuspended in 100µl of ice-cold solution I (See Appendix 8.2.1) by vigorous 
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vortexing. 200µl of freshly prepared solution II (See Appendix 8.2.1) was added 
and the tube was closed tightly, mixed by inverting the tube rapidly five times and 
stored on ice. 150gl of ice-cold solution III (See Appendix 8.2.1) was added and 
vortexed gently in an inverted position for 10 seconds to disperse Solution III 
through the viscous bacterial lysate. The tube was stored on ice for 10 minutes. 
Samples were centrifuged at full speed for 5 minutes at 4°C, and then the 
supernatant was transferred into a fresh tube. 210µl of phenol and 210µd of 
chloroform was added and mixed by vortexing. After centrifuging at full speed for 
2 min at 4°C in a microcentrifuge, supernatant was transferred into a fresh tube. 
The double-stranded DNA was precipitated with two volumes of absolute ethanol 
(about 90011), mixed by vortexing and put into -20°C freezer for 30 minutes. 
Samples were centrifuged at full speed for 5 minutes in a 4°C microcentrifuge and 
the supernatant was removed by gentle aspiration. The pellet of double-stranded 
DNA was rinsed with lml of chilled 75% ethanol. The supernatant was removed 
by gentle aspiration and the pellet of DNA was left to dry in the air for 10 
minutes. The DNA was redissolved in 50µ1 of elution buffer (TE buffer). DNA 
was ready for sequencing. 
2.8.2 Large scale preparation of plasmid DNA 
For this the Plasmid Maxi Prep 500 Kit (Qiagen) was used. A single colony of 
transformed bacteria was picked and grown overnight in a2 ml shaking culture of 
L-Broth containing Ampicillin (50µg/ml) and incubated overnight at 37°C. 250µl 
of this initial starter culture was then used to inoculate 250mis of L-broth with 
ampicillin (50µg/ml) and this culture incubated overnight at 37°C. The bacterial 
culture was centrifuged at 6000rpm for 15 minutes at 4°C. The supernatant was 
decanted off and the bacterial pellet resuspended in 10 ml of buffer P l. The 
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suspension was then incubated with 10ml of buffer P2 and mixed by inverting 4-6 
times and incubated at room temperature for 5 minutes. To this suspension 10 ml 
of chilled buffer P3 was added and gently mixed by inverting 4-6 times and 
incubated on ice for 20 minutes. The suspension was centrifuged at 12,000rpm for 
30 minutes at 4°C. The supernatant was removed and centrifuged at 12,000 rpm 
for another 15 minutes at 4°C. The supernatant was then harvested. A Qiagen-tip 
500 was equilibrated with 10ml of buffer QBT and allowed to flow through by 
gravity flow. The flow through was discarded and the column was washed twice 
with 30 ml of buffer QC. The flow through was discarded and the DNA eluted 
from the column with 15m1 of buffer QF. The DNA was precipitated from the 
supernatant by adding 10.5m1 of room temperature isopropanol. This was mixed 
and centrifuged at 11,000rpm for 30 minutes at 4°C. The supernatant was then 
carefully removed without disturbing the pellet. The DNA pellet was washed with 
5 ml of 70% ethanol and centrifuged at 11,000rpm for 10 minutes. The 
supernatant was again carefully removed without disturbing the pellet. The pellet 
was then allowed to air dry for 5-10 minutes and redissolved in TE buffer. The 
DNA concentration and quality was then checked using a spectrophotometer 
(Genequant, Pharmicia) 
2.9 DNA Sequencing 
2.9.1 Labelling with fluorescent dye and precipitation of products 
Sequencing was performed using the 3100 capillary sequencer from PE Applied 
Biosystems. The labelling reactions were set up using 30-50ng of PCR products, 
lul (3.2pmol) primer, 2µl of Big-DyeTM Terminator Cycle Sequencing Ready 
Reaction kit (PE Applied biosystems) and 6µl of 2.5x sequencing buffer (200 
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mM Tris HCI, 5mM MgC12 pH 9.0). The labelling PCR was carried out for 25 
cycles at 96°C for 10 seconds, 50°C for 5 seconds and 60°C for 4 minutes. The 
labelled products were precipitated with 50µl of 95%(v/v) ethanol and 2µl of 3M 
sodium acetate pH 4.6 in 0.5 ml tubes at room temperature for 30-60 minutes. The 
samples were then micro-centrifuged at full speed for 20 minutes at 4°C. The 
supernatant was removed and the pellets washed by adding 250µl 70% (v/v) 
ethanol and gentle flicking followed by spinning at full speed for 5 minutes. The 
supernatant was then removed and the pellets dried for 30-60 minutes. 10µl of Hi- 
Dye TM (PE Applied Biosystems) was added and the pellet dissolved. 
2.9.2 The 3100 ABI prism DNA capillary sequencer (PE Applied Biosystems) 
Samples were denatured at 95°C for 5 minutes and put on ice for 2 minutes before 
being left at RT ready for use. The buffer chambers were first filled with 2.5x 
EDTA buffer (PE Applied Biosystems) and the water chambers filled 
accordingly. 3100 POP 6TM Performance Optimized Polymer was used to fill the 
50cm sequencer capillary array (PE Applied Biosystems). The 3100 data 
collection software version 1.0 was set for sequencing at: Dye Set, Z; Mobility 
file, DT3100POP6 (BD) v3. mob; BIOLIMS: Project, 3100 Projectl; 
RunModulel, StdSeg50_POP6DefaultModule and analysis Module 1, BC- 
3100_SegOff. saz. The samples were loaded into the appropriate 96 well plates 
and run for approximately 2.5 hours. Following the run, the extracted samples 
were analysed using the ABI sequencing analysis version3.6.1 software and 
results were checked using BLAST (http: //www. ncbi. nlm. nih. govBLAM 
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2.10 Transfection of mammalian cells with plasmid DNA 
2.10.1 Transfection of LMP2 plasmids into 293 cells using lipofectamine 2000 
and Zeocin drug selection 
293 cells were maintained in RPMI DMEM-Hepes medium supplemented with 
10% FCS, 2mM L-glutamine, and 1% penicillin/streptomycin solution. The day 
before transfection, 293 cells were trypsinized, counted and plated into 6-well 
plates to make sure that the confluence of the cells would be 90% on the day of 
the transfection. Antibiotics were avoided during the cell plating. The DNA and 
lipofectamine reagent were diluted with Opti-MEMR I Reduced-Serum Medium 
(Invitrogen) in separate tubes and incubated at RT for 15 minutes. The diluted 
DNA and lipofectamine reagent were combined and mixed well, then incubated at 
RT for 20 minutes. Mixed complexes were gently added into the corresponding 
cell medium and incubated at 37°C for 3 hours. After 3 hours incubation, the fresh 
medium was topped up to bring the final concentration of serum to normal growth 
medium. The day after transfection, cells were passaged into fresh medium and 
the following day, Zeocin (500µg/ml, Invitrogen) was added to select the stably 
transfected cells. It took several weeks to select the 293 cells stably expressing 
LMP2. 
2.11 Purification of LMP2 proteins with Ni-NTA beads 
LMP2A-transfected 293 cells were washed twice in ice-cold PBS and then 
collected by scraping into 3 ml ice-cold PBS. The cells were pelleted by 
centrifugation at 1500rpm for 5 minutes at 4°C. The cell pellet was lysed in 1% 
Triton lysis buffer (pH 8.0) in ice for 30 minutes, and the cell debris pelleted by 
centrifugation at 13000rpm for 10 minutes at 4°C. Protein concentration was 
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determined using the Biorad protein assay. Ni-NTA beads were washed twice 
with pH 8.0 washing buffer with 20mM imidazole. lmg protein was incubated 
with 100 µl of 50% v/v washed Ni-NTA beads at 4°C with rotation for 2 hours. 
The samples were then centrifuged briefly to pellet the Ni-NTA beads and the 
flow-through supernatants transferred to fresh tubes for immunoblotting. The 
beads were washed three times with the same washing buffer. Following the final 
wash, the beads were drained with a fine gauge needle and then the proteins were 
eluted with 100µl of pH 8.0 elution buffer with different concentrations of 
imidazole (100mM, 150mM, 200mM, 250mM) and 0.1% EDTA (pH 8.0). 20gl of 
each eluted protein was loaded for immunoblotting and the membrane was blotted 
with anti-His antibody (1: 1000). To reduce elution of non-specific proteins, the 
concentration of imidazole in washing buffer was increased to 50mM. 
2.12 Stable isotope labelling with amino acids in cell culture (SILAC) 
2.12.1 The principle of SILAC 
293-Zeo cells and 293-2A or 293-2B cells were cultured in media containing 
[12C6]-Arginine and [13C6]-Arginine, respectively and protein lysates were made. 
His-tagged protein from 293-Zeo were mixed at a 1: 1 ratio with protein from 293- 
2A or 293-2B, creating two samples that were then purified with Ni-NTA beads. 
Ni-NTA was used as a bait to enrich His-tagged LMP2 proteins and its binding 
partners. Eluted proteins were boiled in SDS-PAGE sample buffer, resolved on a 
4-21% Tris-glycine gel, and lightly stained using Coomassie Blue. The gel lane 
was excised and cut horizontally into 10 sections of similar size. Proteins were 
digested by trypsin; peptides were extracted with 5% formic acid and analysed by 
mass spectrometry. The ratio of peptide intensities produced from the light and 
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heavy peptides in the MS spectra were determined. The fragmentation pattern of 
the ions in the MS/MS analysis and the mass of the parent peptide were then used 
to search human and EBV databases from NCBI using TurboSequest search 
engines to identify the peptide sequence and to assign the peptide to a particular 
protein. The 6 Da increase in the mass of the heavy peptides was taken into 
account in the search by including a6 Da modification on the Arginine residues. 
Protein abundances were calculated as ratios of the areas of the monoisotopic 
peaks of the light versus the heavy peptides. An outline of the SILAC method is 
shown in Figure 2.2 
90 
Material and Methods 
Figure 2-2 Schematic of the SILAC method 
293-Zeo cells and 293-2A or 293-2B cells were cultured in media containing 
[12C6]-Arginine and [13C6]-Arginine, respectively and protein lysates were 
made. His-tagged protein from 293-Zeo were mixed at a 1: 1 ratio with protein 
from 293-2A or 293-2B, creating two samples that were then purified with Ni- 
NTA beads. Ni-NTA was used as a bait to enrich His-tagged LMP2 proteins and 
its binding partners. Eluted proteins were resolved on SDS-PAGE gel and lightly 
stained using Coomassie Blue. 10 excised sections of gel were digested by trypsin; 
peptides were extracted with 5% formic acid and analysed by mass spectrometry. 
The fragmentation pattern of the ions in the MS/MS analysis and the mass of the 
parent peptide were then used to search human and EBV databases from NCBI 
using TurboSequest search engines to identify the peptide sequence and to assign 
the peptide to a particular protein. The 6 Da increase in the mass of the heavy 
peptides was taken into account in the search by including a6 Da modification on 
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2.12.2 Preparing medium 
5m1 glutamine (Sigma) and 75m1 dialysed FCS (Invitrogen) was added to 500ml 
of DEME+HEPES medium (no Arginine, Sigma) and mixed. The medium was 
split into two labelled sterile bottles. 29mg of normal [12C6]-Arginine (Cambridge 
Isotope Inc) was added to one bottle and 29mg of [13C6]-Arginine (Cambridge 
Isotope Inc) to the other to obtain the final concentration of 100 mg/L arginine. 
2.12.3 Labelling cells and purifying proteins 
2 x108 His-tagged 293-2A or -2B cells were grown in the medium containing 
[1306] - Arginine and His-tagged 293-Zeo cells were grown in medium containing 
normal [12C6]-Arginine. After at least 5 passages, cells were lysed in buffer 
containing 1% (v/v) Triton 100,300 mM NaCl, 50mM NaH2PO, 10mM 
imidazole, pH 8.0 and protease inhibitors (Roche). Lysate of 293-Zeo was mixed 
with lysate from 293-2A or 293-2B in a 1: 1 ratio according to their protein 
concentrations and incubated for 2 hours at 4°C with Ni-NTA beads (Qiagen). 
Beads were washed with washing buffer (See Appendix 8.2.5), boiled in SDS 
sample buffer and resolved on a 4-21% (wtlvol) Novex gel (Invitrogen). 
2.12.4 Colloidal Coomassie Staining 
2.12.4.1 Preparation of staining solution 
The staining solution was prepared by dissolving 40g of ammonium sulphate in 
384m1 of distilled water with 8m1 of orthophosphoric acid. 5% Coomassie 
Brilliant Blue G250 (Sigma) was prepared by mixing thoroughly 0.5g of dye and 
10ml of distilled water. 8m1 of this dye solution was added to the ammonium 
sulphate/phosphoric acid. The final concentration was 0.08% Coomassie Brilliant 
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Blue G250,1.6% Orthophosphoric Acid, 8% Ammonium Sulphate and 20% 
Methanol. 
2.12.4.2 Coomassie Staining and destaining 
After the gels were run they were placed directly into freshly prepared staining 
solution, which also fixes the proteins. The gel was placed on a shaking platform 
in a closed box at RT and left to stain overnight. After the staining solution was 
poured off, the gel was rinsed twice with water to remove excess stain and then 
placed in 1% acetic acid, which was changed regularly to speed up destaining. 
The gel background became completely clear eventually, whilst the proteins 
remained blue. 
2.12.5 In gel digestion 
2.12.5.1 Water wash 
The bands were excised and placed into the pre-washed Eppendorf tubes (rinsed 
with 0.1% formic acid dissolved in 50: 50 water: acetonitrile and dried down), and 
300µl of distilled/deionised water added. After 15 min the water was removed 
carefully using a pipette with a fine tip. This step removes the acetic acid 
contained in the destaining solution. 
2.12.5.2 Wash and pHequilibration 
l00µ1 of 50mM ammonium bicarbonate in 50% acetonitrile was added to each 
tube and incubated, with shaking for 45 min at 37°C. The above step was repeated 
twice to ensure complete equilibration. After the supernatant was removed the gel 
was dried down using a vacuum rotary evaporator to remove the liquid from the 
gel. 
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2.12.5.3 Reduction Step, carboxymethylation and Wash 
50µ1 of 50mM DTT (made up fresh in 100mM ammonium bicarbonate in 10% 
acetonitrile) was added to the dried gel and incubated for 1 hour at 60°C and the 
supernatant removed. 50µl of 100mM iodoacetamide (made up fresh in 100mM 
ammonium bicarbonate in 10% acetonitrile) was added and the tube was 
incubated for 30 minutes at RT in the dark. The supernatant was removed and the 
gels washed as follows; 100µl of 40mM ammoniun bicarbonate in 10% 
acetonitrile was added and incubated for 15 minutes at RT, with shaking and then 
the supernatant removed. This wash was performed 3 times before the gel was 
completely dried again using a vacuum rotary evaporator. 
2.12.5.4 Trypsinization 
The gel was rehydrated using 40pl of 12.5µg/ml sequencing grade modified 
trypsin (Promega) dissolved in 40mM ammonium bicarbonate/10% acetonitrile 
for 1 hour at RT. After the gel was completely re-swelled, 40µl of 40mM 
ammonium bicarbonate in 10% acetonitrile was added and incubated at 37°C 
overnight. 
2.12.5.5 Harvesting the Tryptic Peptides 
The supernatant was carefully removed and replaced with 30µl of 3% formic acid 
in water, incubated for an hour at 37°C and this solution collected and added to 
the initial supernatant. Another 3Oµ1 of 3% formic acid in water was added and 
after incubation for 1 hour, the final supernatant was harvested and pooled with 
the other two. The approximate volume of the combined supernatants was l00µl. 
This solution was ready for direct analysis using an LC-MS/MS based system. 
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2.12.6 Mass Spectrometric analysis 
85µ1 of the peptides were separated on a 75µm i. d. 15cm long C18 PepMap 
reverse phase column (3 µm particle size) (Dionex) using a 5% - 37.5% solvent B 
gradient over 40min (solvent A=5% acetonitrile/0.1% formic acid and solvent B= 
95% acetonitrile/0.1% formic acid) at 200nL/min using a Dionex/LC Packings 
Famos/Switchos/Ultimate nanobore HPLC system. The separated peptides were 
sprayed, using electrospray ionization, directly into a ThermoFinnigan LCQ Deca 
XP Plus ion-trap mass spectrometer via a nasnospray source equipped with a 10 
pM uncoated emmiter tip. A charge of 1.3Kv was applied directly to the liquid 
stream and the mass of the peptide determined in the initial MS analysis and this 
data was used to select ions for MS/MS analysis. The most abundant 5 ions for 
each full scan were analysed sequentially before another full scan was performed. 
The fragmentation spectra were analysed using TurboSequest as part of the 
BioWorks 3.1 suite of data analysis programs and Xcalibur software package. 
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3 Generation and validation of LMP2A or LMP2B expressing Hodgkin's 
lymphoma cell lines 
3.1 Introduction 
Hodgkin's lymphoma differs from other lymphomas because it is characterized by 
rare tumour cells that are surrounded by many more infiltrating cells of the 
immune system (Kanzler et al., 1996; Weiss et al., 1999; Köppers and Hansmann, 
2005). Approximately half of Hodgkin's lymphomas have EBV DNA within the 
tumour cells and LMP2 is consistently expressed in all EBV positive cases 
(Küppers et al., 2004; Young and Rickinson, 2004). This suggests that LMP2 
plays an important role in the pathogenesis of HL. However, the exact function of 
LMP2 in HL still remains unknown. Most research on LMP2 has been performed 
on other B cells and little has been undertaken on HL cells. 
LMP2A is a transmembrane protein that functions to inhibit normal B-cell signal 
transduction by mimicking an activated B-cell receptor (BCR) (Miller et al., 1995, 
Portis et al., 2002). Paradoxically, LMP2A can provide survival signals to B cells 
in vivo, where expression of an LMP2A transgene in mice allows BCR-negative 
cells to exit the bone marrow and survive in peripheral lymphoid organs (Caldwell 
et al., 1998). A recent DNA microarray study demonstrated that LMP2A induced 
alterations in cellular gene expression similar to those previously described to be 
characteristic of HRS cells. These included the downregulation of B cell lineage 
markers and transcription factors important for normal B-cell development, e. g. 
Syk, BLNK (Portis et al., 2003; Schwering et al., 2003). This suggests that 
LMP2A might make an important contribution to the pathogenesis of HL. 
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The study of the function of LMP2 in HL has been hampered by the lack of in 
vitro systems. Therefore in order to investigate the function of LMP2A and 
LMP2B in HL, it is important to generate the appropriate cell line models. 
Most B lymphoma cell lines including those of HL cannot be transfected easily; 
this is especially true in the case of LMP2A and LMP2B, which are 
transmembrane proteins and toxic to cells. Several nonviral approaches have been 
attempted to enhance the transfection efficiency of lymphoma cells; include these 
the gene gun (Burkholder et al., 1991), electroporation (Lenz et al., 2003; 
Brielmeier et al., 1998), Lipofection (Zelphati et al., 2001, ) and a novel 
electroporation-based technique, termed nucleofection (Thiel et al., 2001). 
However, transfection efficiency is problematic for all these physical approaches 
(Brielmeier et al., 1998, Coonrod et al., 1997). It was reported that B-lymphoma 
cell lines and primary lymphoma cells can be efficiently transduced using an 
adenoviral vector system (Buttgereit et al., 2000); this suggests this approach 
might be a feasible approach to obtain LMP2 expression in HL cell lines. 
Retroviral packaging cell lines producing LMP2A, LMP2B, or the neomycin 
control retrovirus were used for the transduction of established epithelial cell lines 
(Allen et al, 2005; Dawson et al., 2001). The advantages of using retroviral 
transduction over standard DNA transfection are several folds. First, the retroviral 
transduction is more efficient and more reliable than lipid or electroporation-based 
transfection methods. Second, the retroviral method produces a polyclonal 
population of cells that overcomes concerns over clonal selection. Third, and once 
the stable retroviral packaging cell lines are established, an unlimited supply of 
retrovirus can be obtained. 
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Aims of this study: 
1. To generate HL cell lines stably expressing LMP2A and LMP2B. 
2. To investigate the impact of LMP2A and LMP2B on cellular phenotype 
using growth and viability assays. 
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3.2 Results 
3.2.1 Generation of LMP2A- and LMP2B-expressing KMH2 and L428 cell 
lines and confirmation of expression at the RNA level 
The A13 stably transfected packaging cells with the retrovirus carrying vector 
pLNSX (Neo), pLNSX-LMP2A and pLNSX-LMP2B plasmids were seeded into 
6cm Petri dishes and the recombinant retroviruses produced by these cells were 
shed into the surrounding media. The conditioned media containing retrovirus 
carrying empty vector pLNSX control (Neo), pLNSX-LMP2A or pLNSX- 
LMP2B were collected after 48 hours incubation, and used to transduce KMH2 
and L428 cell lines. The cells stably transduced with retroviruses carrying Neo, 
LMP2A and LMP2B were grown in RPMI 1640 medium under pressure of G418 
(1mg/ml) drug selection, along with parental KMH2 and L428 cells. Parental cells 
died off in one week of drug selection. 1 clone of Neo, 5 clones of LMP2A and 1 
clone of LMP2B were generated from each HL cell line. 
Table 3-1 Key to the nomenclature of cell lines generated in this study 






KMH2 K-Neo K-2A1 K-2A2 K-2A3 K-2A4 K-2A5 K-2B 
L428 L-Neo L-2A1 L-2A2 L-2A3 L-2A4 L-2A5 L-2B 
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3.2.1.1 Confirmation of the expression of LMP2A in the transduced HL cell 
lines, KMH2 and L428 by RT-PCR 
Transduced cells were harvested two weeks post infection. RNA was extracted 
and cDNA was made with a specific LMP2A reverse primer. The LMP2-positive 
LCL cell line, X50-7, was used as positive control. All 5 clones of infected 
KMH2 and L428 were LMP2A positive, but the expression level of LMP2A was 
variable; clones K-2A1, K-2A4 and K-2A5 showed higher levels of LMP2A 
expression than the others (Figure 3.1A). For L428 cells, clones L-2A1, L-2A4 
and L-2A5 showed the strongest expression and clone L-2A2 the weakest one 
(Figure 3.1B and Q. As expected, parental KMH2 and L428 cells showed no 
expression of LMP2A. X50-7 cells expressed LMP2A at higher levels when 
compared to all of newly infected KMH2 and L428 cells. RT-PCR for GAPDH 
showed equal loading for all samples. 
RT-PCR for LMP2A was repeated 6 weeks post infection. Interestingly, this time 
the expression of LMP2A in all 5 clones of KMH2-LMP2A and L428-LMP2A 
was the same and stronger than at two weeks post infection. Furthermore, after 5 
months the expression of LMP2A remained at the same level as that detected at 6 
weeks. Thus, except after the initial phase when expression increased, the 
expression of LMP2A in the infected cell lines remains stable over time. 
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Figure 3-1 Expression of LMP2A in transduced HL cell lines, KMH2 and 
L428 two weeks post infection 
RNA was extracted from 5 clones of LMP2A transduced KMH2 and L428 cells 
(K-2A1-5, L-2A1-5), A single clone of each empty vector transduced KMH2, 
L428 cells (K-Neo, L-Neo), parental KMH2, L428 cells, and X50-7 cells. 
(A) All 5 clones of infected KMH2 and L428 cells were LMP2A positive, but the 
expression level of LMP2A was variable; clones K-2A1, K-2A4 and K-2A5 
showed higher levels of LMP2A expression than the others. 
(B and C) For L428 cells, clones L-2A1, L-2A4 and L-2A5 showed the strongest 
expression and clone L-2A2 the weakest. Parental KMH2, L428, K-Neo, L-Neo 
cells and negative controls showed no expression of LMP2A. X-50-7 cells 
expressed LMP2A at higher levels compared to all of newly infected KMH2 and 
L428 cells. RT-PCR for GAPDH was run at the same time as a loading control. 
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Figure 3-2 Comparison of LMP2A expressing KMH2 and L428 cells at 6 
weeks and 5 months post infection 
The expression of LMP2 was confirmed by RT-PCR at 6 weeks and 5 months 
post infection. 
(A) At 6 weeks, the expression of LMP2A in all the 5 clones of KMH2-LMP2A 
and L428-LMP2A was the same and stronger than at two weeks (K-2A1 at 2 
weeks is included as a baseline). 
(B) Comparison of the samples K-2A1 and L- 2A1 6 weeks post infection with 
the corresponding samples 2 weeks post infection, clearly demonstrated this 
difference (3.2 B). 
(C) Furthermore, the expression of LMP2A remained at the same level after 5 
months in culture. Thus, after the initial phase, the expression of LMP2A in 
infected cell lines remains stable over time. RT-PCR for GAPDH was run along 
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3.2.1.2 Confirmation of the expression of LMP2B in transduced KMH2 and 
L428 cells 
KMH2 and L428 cells expressing LMP2B were generated in the same way as 
described above for LMP2A. RNA was extracted from 1 clone each of LMP2B 
transduced KMH2 and L428 cells (K-2B 1, L-2B 1), 1 clone each of empty vector 
transduced KMH2 and L428 cells (K-Neo, L-Neo), parental KMH2 and L428 and 
X50-7 cells. cDNA was made with a specific LMP2B reverse primer. The 
expression of LMP2B was detectable two weeks post infection in both cell lines, 
but was weaker than in X50-7 cells (Figure3.3A). 
The expression of LMP2B in KMH2 cells 6 weeks post infection was stronger 
than at two weeks, was unchanged at 5 months, but was never as strong as in X50- 
7 cells. K-Neo and negative control showed no expression of LMP2B (Figure 3.3 
B). Likewise, the expression of LMP2B in L428 cells was stronger at 6 weeks and 
5 months post infection compared with 2 week time point (Figure 3.3 C). 
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Figure 3-3 Expression of LMP2B in transduced KMH2 and L428 cells 
(A)Expression of LMP2B was detectable two weeks post infection in both cell 
lines, but was weaker than that of X50-7 cells. 
(B) The expression of LMP2B in KMH2 cells was increased 6 weeks post 
infection compared to 2 weeks and was unchanged at 5 months. 
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3.2.2 Confirmation of expression of LMP2A and LMP2B protein in retrovirus 
transduced KMH2 and L428 cells 
Having determined that the transduced cells expressed LMP2A and LMP2B 
mRNA, cells were tested for expression of the respective proteins. To do this 
immunofluorescence staining was performed using serum from an NPC patient 
(Bala), which contains antibodies to LMP2A and LMP2B proteins (Dawson et al., 
2001). Size 12 Teflon-coated slides (Hendley-Essex) were autoclaved and coated 
with 50 µl of fibronectin in a sterile petridish at 4°C overnight. 50µl of a cell 
suspension was loaded onto each well of the slide and incubated at 37°C 
overnight, fixed with 4% PFA (Paraformaldehyde) for 10 minutes and 
permeabilized with 0.1% (vol/vol) TritonX-100 for 2 min. Primary and secondary 
antibody incubations were lh each, and the slides were washed twice with PBS 
between each of incubations. Coverslips were mounted on glass slides and imaged 
using a UV microscope. LMP2A transduced KMH2 and L428 cells showed strong 
granular membrane staining, but the staining of LMP2B was much weaker. 
Control KMH2-Neo and L428-Neo cells were negative as expected (Figure 3.4). 
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Figure 3-4 Confirmation of expression of LMP2A and LMP2B protein in 
retrovirus transduced KMH2 and L428 cells 
NPC patient serum (Bala) was used as primary antibody (1: 50 dilution) and then 
visualized with Goat-anti-human FITC (1: 1000). K-2A and L-2A cells showed 
bright, granular membrane staining, but the K-2B and L-2B cells were more 
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3.2.3 Impact of LMP2 expression on the growth and survival of HL cells 
3.2.3.1 Proliferation assay 
The WST-1 cell proliferation assay was performed on the LMP2A, LMP2B or 
Neo transduced KMH2 and L428 cells two weeks post infection (See section 
2.5.1). 5x 104 Cells from each cell line were washed in serum-free media, 
resuspended in RPMI medium containing 1%, 5% and 10% B-cell serum (BCS). 
The WST-1 reagent measures the activity of mitochondrial dehydrogenases in the 
sample. The tetrazolium salts in the reaction are cleaved to formazan, and the 
augmentation in enzyme activity leads to an increase in the amount of formazan 
dye formed, which directly correlates with the number of metabolically active 
cells in the culture. All quantifiable data were subjected to statistical analysis in 
MicrosoftC' Excel using a two-tailed student's T-test assuming the two samples 
displayed unequal variance. The p-values indicated a significant difference 
between the data sets when the p-value was <0.05. The error bars on charts 
represent the standard error of the mean for each triplicate data set. 
In 10% and 5% serum concentrations LMP2A or LMP2B expressing cells showed 
very little differences on cell proliferation compared with Neo control cells 
(Figure 3.5 and 3.6). In 1% serum LMP2A expressing KMH2 cells showed lower 
cell proliferation at the later time points. This might reflect a toxic effect of high 
level LMP2A expression in KMH2 cells in low serum. 
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Figure 3-5 Cell proliferation of K-2A, K-2B and K-Neo expressing cells 
5x 104 cells from each cell line were pelleted at 1500 rpm for 5 minutes and 
resuspended in 5 ml PBS. Cells were washed three times with PBS to remove any 
trace of serum. Finally, cells were resuspended in 2 ml of growth medium 
RPMI1640 containing glutamine, penicillin/streptomycin solution and 10%, 5%, 
or 1% B cell serum without G418 presence. 100 µl of cell suspension from each 
concentration of serum was pipetted in triplicate to 5 separate 96-well plates. The 
plates were labelled Day 0,2,4,6 and 8 and incubated at 37°C in 5% CO2 for up 
to 8 days without changing the medium. Every 2 days (starting at Day 0), a plate 
was removed for WST-1 assay. Assessment of cell proliferation was carried out 
every two days for serum concentration. 
When compared under different serum concentration LMP2A or LMP2B 
expressing in KMH2 cells had little impact on proliferation. The exception was a 
marginal decrease in LMP2A expressing cells at 144 and 192 hours in 1% serum 
(P=0.01, p<0.05). This is possible LMP2 toxicity may predominate over any 
effect on proliferation. K-2B cells showed a significantly increase in proliferation 
at 192 hours (p<0.05). 
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Figure 3-6 Proliferation of L-2A, L-2B and L-Neo expressing cells 
5x 104 cells from each cell line were pelleted at 1500 rpm for 5 minutes and 
resuspended in 5 ml PBS. Cells were washed three times with PBS to remove any 
trace of serum. Finally, cells were resuspended in 2 ml of growth medium 
RPMI1640 containing glutamine, penicillin/streptomycin solution and 10%, 5%, 
or 1% B cell serum without G418 presence. 100 µ1 of cell suspension from each 
concentration of serum was pipetted in triplicate to 5 separate 96-well plates. The 
plates were labelled Day 0,2,4,6 and 8 and incubated at 37° C in 5% CO2 for up 
to 8 days without changing the medium. Every 2 days (starting at Day 0), a plate 
was removed for WST-1 assay. Assessment of cell proliferation was carried out 
every two days (starting at Day 0) for serum concentration. 
Compared with L-Neo cells, expression of LMP2A or LMP2B in L428 cells 
showed no significant difference in proliferation under three different serum 
conditions and 5 time points. 
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3.2.3.2 Survival assay 
Trypan blue exclusion assays were performed on LMP2A, LMP-2B and Neo 
transduced KMH2 and L428 cells two weeks post transfection (see Section 2.5.2). 
1.2 x 106 Cells were washed in serum-free media and resuspended in RPMI 
containing 1%, 5% and 10% BCS. Cells were stained with trypan blue (final 
concentration, 20% v/v) for 2 minutes and counted. All quantifiable data were 
subjected to statistical analysis in Microsoft Excel using a two-tailed Student t 
test. The generated P values indicate a significant difference between the data sets 
when P<0.05. 
Compared with K-Neo cells, K-2A cells showed decreased viability at most time 
points and serum concentrations (Figure 3.7), the two exceptions being at 192 
hours in 10% serum and at 144 hours in 5% serum where LMP2A expressing cells 
were more viable than control cells. This is possible LMP2 toxicity may 
predominate over any effect on proliferation, particularly at long hours with low 
serum condition. In contrast, the viability of K-2B cells was increased up to144 
hours under all serum conditions (Figure 3.7). These data suggest a toxic effect of 
LMP2A and a beneficial effect of LMP2B on cell viability in KMH2 cells. 
In L428 cells, LMP2A-expression increased viability but only in 5% and 10% 
serum and at the latter time points (Figure 3.8). In contrast, L-2B cells showed no 
significant difference compared with L-Neo cells under most conditions (Figure 
3.8). This result suggests LMP2A is more tolerable in L428 cells than in KMH2 
cells, even if in the low serum condition. LMP2B showed less function in L428 
cells than in KMH2 cells. 
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Figure 3-7 Viability of K-2A, K-2B and K-Neo expressing cells 
1.2 x 106 cells from each cell line were pelleted at 1500 rpm for 5 minutes and 
resuspended in 5 ml PBS. Cells were washed three times to remove any trace of 
serum. Finally, cells were resuspended in 4 ml cell maintenance medium, 
RPMI1640 containing glutamine, penicillin/streptomycin solution and 10%, 5%, 
or 1% B cell serum without G418 presence. 200 91 of each cell suspension at each 
of the different serum concentrations was pipetted in triplicate into 5 separate 48- 
well plates. Plates were labelled Day 0,2,4,6 and 8 and incubated at 37° C in 5% 
CO2 for up to 8 days without changing the medium. Every 2 days (starting at Day 
0), a trypan blue viability assay was carried out with trypan blue reagent. 80 gI of 
cell suspension was mixed with 20 µl trypan blue reagent for 2 minutes and the 
cell viability was evaluated by direct counting of unstained cells under a 
microscope. 
Compared with K-Neo cells, K-2A cells showed decreased viability at most time 
points and three serum concentrations; the exception being at 192 hours in 10% 
serum and at 144 hours in 5% serum where LMP2A expressing cells showed 
increased viability compared with K-Neo cells. In contrast, the viability of K-2B 
cells was usually higher than K-Neo cells. All results are expressed as the number 
of viable cells times 10 thousands at each time point, and represent the mean of 3 
independent experiments. 
119 

















  K-2A 1 
  K-2B1 
Q K-Neo1 
120 
Results Chapter 3 
Figure 3-8 Viability of L-2A, L-2B and L-Neo expressing cells 
1.2 x 106 cells from each cell line were pelleted at 1500 rpm for 5 minutes and 
resuspended in 5 ml PBS. Cells were washed three times to remove any trace of 
serum. Finally, cells were resuspended in 4 ml cell maintenance medium, 
RPMI1640 containing glutamine, penicillin/streptomycin solution and 10%, 5%, 
or 1% B cell serum without G418 presence. 200 µl of each cell suspension at each 
of the different serum concentrations was pipetted in triplicate into 5 separate 48- 
well plates. Plates were labelled Day 0,2,4,6 and 8 and incubated at 37° C in 5% 
CO2 for up to 8 days without changing the medium. Every 2 days (starting at Day 
0), a trypan blue viability assay was carried out with trypan blue reagent. 80 µl of 
cell suspension was mixed with 20 µl trypan blue reagent for 2 minutes and the 
cell viability was evaluated by direct counting of unstained cells under a 
microscope. 
Compared with L-Neo cells, L-2A cells showed no significant difference in 
viability in 1% serum; however, viability of LMP2A-expressing cells was 
increased at 144 hours and 192 hours in 5% serum and at 192 hours in 10% 
serum. Overall, viability of L-2B cells was not different to that of L-Neo cells. All 
results are expressed as the number of viable cells times 10 thousands at each time 
point, and represent the mean of 3 independent experiments. 
121 













© L-2A 1 
  L-2B1 
Q L-Neol 
122 
Results Chapter 3 
3.3 Discussion 
The consistent expression of LMP2A in primary HL suggests an important 
function for this protein in the pathogenesis of this tumour but this remains to be 
shown. The lack of in vitro systems whereby LMP2 is expressed in a relevant cell 
background has hampered the research in this field. The transfection of HL cell 
lines is always regarded as problematic and possibly more so if the transgenes are 
toxic transmembrane proteins. Many efforts to establish HL cells stably 
expressing LMP2 have failed. In this study stable expression of both LMP2A and 
LMP2B was achieved in HL cells using retrovirus infection. 
The pattern of LMP2 expression documented here is similar in both HL cell lines. 
Two weeks post transduction, the expression of both LMP2A and LMP2B was 
detectable but variable between different clones. However, at 6 weeks with drug 
selection, the expression of the LMP2A and LMP2B increased and remained 
constant over time under drug pressure. LMP2A and LMP2B expression was 
lower or the same as X50-7 cells suggesting "physiological" levels of expression 
has been achieved. Lower expression soon after infection may have been because 
drug selection was still not complete at that time. This work demonstrates the 
advantages of using retroviral transduction over standard DNA transfection to 
provide a reliable method to transduce HL cell lines with LMP2. The generation 
of HL cell lines stably expressing LMP2A or LMP2B enables the study of the 
phenotypic effects of LMP2 in this environment. This is the first time that stable 
LMP2A or LMP2B expression has been achieved in EBV-negative HL cells. 
LMP2A activates P13-K/Akt pathway, which acts as a cell survival signal in B- 
cell lines (Swart et al., 2000). LMP2A also appears to be a key determinant in the 
alteration of epithelial cell growth by activating Akt and c-Jun and leading to 
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enhancement of cell growth (Chen et al., 1999; Scholle et al., 2000). In addition, 
LMP2A expression is important in epithelial cell clone outgrowth following 
infection of epithelial cells (Moody et al., 2003). Another report showed that 
LMP2A mediated the survival of primary, BCR-negative B cells by constitutive 
activation of the Ras/PI3K/Akt pathway (Portis and Longnecker, 2004). EBV- 
infected KMH2 cells, displaying a pattern of virus gene expression largely 
restricted to Qp-driven EBNA1, LMP2, EBERs, and the BamH1A transcripts, 
showed significantly increased cell growth and survival compared with uninfected 
controls (Baumforth et al., 2005). Thus, LMP2 might play an important role in 
inducing the growth and survival of EBV-positive HRS cells. Interestingly, the 
LMP2 transduced HL cell lines failed to show any clear increase in proliferation 
compared with control cells. There are a number of possible explanations: First, 
the assays were performed 2 weeks post infection; at this time cells were still in 
the initial stages of selection. Second, it is possible LMP2 toxicity may 
predominate over any effect on proliferation, particularly it was shown at, 144 and 
192 hours with low serum medium. This problem may be overcome by changing 
the medium during the assay. Third, the effects of LMP2 might also depend on 
levels of expression; whether higher levels of LMP2 expression induces the cell 
proliferation remains to be investigated. The effects of LMP2A and LMP2B on 
survival were also not consistent and varied between the two cell lines; this might 
reflect their different sensitivity to the toxic effect of LMP2A or LMP2B protein; 
LMP2A approved to be better tolerated by L428 cell than KMH2 cells. 
In conclusion, this study has generated cell line models that enable the influence 
of LMP2A and LMP2B expression to be assessed in an HL cell background. The 
failure to identify any clear major phenotype effect of either protein in HL cells 
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might suggest more subtle effect of these two viral genes in the pathogenesis of 
HL. 
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4 Analysis of the influence of LMP2 expression on the cellular 
transcriptional programme of Hodgkin's lymphoma cells 
4.1 Introduction 
Classical HL is characterized by the presence of usually less than 1% of HRS cells 
in the tumour tissues. HRS cells show a peculiar phenotype that includes 
downregulation of B cell markers and expression of markers of other 
hematopoietic lineages (Kuppers, 2002, kuppers 2004). About 50% of HL are 
associated with EBV, and LMP2 is consistently expressed. Expression of LMP2A 
in transgenic mice alters B-cell development by inhibiting Ig heavy-chain gene 
rearrangement and expression of a functional BCR (Caldwell et al., 2000; 
Caldwell et al., 1998). This suggests that LMP2A may alter the expression and/or 
activity of transcription factors or signalling molecules required for proper B-cell 
development. However, the exact function of LMP2 in the pathogenesis of HL 
remains unknown. To obtain further insight into the role of LMP2A in the 
pathogenesis of HL, a global gene expression analysis was carried out on LMP2- 
expressing HL cells using microarray analysis. 
The development of microarray analysis has provided a powerful tool to study 
altered gene expression patterns in biological systems. Recently, DNA microarray 
technology performed with LMP2A transgenic mice, LMP2A-expressing human 
B-cell lines, and LMP2A-positive and -negative EBV-infected lymphoblastoid 
cell lines (LCLs) demonstrated that LMP2A increased the expression of genes 
associated with cell cycle induction and inhibition of apoptosis. LMP2A also 
altered the expression of genes involved in DNA and RNA metabolism, and 
decreased the expression of B-cell-specific factors and genes associated with 
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immunity. Indeed, many alterations in gene expression induced by LMP2A were 
similar to those recently described in HRS cells of Hodgkin's lymphoma and 
activated, proliferating germinal centre centroblasts/centrocytes (Portis and 
Longnecker, 2003; Portis et al., 2003). To date, there has been no comprehensive 
study of the impact of LMP2 expression in HL cells. In our laboratory, EBV 
negative KMH2 cells have already been stably infected with recombinant Akata- 
derived EBV (Baumforth et al., 2005) and subjected to global gene expression 
analysis when compared to their EBV-negative parental counterparts. In this 
study, microarray analysis was performed on the KMH2 cells described in chapter 
3 which stably expressed either LMP2A or LMP2B. 
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Aims of this study: 
1. Detection of global gene expression alterations in KMH2 cells expressing 
LMP2A or LMP2B through the use of gene expression microarrays. 
2. Validation of the selected gene expression changes observed by semi-Q- 
PCR 
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4.2 Results 
4.2.1 Gene expression array analysis of the contribution of LMP2 to cellular 
gene transcription in the HL-derived cell line, KMH2 
Affymetrix gene expression arrays were used to investigate the effect of LMP2 
expression in KMH2 cells. RNA was extracted from all three cell lines, used to 
make cDNA, cleaned up, converted to antisense RNA by in vitro transcription, 
fragmented and hybridised to an Affymetrix Human U133 Plus 2 arrays according 
to the methods detailed in section 2.6. Retrovirus carrying LMP2A, LMP2B and 
control Neo gene infected KMH2 cells were used (Chapter3). Clone K-2A1 was 
selected to carry out the array assay because the expression level of LMP2A is 
close to its physiological level. Too high expression of LMP2A possibly results in 
false results and low expression of LMP2A wouldn't cause cellular gene 
alteration. Each experiment was performed in triplicate using RNA from separate 
flasks of cells, one flask of which were 2 weeks post infection (2AI, 2BI, Neol) 
and another two flasks of which were 8 weeks post infection (2AII, 2AIII, 21311, 
2BIII, NeoII, NeoIII). The arrays were scanned and analysed using RAM and rank 
products method as described in section 2.6.10, to identify those genes 
significantly up or down regulated in the presence of either LMP2A or LMP2B 
expression. Differentially expressed genes were then clustered in a "heatmap" 
using dChip where their relative expression intensities were compared. In the 
"heatmap" for each gene, white represents the mean expression level of the three 
biological replicates, increasing intensity of red or blue represent increased or 
decreased expression relative to the mean in LMP2A or LMP2B expressing cells 
compared to control cells. Gene changes were deemed significant when the 
percentage of false-positives (pfp) was <10%. 
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197 genes were significantly altered by LMP2A, including 143 up regulated genes 
(Figure 4.1 A) and 54 down regulated genes (Figure 4.1 B). 
There were 49 genes significantly changed in the presence of LMP2B in KMH2 
cells, including 47 up regulated genes and 2 down regulated genes (Figure 4.2). 
49% of genes altered by LMP2B were also affected by LMP2A (23 upregulated 
and 1 downregulated) (Figure 4.3). 
It was clear from the heatmap that the expression level of a significant number of 
genes was influenced by the time post-infection at which the cells were harvested. 
Thus, the first replicate for LMP2A, LMP2B or Neo expressing cells was 
harvested at 2 weeks, whereas the two others were taken at 8 weeks. Since it was 
previously shown that LMP2A or LMP2B expression increased at 8 weeks 
compared to 2 weeks, it is possible that these differences in cellular gene 
expression are a consequence of the differing levels of each protein. 
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Figure 4-1 Heatmap of microarray data comparing cellular gene expression 
between LMP2A-expressing KMH2 cells and vector only control cells 
Colour intensities represent the mean expression level of the three biological 
replicates; increasing intensity of red or blue represent increased or decreased 
expression relative to the mean (white) in LMP2A-expressing KMH2 cells 
compared to vector only control cells. Clone K-2A1 was selected to carry out the 
array assay because the expression level of LMP2A is close to its physiological 
level and low expression of LMP2A wouldn't cause cellular gene alteration. Each 
experiment was performed in triplicate using RNA from separate flasks of cells, 
one flask of which were 2 weeks post infection (2AI and Neol) and another two 
flasks of which were 8 weeks post infection (2AII, 2AIII, Neoll and NeoIII). 197 
genes were significantly altered by LMP2A, including 143 up regulated genes (A) 
and 54 down regulated genes (B). Among the genes changed in the presence of 
LMP2A, there was a clear difference in gene expression between cells 2 weeks 
post infection (Al) compared to 8 weeks post infection (All and AIII). 
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Figure 4-2 Heatmap of microarray data comparing cellular gene expression 
between LMP2B-expressing KMH2 cells and vector only control cells 
Colour intensities represent the expression level of the three biological replicates; 
increasing intensity of red or blue represent increased or decreased expression 
relative to the mean (white) in LMP2B-expressing KMH2 cells compared to 
vector only control cells. Each experiment was performed in triplicate using RNA 
from separate flasks of cells, one flask of which were 2 weeks post infection (2BI 
and Neol) and another two flasks of which were 8 weeks post infection (2BII, 
213111, NeoII and NeoIII). 49 genes were significantly altered by the presence of 
LMP2B, including 47 genes up regulated and 2 down regulated genes. Among the 
genes changed in the presence of LMP2A, there was a clear difference in gene 
expression between cells 2 weeks post infection (BI) compared to 8 weeks post 
infection (BII and BIII). 
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Figure 4-3 Cellular genes altered by both LMP2A and LMP2B expression 
Colour intensities. represent the mean expression level of the three biological 
replicates; increasing intensity of red or blue represent increased or decreased 
expression relative to the mean (white) in LMP2A-expressing KMH2 cells (2AI, 
2AII, 2AIII), LMP2B-expressing KMH2 cells (2BI, 2BII, 2BIII, ) compared to 
vector only control cells (Neol, NeoII, NeoIII). 49% of the genes altered by 
LMP2B were also changed by LMP2A. These included 23 up regulated genes and 
1 down regulated gene. Gene symbol relative to Neo control of these are listed. 
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4.2.2 Classification of genes regulated by LMP2 
In order to further define the effects of LMP2 in HL cells, genes identified from 
each microarray were placed into the following functional categories; anti- 
apoptosis, cytoskeleton, metabolism, immunity, signal transduction, transcription, 
transport protein and oncogenes/TSG (tumour suppressor gene). Those genes 
whose function was unknown or that could not be classified into one of the above 
categories were designated other/unknown. Gene function was ascertained from 
published papers at www. pubmed. ov. The lists of genes changed by LMP2A or 
LMP2B are presented in the Appendix (Table 8.1 and Table 8.2). A summary of 
gene function influenced by LMP2A, LMP2B or both, is given in Figure 4.4 A 
and Figure 4.4 B. Overall, the proportions of genes categorised as having a 
function associated with cytoskeleton, differentiation, immunity, metabolism, and 
transport protein were very similar, but the contributory genes were often 
different. A larger proportion of genes involved in signal transduction and 
transcription were altered by LMP2A compared with LMP2B. In contrast, a 
higher proportion of genes involved in motility, apoptosis and categorised 
oncogenes/TSG, were altered by LMP2B expression compared with LMP2A. 
Figure 4.4 B shows that 30% of the genes that were differentially expressed in 
both LMP2A and LMP2B cells might suggest a role for LMP2A and LMP2B in 
the rescue of pre-apoptotic germinal centre B cells. 
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Figure 4-4 Sub-categorisation of genes altered by LMP2A and LMP2B 
(A) Shows the relative proportion of genes within each functional category 
influenced by either LMP2A or LMP2B. 
(B) Shows that the relative proportion of genes within each functional category 
influenced by both LMP2A and LMP2B. 
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4.2.3 Correlation of differentially expressed genes with those reported to be 
associated with Hodgkin's lymphoma 
Cellular genes differentially expressed in the presence of LMP2A or LMP2B were 
annotated on the basis of any previously reported association with HL using 
PubMed searches www. pubmed. gov. 14 genes were identified which had 
previously been reported to be associated with HL; 11 of these were altered by 
LMP2A alone; 2 by LMP2B alone and one gene, AICDA, by both LMP2A and 
LMP2B. These genes are listed in Table 4.1. GAS6, CD24, ETV5, EZH2, 
ADAMTS2 and IL6R were up regulated by LMP2A or LMP2B and have been 
previously shown to be highly expressed in HL, of which GAS6, CD24, ETVS and 
EZH2 were reported as oncogenes. ADAMTS2 and IL6R regulated abnormal 
STAT signalling and are associated with the proliferation of HRS cells. Both 
BLNK and AICDA are highly expressed in lymphocyte-predominant HL, but 
absent or infrequently in cHL. HEBP1 acts as an immunomodulator contributing 
to the immunodeficiencies associated with HL. 
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Table 4-1 Cellular genes changed by LMP2A or LMP2B and also previously 
reported to be associated with HL 
Gene Gene Title Fold LMP2 Reference Summary 
Symbol 
PRL prolactin -2.3 LMP2A PMID: 9458932 Prolactin was used as hormane indicator of 
PMID: 2038709 reproductive and ovarian function of 
Hodgkin's lymphoma patients with 
chemotherapy and radiotherapy 
TPO thyroid peroxidase -1.9 LMP2A PMID: 9226215 Hodgkin's lymphoma patients display 
altered TPO antibody-dependent immune 
function with chemotherapy and 
radiotherapy 
ELK! ELK!, member of -1.8 LMP2A PMID: 6226085 ELKI related with a lower number of T 
ETS oncogene lymphocytes was demonstrated in HL 
family patients with advanced disease 
LCAT lecithin- 1.5 LMP2A PMID: 3768760 Synthesis or release of lecithin: cholesterol 
cholesterol acyltransferase was found in a HL patient 
acyltransferase after chemotherapy 
ETV5 ets variant gene 5 1.8 LMP2A PMID: 15632006 ERM expression was observed in all HL 
(ets-related and LBCL cell lines and related with the 
molecule) production of various cytokines 
IL6R interleukin 6 2.2 LMP2A PMID: 11468177 IR6R is expressed in HL cell lines, but 
receptor PMID: 10379062 antibody against IL-6R did not inhibit the 
DNA-binding activity of STAT3 
HEBPI heme binding 1.8 LMP2A PMID: 2690234 HBP recognize the Hodgkin's lectin, which 
protein 1 PMID: 3567932 suggests its role as an immunomodulator 
contributing to the immunodeficiencies 
associated with Hodgkin's disease. 
BLNK B-cell linker 1.9 LMP2A PMID: 12881301 BLNK was consistently absent from Reed- 
PMID: 15744341 Sternberg cells in classical Hodgkin's 
lymphoma, but it was positive in the 
lymphocyte predominance Hodgkin's 
lymphoma. 
EZH2 Enhancer of zeste 1.9 LMP2A PMID: 14982841 Co-expression of BMI-1 and EZH2 in 
homolog 2 PMID: 10980109 Hodgkin/Reed-Sternberg (H/RS) cells 
(Drosophila) contributes to development of HL 
DMD dystrophin 1.9 LMP2A PMID: 14707720 A Hodgkin's lymphoma patient was 
(muscular associated with Becker muscular dystrophy 
dystrophy, 
Duchenne 
and Becker types) 
ADAMTS2 A disintegrin-like 2.2 LMP2A PMID: 11468177 Expressed in Hodgkin's lymphoma cell 
and PMID: 10379062 lines and regulated abnormal STAT 
metalloprotease signalling and growth 
with 
thrombospondin 
type 1 motif, 2 
AICDA activation-induced 6.8 LMP2A/2B PMID: 16126891 Aid related with somatic hypermutation 
cytidine PMID: 15732141 may remain active in L&H cells, 
deaminase increasing the risk of acquiring further 
transforming mutations. AID is 
consistently expressed in the neoplastic 
cells of nodular lymphocyte-predominant 
Hodgkin lymphoma (HLnlp) but only 
infrequently in classical HL (cHL). 
GAS6 Growth arrest- 1.7 LMP2B PMID: 10400186 GAS6 was expressed in a proportion of T-, 
specific 6 B- original lymphoma cell lines and 
Hodgkin's lymphoma cell lines suggested 
GAS6 caused disordered growth or 
chemotaxis/adhesion f leukemia and 
lymphomas. 
CD24 CD24 antigen 1.3 LMP2B PMID: 9935206 CD24 expressed in the Hodgkin's 
(small cell PMID: 1531569 lymphma and LCL cells. 
lung carcinoma 
cluster 4 antigen) 
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4.2.4 Cellular genes altered by LMP2A or LMP2B previously reported to be 
associated with EBV 
Differentially expressed genes were also annotated according to any previous 
reports of their association with EBV. 12 genes had been reported in association 
with EBV; 8 of which were altered by LMP2A and 4 by LMP2B. These are listed 
in Table 4.2. Four genes, ID3, IL6R, GAS6 and CD24 were also reported to be 
associated with HL (section 4.2.3). BDNF and NR3C1 were both up regulated by 
LMP2A and have been detected in EBV transformed B cells. MAP3K8 (Tp12) is a 
component of LMP 1 signalling downstream of TRAF2 and was upregulated by 
LMP2A. ID3 is downregulated by LMP2A but upregulated by LMP1. Three 
genes (PTGS 1, GAS6 and CD24) were up regulated by LMP2B were all 
oncogenes detected in EBV transformed cell lines. 
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Table 4-2 Cellular genes targeted by LMP2 also previously reported to be 
associated with EBV 
Gene Gene Title Fold LMP2 Reference Summary 
Symbol change 
GAGE2 G antigen 2 -2.4 LMP2A PMID: 10928100 EBV infection appears to induce IFN-gamma 
gene expression in most of undifferentiated 
carcinoma of nasopharyngeal type (UCNT), 
but GAGE-1/-2 expression in only some 
tumours. 
ID3 inhibitor of DNA -1.7 LMP2A PMID: 15564458 LMP1 transduced human cervical carcinoma 
binding 3, cell line C33A induced high expression of ID1 
dominant negative and ID3. 
helix-loop-helix 
protein 
PIASI Protein inhibitor 1.5 LMP2A PMID: 15229220 Epstein-Barr virus (EBV) expresses an 
of activated immediate-early protein, Rta, to activate the 
STAT, 1 transcription of EBV lytic genes and the lytic 
cycle. Ubc9 and PIASI were identified as 
binding partners of Rta. PIASI stimulates 
conjugation of SUMO-1 to Rta and indicates 
that sumoylation of Rta may be important in 
EBV lytic activation. 
COLIAI collagen, type 1, 1.6 LMP2A PMID: 10942108 Osteogenesis imperfecta (01) is an autosomal 
alpha 1 dominant genetic disorder as a result of 
mutations in the genes that encode the chains 
of type I collagen, the major protein of bone. 
EBV transformed lymphoblasts resulted in 
87% and 85% for 01 type I and 01 type IV 
respectively and the allele drop-out (ADO) 
rate was assessed at 11.5% and 11.1% for 01 
type I and 01 type IV respectively. 
BDNF brain-derived 1.7 LMP2A PMID: 8632056 EBV transformed B cells express detectable 
neurotrophic levels of transmembrane tyrosine kinase b(Trk 
factor b) and its mRNA. Exposure of EBV- 
transformed B lymphocytes to brain-derived 
neurotrophic factor (BDNF) triggered the 
hos ho lation of Trk b. 
MAP3K8 Mitogen-activated 1.7 LMP2A PMID: 11932422 Tpl-2 as a component of LMPI signaling 
protein kinase downstream of TRAF2 and as a modulator of 
kinase kinase 8 LMP1-mediated effects. 
NR3C1 Nuclear receptor 1.8 LMP2A PMID: 3002935 EBV transformation is associated with 
subfamily 3. PMID: 2157866 increases in the concentration and the absolute 
group C, member number of glucocorticoid receptors 
1 (glucocorticoid 
receptor) 
IL6R interleukin 6 2.2 LMP2A PMID: 11468177 IL6R is expressed in HL cell lines, but 
receptor PMID: 10379062 antibody against IL-6R did not inhibit the 
DNA-binding activity of STAT3 
CDH13 cadherin 13, H- 2.5 LMP2B PMID: 15172980 Promoter methylation of CDHI and CDH13 
cadherin (heart) were noted in dual SV40- and EBV-infected 
PBMC, and these two genes were also highly 
significantly correlated to the presence of 
SV40 sequences in tumors. 
PTGS1 prostaglandin- 2.1 LMP2B PMID: 10843703 EBV was found to impact on the NF-kappaB 
endoperoxide activation pathway, which plays an essential 
synthase 1 role in the induction of COX-2 in monocytes. 
(prostaglandin 
G/H synthase and 
c cloox enase 
GAS6 Growth arrest- 1.7 LMP2B PMID: 10400186 GAS6 was expressed in a proportion of T-, B- 
specific 6 original lymphoma cell lines and Hodgkin's 
lymphoma cell lines suggested GAS6 caused 
disordered growth or chemotaxis/adhesion of 
leukemia and lymphomas. 
CD24 CD24 antigen 1.3 LMP2B PMID: 9935206 CD24 expressed in the Hodgkin's lymphma 
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4.2.5 LMP2A up regulates some B cell markers lost in HL cell lines 
17 genes up regulated in LMP2A expressing KMH2 cells were previously shown 
to be down regulated in HL. 9 of these genes were involved in B cell receptor 
signalling. 2 genes (ID3, NAPSB) were down regulated and 3 genes (COLJA1, 
IGSF3, SLC7A11) were up regulated in both LMP2A expressing cells and HL 
cells (Table 4.3). 
BLNK and BRDG1 are docking proteins that function in downstream BCR 
signalling. BLNK expression was reported to be lost in HRS cells (Schwering et 
al., 2003). IGKC/V and AICDA are involved in gene rearrangement; AICDA, 
initiates somatic hypermutation in B cells. NEDD9 and RGS3 regulate B cell 
adhesion, migration and the immune response. PTPRC, MYBL1 and TNFRSFI7 
function as transcriptional transactivators and enhance proliferation. Taken 
together, these data suggest that LMP2A might upregulate specific components of 
BCR signalling to provide survival and anti-apoptotic signals to allow the survival 
of HRS cells in the absence of BCR expression. 
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Table 4-3 LMP2A regulated genes known to be upregulated or 
downregulated in HL 
Gene Gene title BCR Fold Function Reference 
Down in HL, up in LMP2A 
protein tyrosine CD45 exiting widely in T and B cells has an 
phosphatase, receptor important role in the early events of receptor PMID: 15622930 
PTPRC type, C YES 1.6 signalling PMID: 12588355 
v-myb myeloblastosis Functioning as transcriptional 
viral oncogene homolog transactivators and enhancing peripheral B PMID: 10910917 
MYBLI avian like I YES 2.1 cell survival or proliferative capacity PMID: 11207276 
B cell maturation Ag (BCMA), a member of 
tumor necrosis factor the TNFR superfamily expressed on B cells, PMID: 16116167 
receptor superfamily, binds to a proliferation-inducing ligand PMID: 14978135 
TNFRSFI7 member 17 YES 2.1 APRIL and activates the JNK pathway. PMID: 15070697 
immunoglobulin kappa 
IGKCN5 constant ///variable 1-5 YES 2.4 Gene rearrangement PMID: 1961033 
Immunoglobulin heavy 
IGHG1 constant gamma 1 YES 1.5 Immunity PMID: 9531163 
BLNK is a component of BCR as well as of PMID: 12881301 
BLNK B-cell linker YES 1.9 the pre-BCR signalling pathway. PMID: 15744341 
BRDG1 functions as docking protein acting 
BCR downstream downstream of Tec family (PTKs) in BCR PMID: 10518561 
BRDGI signaling I YES 2.2 signalling. PMID: 12540842 
AICDA initiates switch recombination and 
somatic hypermutation in B cells by targeted 
deamination of transcribed genes and 
activation-induced contribute to the genetic instability of c- PMID: 15940261 
AICDA cytidine deaminase YES 6.8 MYC in B-cell malignancies PMID: 15732141 
neural precursor cell 
expressed, HEFT-associated AND-34 regulates B cell 
developmentally down- adhesion and motility through a Cdc42- PMID: 9498705 
NEDD9 regulated 9 YES 1.8 mediated signaling pathway PMID: 12517963 
RGS molecules in helping regulate cell 
positioning in lymphoid organs during the 
regulator of G-protein immune response, lymphocyte migration PMID: 15047827 
RGS13 signalling 13 YES? 1.8 and chemokine receptor signalling. PMTD: 15313557 
Nuclear receptor 
subfamily 3, group C, Glucocorticoid receptor is a transcriptional 
member I regulator of cell death during tumorigenesis PMID: 12637494 
NR3CI (glucocorticoid receptor) NO 1.8 of fibrosarcoma development PMID: 15770078 
TRA2A Transformer-2 alpha NO 1.6 differentiation PMID: 15210204 
leucine-rich repeats and LRIG1 is a negative regulator of ErbB 
immunoglobulin-like family receptor tyrosine kinases and links to PMID: 15686631 
LRIG1 domains 1 NO 2.5 c-Cbl and receptor ubiui lation PMID: 15345710 
A marker for early stages in chondrogenesis 
integral membrane and T-cell development. ITM2A enhances PMID: 15325075 
ITM2A protein 2A NO 2.3 mo enic differentiation in vitro. PMID: 14984746 
KLF13's repression of LDLR promoter PMID: 16303770 
KLF13 Kruppel-like factor 13 NO 1.6 activity regulates Cholesterol homeostasis PMID: 15716005 
ZFP91 is likely to play an important role in 
zinc finger protein 91 cell proliferation and/or anti-apoptosis in PMID: 12738986 
ZNF91 (HPF7, HTF10 NO 1.6 acute m elo enous leukemia PMID: 11470777 
family with sequence 
FAM46C similarity 46, member C NO 2.1 
Down in HL, down in LMP2A 
ID3 blocks B lymphocyte maturation at an 
inhibitor of DNA early differentiation step and works as an PMID: 6297338 
ID3 binding 3 YES -1.7 anta anist of E protein PMID: 15769946 
napsin B aspartic PMID: 16162398 
NAPSB peptidase pseudo gene NO -1.7 metabolism PMID: 14674886 
Up in HL, u in LMP2A 
Osteogenesis imperfecta is secondary to PMID: 15339338 
COLIAI collagen, type 1, alpha I NO 1.6 mutations of COLIAI and COLIA2. PMID: 11479215 
IGSF3 contributes to a variety of CD9 and 
immunoglobulin CD81 functions in virus-induced cell-cell 
IGSF3 su erfamil member 3 NO 1.7 fusion and virus entry into and/or release. PMID: 11504738 
solute carrier family 7, Mediates cystine-glutamate exchange and 
SLC7AI I member 11 NO 1.7 regulates intracellular glutathione levels. PMID: 16103098 
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4.2.6 Expression of IFI27 and AICDA as determined by GCOS signal from 
microarrays 
Two genes were selected for initial validation, IFI27 and AICDA. GCOS signals 
for each gene were plotted and are shown in Figure 4.5. This result shows that 
although AICDA was up regulated in both LMP2A and LMP2B-expressing 
KMH2 cells, the upregulation is only convincing in the later passages of LMP2A- 
expressing cells. The expression of IFI27 was down regulated by LMP2A, but not 
LMP2B. 
146 
Results Chapter 4 
Figure 4-5 GCOS signals of IFI27 and AICDA detected on microarray 
GCOS signals for each gene were plotted. This shows that although AICDA was 
up regulated in both LMP2A and LMP2B-expressing KMH2 cells, the 
upregulation is only convincing in the later passages of LMP2A-expressing cells. 
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4.2.7 Validation of cellular gene targets of LMP2 
4.2.7.1 Expression of AICDA detected by semi-Q-PCR in different passages of 
LMP2 positive KMH2 cells 
From the array result, AICDA was upregulated by LMP2A, so semi-Q-PCR was 
performed with RNA extracted from K-2A, K-2B and K-Neo cells, 2 weeks, 4 
weeks and 8 weeks post infection. Semi-quantitative PCR (see Section 2.3.1.4) 
was run for 20,25,30 and 35 cycles and resolved by electrophoresis on 1.2% 
agarose gel. Interestingly, there was no AICDA signal was detected from RNA of 
K-2A 2 weeks post infection , even after 35 cycles, but the signal of K-2B was 
stronger than K-Neo (Figure 4.6A). Compared with the RNA from 4 weeks post 
infection, there was a weak signal of AICDA detected from K-2A at 35 cycles, 
but it was still weaker than that from K-2B and K-Neo (Figure 4.6 B). The same 
semi-Q-PCR was performed with the RNA from 8 weeks post infection, the signal 
of AICDA from both K-2A and K-2B was stronger than that of K-Neo at 30 and 
35 cycles and the signal from K-2A was much stronger than the other two by 8 
weeks (Figure 4.6. C). RT-PCR of GAPDH was run along side as a loading 
control. 
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Figure 4-6 Expression of AICDA detected by semi-Q-PCR 
Semi-Q-PCR was performed with RNA extracted from K-2A, K-2B and K-Neo 
cells at 2 weeks, 4 weeks and 8 weeks post infection for 20,25,30 and 35 cycles. 
(A) AICDA expression was not detectable in LMP2A-expressing cells at 2 weeks 
post infection. 
(B) At 4 weeks AICDA expression was still weaker in K-2A cells than in K-2B 
and K-Neo cells. 
(C) However, at 8 weeks AICDA expression was stronger in both K-2A and K-2B 
in K-Neo cells. 
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4.2.7.2 Expression ofAICDA in HL cell lines 
As described in Chapter 3, the expression level of LMP2A in K-2A cells was 
lower in the early passages. The expression of LMP2A in K-2A cells 8 weeks post 
infection was compared with EBV positive HL cell lines KMH2-EBV (K-EBV), 
L591 and their EBV-negative counterparts KMH2 and L-591-SD3 (Figure 4.7 A). 
EBV-negative clone L591-SD3 was generated from EBV-positive L591 cells by 
being serially diluted for up to 6 weeks (Baumforth et al, 2005). Expression of 
LMP2A was strong in K-2A cells and weak expression in L591 cells. The other 
cell lines were LMP2A-negative. The expression of AICDA was slightly stronger 
in KMH2 cells than in K-EBV cells (Figure 5.7 B). The same assay was 
performed with L591 and L591-SD3 cells. The expression of AICDA in L591- 
SD3 cells was much stronger than their counterparts (Figure 5.7 Q. 
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Figure 4-7 Expression level of LMP2A and AICDA detected by RT-PCR 
The expression of LMP2A was compared by RT-PCR in K-2A cells 8 weeks post 
infection and in a panel of with other EBV positive HL cell lines compared with 
their EBV-negative counterparts. 
(A) K-2A cells showed strong expression of LMP2A and a very weak one was 
detected in L591 cells. 
(B) The expression of AICDA was slightly stronger in KMH2 cells than in K- 
EBV cells. 
(C) The expression of AICDA in L591-SD3 was much stronger than in L-591. 
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4.2.7.3 Expression ofIFI27 in HL cell lines 
By array analysis, IFI27 expression was down regulated in K-2A cells, but not in 
K-2B cells. Figure 4.8 A shows that IFI27 mRNA levels at two weeks post 
infection were lower in K-2A than in either K-2B or K-Neo. The expression of 
IFI27 in K-2A was not different at 2 and 8 weeks (data not shown). Figure 4.8 B 
shows that the expression of IFI27 was also lower in EBV-positive KMH2 cells 
(K-EBV) compared with parental KMH2 cells. Furthermore, IFI27 expression 
was also lower in EBV-positive L591 cells compared with EBV-negative clones, 
L591-SD3 cells (Figure 4.8 Q. These data not only confirm the results of the 
array analysis, but also suggest that LMP2A also downregulates IFI27 in the 
presence of EBV infection. 
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Figure 4-8 Expression of IFI27 in HL cell lines 
IFI27 expression was studied by semi-Q-PCR. K-2A, K-2B and K-Neo two weeks 
and eight weeks post infection; recombinant EBV and its empty vector Neo 
infected KMH2 cells; EBV positive HL cell line L591 and its negative counterpart 
L591-SD3. RNA was extracted from all these cells and cDNA was made. Each 
cDNA sample was run semi-quantitative PCR for 20,25,30 and 35 cycles. 
(A) The signal of K-2A was weaker than K-2B and K-Neo at 30 and 35 cycles. 
(B) The signal of K-EBV was weaker than K-Neo at 25,30 and 35 cycles. 
(C) The signal of L591 was weaker than L591-SD3 at 30 and 35 cycles. All 
above results suggested that IFI27 was down regulated by LMP2A or EBV. 
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4.3 Discussion. 
Classical Hodgkin's lymphoma is characterized by the presence of multinucleated, 
malignant HRS cells, which constitute only a minority of the tumour cells 
(Kuppers et al., 2002). HRS cells are presumed to derive from germinal centre B 
cells that have lost their expression of immunoglobulin (Ig) and other B-cell- 
specific characteristics (Kuppers et al., 2002; Cossman et al., 1999; Marafioti et 
al., 2000). It has been estimated that nearly half of all HL contain EBV DNA 
(Kuppers et al., 2002; Khan and Coates, 1994; Pallesen et al., 1991; Wu et al., 
1990) and the consistent detection of LMP2A transcripts in both tumour cells and 
latently infected B cells in vivo suggests that LMP2A plays an important role in 
viral persistence and in the development of HL. In this study, the impact of 
LMP2A and of LMP2B on global gene expression was investigated in KMH2 HL 
cells. Many genes found in this study have been previously reported in association 
with HL or EBV, these were mainly oncogenes or genes involved in signal 
transduction. Compared with LMP2B, LMP2A altered a greater proportion of 
genes involved in signal transduction and transcription; confirming previous 
studies that show the N-terminus of LMP2A, particularly its ITAM to be 
important for signalling (Longnecker, 2000). LMP2B was reported to play a role 
in cell adhesion and motility of epithelial cells (Allen et al., 2005). In HL cells, 
LMP2B also altered a proportion of genes related to adhesion and motility. 
HRS cells have lost the expression of most B-cell-specific genes, including the 
kinases Syk and Lyn and the adaptor molecule BLNK (Schwering et al., 2003). 
Studies utilizing mice deficient in the BCR signalling molecules BLNK and 
Bruton's tyrosine kinase (BTK) have demonstrated that LMP2A utilizes these 
molecules for the effects on B cell development and survival (Engels et al., 2001; 
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Merchant and Longnecker, 2002). These molecules are not only crucial for BCR 
signalling, but are also essential components of the signalling pathway (Engels et 
al., 2001). In this study, many genes involved in BCR signalling, which were 
reported to be down regulated in HL were found to be up regulated by LMP2A 
(Shaffer et al, 2002; Portis et al., 2004; Schwering et al., 2003A; Schwering et al., 
2003B; Shen et al., 2004; Feldhahn et al., 2002; Wright et al., 2003). These 
included BLNK and BRDG, which are docking proteins of downstream BCR 
signalling. They also included IGKC/V and AICDA which are involved in gene 
rearrangement; AICDA initiates somatic hypermutation (SHM) in B cells. 
NEDD9 and RGS3 regulate B cell adhesion, migration and immune responses. 
Taken together, these results suggest that LMP2A might use some components of 
the BCR signalling pathway and in doing so, maintain EBV latency, provide 
survival and anti-apoptotic signals for HRS cells, possibly transform B cells into 
HRS cells and allow survival of the transformed cells in the absence of a BCR. 
Thus, LMP2A might be important in HL because it selectively utilises some of the 
B cell signalling machinery. 
AICDA was discovered as an APOBECI homolog with cytidine deaminase 
properties in stimulated B cell lines (Muramatsu et al., 1999). AICDA is 
necessary for somatic hypermutation, class switch recombination and gene 
conversion. Inappropriate expression of cytidine deaminases might be 
tumorigenic. Consistent with this, inappropriate or down-regulated expression of 
cytidine deaminases was often found in tumors (Anant and Davidson, 2003). As 
abnormal SMH targets many proto-oncogenes PIMI, PAX5, Rho/TTF and cMYC, 
AICDA is regarded as a potential oncogene as well (Pasqualucci et al., 2004). 
AICDA was constitutively expressed in GC B-cells and in GC-derived B-cell 
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lymphomas, including follicular lymphoma (FL), Burkitt lymphoma (BL) (Smit et 
al., 2003; Greeve et al., 2003), and chronic lymphocytic leukemia (Oppezzo et al., 
2003). Clonal Ig gene rearrangements had been detected in HRS cells identifying 
the majority of cases as B-cell-derived (Kuppers et al., 1994). Evidence of SHM 
was found in the Ig V genes of major types, cHL and HLnlp (Kanzler et al., 1996; 
Marafioti et al., 2000). However, AICDA was consistently expressed in the L&H 
cells in HLnlp, but not in HRS cells in cHL cases (Greiner et al., 2005). Although 
AICDA was initially identified as a gene upregulated by LMP2A, it was clear that 
this was only the case when LMP2A levels were higher, ie at 8 weeks post 
infection. In contrast, at two weeks post-infection, when LMP2A levels were low, 
AICDA was downregulated compared to control cells. Furthermore, AICDA was 
also downregulated in KMH2 cells infected with EBV and also EBV positive 
L591 cells compared with their counterparts. Thus it appears that `physiological' 
levels of LMP2A might be actually associated with AICDA downregulation. 
Unfortunately, AICDA antibodies are not commercially available, 
immunoblotting with the anti-AICDA monoclonal antibody described by Greiner 
et al., (2005) gave poor results. Therefore, it will still be necessary to confirm the 
RNA expression change described here at the protein level. 
IFN-a mediates several biological responses, including inhibition of cell 
proliferation, antiviral reactions and immunoregulation (Stark et al., 1998). These 
biological responses are initiated through the binding of IFN-a to cell-surface 
receptors, which activate signalling cascades that lead to changes in the 
transcription of target genes. Interferons exert their biological function mainly 
through the activation of interferon-stimulated genes (ISGs). IFI27 belongs to the 
family of small, IFN-a inducible genes of unknown function. It was first 
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described in 1993 and was found to be up-regulated in -50% of breast carcinomas 
(Rasmussen et al., 1993). IFI27 localises to the nuclear membrane (Martensen et 
al., 2001). Recently, it was shown that STAT2-regulated expression of IFI27 was 
selectively enhanced by the chromatin remodelling factor BRG1 (Brahma-related 
gene 1) (Huang et al., 2002). BRG1 has been implicated in regulating gene 
expression, cell-cycle control and tumourigenesis (Khavari PA et al., 1993). IFI27 
was shown by microassay analysis to be upregulated in PAL (Pyothorax- 
associated lymphoma) (Nishiu et al., 2004). PAL is a unique lymphoma, which 
shows a strong association with EBV infection. Over-expression of IFI27 was also 
found in cell lines derived from PAL by Q-RT-PCR, but not in other lymphoid 
cell lines, Raji (EBV-positive BL cell line), BJAB (EBV-negative BL cell line), 
Namalwa (EBV-positive BL cell line), and LCL (EBV-positive lymphblatoid cell 
line). In this study, IFI27 was found to be down regulated by LMP2A, but not 
LMP2B. Unfortunately, these expression changes could not be confirmed at 
protein level since a suitable antibody was not available. Furthermore, down 
regulation of IFI27 was also observed in EBV infected KMH2 cells and L591 
cells compared with their EBV-negative counterparts compared with its parental 
counterparts. However, how LMP2A or EBV downregulate IFI27 in HL cell lines 
and what the consequences of this downregulation are need to be further 
investigated. 
In conclusion, this study shows the value of gene microarray technology to study 
altered gene expression in HL cells in response to LMP2 expression. LMP2A 
induced more marked effects on gene expression than LMP2B, particularly on 
genes with a transcriptional and signal transduction function. LMP2A might 
selectively utilise some components of the BCR signalling pathway to induce 
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cellular responses of relevance to the pathogenesis of HL. AICDA was 
downregulated in KMH2 cells expressing lower levels of LMP2A, KMH2 cells 
infected with EBV, and EBV positive L591 cells. In contrast, later passage cells 
expressing higher levels of LMP2A upregulated AICDA. Thus it appears that 
`physiological' levels of LMP2A are important in determining the gene 
expression consequence of this protein. LMP2A might maintain EBV latency and 
provide its survival signals for HRS cells through down regulating IFI27. The 
relationship between LMP2 and cellular gene expression levels in HL are only 
descriptive at this stage, but have identified a number of areas for further study. 
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5 Identification of cellular binding partners of LMP2A and LMP2B 
5.1 Introduction 
LMP2A and LMP2B are expressed in the majority of EBV-associated 
malignancies and also in the B cells of asymptomatic carriers suggesting they are 
important not only to the development and maintenance of the transformed 
phenotype but also to viral persistence. 
LMP2 has been shown to alter cellular signalling; it can inhibit the switch from 
latent to lytic cycle in B cells by blocking BCR signals (Miller et al., 1993; Miller 
et al., 1995; Longnecker 2000), particularly the LMP2A N-terminus, which 
encodes a 119-amino-acid N-teminal cytoplasmic domain (LMP2A-N) is unique 
to LMP2A. It contains an immunoreceptor tyrosine-based activation motif 
(ITAM) (Fruehling et al., 1996; Fruehling and Longnecker, 1997; Fruehling et al., 
1998; Longnecker, 2000) and has been shown to be responsible for blocking 
BCR-stimulated calcium mobilisation, tyrosine phosphorylation and activation of 
the EBV lytic cycle in B cells (Miller et al., 1995). 
In vivo models of EBV latent infection show that LMP2 can provide a survival 
signal to primary B lymphocytes. LMP2 is also important for virus persistence in 
the human host (Caldwell et al., 1998; Caldwell et al., 2000). It has already been 
reported that LMP2 associates with LMP 1, Src family tyrosine kinases, the Syk 
tyrosine kinase, Nedd4 ubiquitin ligases, and with at least four unidentified cell 
proteins, several of which are tyrosine phosphorylated (Stewart et al., 2005; 
Longnecker, 2000; Dykstra et al., 2001; Ikeda et al., 2000; Fukuda et al., 2004; 
Fukuda et al., 2005; Ikeda et al., 2003; ingham et al., 2005). LMP2A interacts 
with the extracellular signal-regulated kinase 1 (ERK1) mitogen-activated protein 
kinase (MAPK), and might contribute to LMP2A-induced activation of JUN, 
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MAPK kinase and the PI3K/Akt pathway (Chen et al., 2002; Swart et al., 2000; 
Fukuda et al., 2004). However, most of these interactions were defined by 
methods such as immunoprecipitation, and are likely to represent only a fraction 
of the interactions that are important for the function of LMP2. To date, there has 
been no large scale systematic study to identify LMP2 interacting cellular 
proteins. 
Mass spectrometry techniques have been developed for large-scale screening to 
identify interactions, but the nonquantitative nature of mass spectrometry restricts 
the ability to detect specific alterations in the composition of a protein complex. 
Mann and his colleagues established the SILAC technology (Ong et al., 2002; 
Ong et al., 2003a; Blagoev et al., 2003; Foster et al., 2003; Ong et al., 2003b). 
Recently there have been many reports that document its successful use in 
identifying protein-protein interactions (Zhang et al., 2006; Romijn et al, 2005; 
Gruhler et al., 2005; Foster et al., 2006; Amanchy et al., 2005; Everley et al., 
2005). In this study, SILAC combined with LC-MS/MS analysis was used to 
identify potential LMP2A and LMP2B interacting proteins. 
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Aims of this research: 
1 To generate His-tagged constructs of LMP2A, LMP2B and LMP2A-N. 
2 To generate LMP2A and LMP2B expressing HEK cells. 
3 To identify LMP2-interacting cellular proteins in these cells using the SILAC 
method. 
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5.2 Results 
5.2.1 Production of plasmids 
5.2.1.1 PCR for LMP2A, LMP2B and LMP2A-N 
PCR was used to amplify LMP2A, LMP2B and LMP2A-N (Table 5.1) using 
pSG5-LMP2A plasmid DNA as template, which contains full length LMP2 gene 
(Gifted from Dr CW Dawson, university of Birmingham). Primers were designed 
to include the two cloning site sequences of pCDNA4 max/His A vector (see 
section 2.7.1), KpnI (GGTACC) and Xbal (TCTAGA). PCR conditions were 
optimised for different concentrations of MgCl2 (1.0mM, 1.5mM, 2.0mM, and 
2.5mM). For LMP2A, there was no difference among different concentrations of 
MgCl2; for LMP2B, there were strong signals with 2.0mM and 2.5mM of MgC12, 
but no signal with 1.0 and 1.5 mM of MgC12. For LMP2A-N-terminus, the signal 
with 2.5mM of MgC12 was weaker than the others (Figure 5.1). 
Table 5-1 Key to the nomenclature of plasmids and their products 
Plasmids pcDNA4-LMP2A pcDNA4-LMP2B pcDNA4-LMP2A-N- 
terminus 
pcDNA4 Max/His A 
Short name LMP2A LMP2B LMP2A-N vector 
Size of PCR products 1565bp 1137bp 368bp 5.3kb 
Transfected cell lines 293-2A 293-2B 293-2A-N Zeo 
Size of proteins 54KDa 38KDa 16KDa 
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Figure 5-1 PCR results for LMP2A, LMP2B and LMP2A-N 
(A) The LMP2A PCR product was 1565bp in size. The intensity was unaffected 
by different concentrations of MgC12. 
(B) The LMP2B PCR product was 1137bp in size. There were strong signals with 
2.0mM, 2.5mM MgCl2 and no signal with 1.0mM and 1.5 mM MgC12. 
(C) The LMP2A-N PCR product was 368bp in size. The signal with 2.5mM 
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5.2.1.2 Restriction digest of LMP2A, LMP2B, LMP2A-N and Vector DNA 
100 µl of each PCR product of LMP2A, LMP2B and LMP2A-N was purified and 
eluted in S0µ1 elution buffer. 3µg each of LMP2A, LMP2B or LMP2A-N DNA 
were digested with enzymes, KpnI and Xbal at room temperature overnight. 
Following restriction digest of DNA, strong and intense bands were observed at 
1565bp for LMP2A, 1137bp for LMP2B and 368bp for LMP2A-N (Figure 5.2 A, 
B). The target vector, 5.3 kb was restricted with KpnI and Xbal, and resolved by 
agarose gel electrophoresis (Figure 5.2 C). These bands were cut from the gel and 
purified. Resulting DNA of vector was dephosphorylated to reduce the risk of re- 
circularisation. The ligated DNA was transformed into DH5a bacteria. Plasmid 
DNA was extracted from each clone of LMP2A, LMP2B and LMP2A-N. 
5.2.1.3 Restriction digest of Mini prepare and Bulk prepare plasmid DNA, 
LMP2A, LMP2B and LMP2A-N 
Restriction digest of LMP2A, LMP2B, and LMP2A-N using KpnI and Xbal 
produced fragments corresponding to the presence of LMP2A, LMP2B and 
LMP2A-N (1565bp, 1137bp and 368bp respectively) and 5.3kb vector. 6 of 7 
LMP2A clones, 9 of 10 LMP2A-N clones and 8 of 10 LMP2B clones had the 
correctly sized DNA (Figure 5.3 A-C). The plasmids were then sequenced to 
ensure error free insertion of each gene, then bulked and restricted (Figure 5.3 D). 
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Figure 5-2 Agarose gel electrophoresis following restriction digest of LMP2A, 
LMP2B, LMP2A-N and vector DNA 
DNA was digested by two restriction enzymes, KpnI and Xbal. 
(A) There were multiple bands for LMP2A, but the strong and intense band was at 
1565bp. A clear single band was for LMP2A-N (368bp). 
(B) Clear single bands were present for LMP2B (1137bp). 
(C) The bands of 5.3kb in size were for the vector. 
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Figure 5-3 Analysis of restriction digest of Mini-prepare and Bulk-prepare 
plasmids, LMP2A, LMP2B and LMP2A-N 
LMP2A, LMP2B and LMP2A-N plasmids were digested with KpnI and Xbal. 
(A) 6 of 7 clones showed the correctly sized LMP2A insert (1565bp). 
(B) 8 of 10 clones showed the correctly sized the LMP2B insert (1137bp). 
(C) 9 of 10 clones showed the correctly sized LMP2A-N insert (368bp). 
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5.2.2 Expression of LMP2 in HEK293 cells 
Various techniques were tried to transfect HL cell lines with the His-tagged 
versions LMP2 plasmids generated above was unsuccessful, so they were used to 
transfect HEK293 cells, which are much more tolerable than HL cells. The Tag 
was used as a target to detect the expression of LMP2 in the transfected cells, but 
also as a bait for the purification of LMP2 proteins with Ni-NTA (nickel 
nitrilotriacetic acid). 
5.2.2.1 Generation of LMP2-expressing HEK293 cell lines 
293 cells were transfected with His-tagged plasmids or an empty vector as a 
control, using Lipofectamine 2000 reagent according to the procedures outlined in 
Chapter 2 Section 2.10.1. Zeocin (500ug/ml) was used to select the stably 
transfected cells and expression was confirmed by RT-PCR. Figure 5.4 shows 
expression of LMP2A, LMP2B and LMP2A-N in each cell line. 
Immunofluorescence was used to confirm protein expression. Cells grown on 
Teflon-coated slides were stained using anti-His antibody (Upstate, 1: 200) and 
Bala serum (1: 50) (Figure 5.4). Control cells gave only a low background level of 
staining, whereas 293-LMP2A cells showed staining of perinuclear and cytosolic 
vesicles with both reagents. 293-2B and 293-2A-N cells were also stained with 
either reagent. However, 293-2B cells showed 100% positivity with Bala serum 
with strong, bright vesicular staining, but only a few cells showed perinuclear 
staining with His-antibody which was colocalised with the brightest staining of 
the Bala reagent. Only about 10% of 293-2A-N cells showed positive staining 
with both reagents (data not shown). 
174 
Results Chapter 5 
Figure 5-4 Confirmation of expression of LMP2A, LMP2B and LMP2A-N in 
transfected cell lines 
(A) HEK293 cells transfected with His-tagged plasmids were subjected to RT- 
PCR to confirm expression from each construct. Full length LMP2A (1565bp) and 
LMP2B (1137bp) were amplified. Furthermore, LMP2A specific primers were 
designed that would specifically amplify a sequence unique to LMP2A (279bp) 
and were used to detect LMP-2A-N expression. Both 293-Zeo and K-Neo cells 
showed no signal for LMP2A. X50-7 was used as a positive control. GAPDH 
PCR was performed to ensure RNA integrity. 
(B) Immunofluorescence staining showed that the 293-2A cells had strong, bright 
and vesicular staining with anti-His antibody and Bala serum, which was similar 
between the two reagents. 293-2B cells were also stained with both Bala serum 
and anti-His antibody. However, whereas all 293-2B cells were positive with Bala 
serum with strong, bright vesicular staining, only a few cells showing perinuclear 
staining were stained with the anti-His antibody which was colocalised with the 
brightest staining of the Bala reagent. 293-Zeo cells were used as a negative 
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To establish that transfected HEK293 cell lines were expressing full length tagged 
versions of LMP2A, LMP2B or LMP2A-N, protein expression was investigated 
by immuno-blotting (Section 2.4.2). Protein lysates were prepared with 1% Triton 
100 (Sigma) and exposed to anti-His antibody (Upstate, 1: 1000) and goat anti- 
mouse HRP secondary antibody (Dako, 1: 1000). A series of concentrations from 
293-2A cells (50µg, 25µg, 12.5µg and 7.51tg) were tested alongside 50µg of 
protein from parental 293 cells and from 293-2A-N cells. 5011g of protein from 
293 cells transiently transfected with LMP2A were used as a positive control. 
Figure 5.5 A shows that full length LMP2A (54kDa) could be detected in 293-2A 
cells down to 12.51tg of protein. A very faint signal (14kDa) was detected from 
one clone of LMP2A-N cells. Figure 5.5 B shows the detection of LMP2B at the 
expected molecular weight (4OkDa). It was observed that the signal for LMP2B 
was stronger if lysates of 293-2B cells were prepared using 8M Urea buffer 
instead of 1% Triton-100 (data not shown). 
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Figure 5-5 Expression of LMP2A and LMP2B in 293 cells detected by 
immunoblotting 
(A) A series of protein concentrations from 293-LMP2A cells (50µg, 25µg, 
12.5µg and 7.5µg) along with the 50µg of protein from 293-Zeo cells and from 
two clones of 293-2A-N cells. 50µg of protein from transiently transfected 293 
cells with LMP2A was used as a positive control. The 54kDa LMP2A protein 
could be detected in 293-2A cells down to 12.5µg of protein. As expected, 293- 
Zeo cells showed no signal for LMP2A. A very faint signal for LMP2A-N 
(14kDa) was detected from one clone (pointed by an arrow). 
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5.2.3 Purification of LMP2 proteins with Ni-NTA 
The His-tagged LMP2 proteins were purified as described in section 2.11.1mg 
protein was incubated with l001i1 of 50% v/v washed Ni-NTA beads. The proteins 
were eluted with 100µl pH 8.0 elution buffer with different concentration of 
imidazole (100mM, 150mM, 200mM, 250mM) and O. 1M EDTA (pH 8.0). 20µl of 
each eluted protein was loaded for western blotting and the membrane was blotted 
with anti-His antibody (1: 1000). Figure 5.6A shows the purification of LMP2A. 
50µg of LMP2A crude lysate was run as a control. Flow-through fractions (FT) 
and 2 washing fractions (wash) were run in the same panel. 4 samples were eluted 
with different concentrations of imidazole and Figure 5.6 A shows that the highest 
concentration of imidazole gave the best efficiency of elution. 0.1M EDTA eluted 
most of the bound His-tagged LMP2A proteins, but also increased the elution of 
non-specific binding proteins. However, when the concentration of imidazole was 
increased to 50mM in the washing buffer, the non-specific binding was decreased 
dramatically and a clear single band of the purified LMP2A eluted with O. 1M 
EDTA compared with the crude lysates from 293-2A and 293-2A-N (Figure 5.7 
B). Unfortunately, LMP2A-N could not be detected after purification. Figure 5.7 
C shows there were more LMP2B proteins in the flow-through than in the elution. 
Immunoblotting also showed the signal of LMP2B was stronger if the lysate was 
prepared in 8M urea buffer than in 1% Triton lysis buffer (data not shown). Taken 
together with the staining results these data suggest that the His-tag of LMP2B 
might have been partially hidden in the native conditions because of the 
conformation of the protein. 
180 
Results Chapter 5 
Figure 5-6 Purification of LMP2 proteins with Ni-NTA 
(A) Purification of LMP2A. 50µg of LMP2A crude lysate (CL) was run as a 
control. Flow through (FT), washl and wash2 were run in the same panel. 4 
samples were eluted with different concentrations of imidazole (100mM, 150mM, 
200mM, and 250mM). The highest concentration of imidazole gave the best 
efficiency of elution. 0.1 M EDTA eluted most of the bound His-tagged LMP2A 
proteins, but also some non-specific proteins. 
(B) A clear band of LMP2A (arrowed) was eluted with O. 1M EDTA when the 
concentration of imidazole was increased to 50mM in the washing buffer. No 
signal of LMP2A-N was shown after the purification. 
(C) There were more LMP2B proteins in the FT than in the elution; this might be 
because the His-tag of LMP2B was partially hidden because of the protein 
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Key: CL=crude cell lysate FT=Flow-through fractions. Wash=washing 
fractions. ET=Elution fractions 
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5.2.4 Identification of LMP2A or LMP2B interacting proteins 
5.2.4.1 Mass spectrometry 
Mass spectrometry is a powerful analytical technique that is used to identify 
unknown compounds, to quantify known compounds, and to elucidate the 
structure and chemical properties of molecules. The mass spectrometer is 
composed of an ionisation source, an analyser, and a detector (Figure 5.7). The 
sample is introduced into the ionisation source to be ionised before the mass 
spectrometer can influence it in an electric field. These ions are extracted into the 
analyser region of the mass spectrometer where they are separated according to 
their mass (m) -to-charge (z) ratios (m/z). The separated ions are detected and this 
signal sent to a data system where the m/z ratios are stored and the m/z values of 
the ions are plotted against their intensities to show the number of components in 
the sample (a mass spectrum). 
Figure 5-7 The components of a Mass Spectrometer 
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MS/MS is a coupling of two stages of mass analysis. From a mixture of ions in 
the source region, ions of a particular m/z value are selected in the first stage of 
mass analysis. These "parent" or "precursor" ions are fragmented and then the 
product ions resulting from the fragmentation are analyzed in a second stage of 
the mass analysis (Figure 5.8). 
Figure 5-8 Schematic of MS/MS analysis 
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Fragmentation is a reaction whereby an ion is broken down into ions with smaller 
masses. The accepted nomenclature for fragment ions was first proposed in 1984 
(Roepstorff and Fohlman, 1984) and subsequently modified in 1987 (Johnson et 
al., 1987). There are three different types of bonds that can fragment along the 
amino acid backbone: the NH-CH, CH-CO, and CO-NH bonds. Each bond 
breakage gives rise to two species, one neutral and the other one charged, and 
only the charged species is monitored by the mass spectrometer. There are six 
possible fragment ions for each amino acid residue and these are labelled as the a, 
b, and c ions having the charge retained on the N-terminal fragment, and the x, y, 
and z ions having the charge retained on the C-terminal fragment. The most 
common cleavage sites are at the CO-NH bonds which give rise to the b and/or 
the y ions The a ions are often used as a diagnostic for b ions, such that a-b pairs 
are often observed in fragment spectra. The a-b pairs are separated by 28units, 
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the mass for the carbonyl, C=O. The precursor ion can be singly, doubly or triply 
charged. A doubly charged precursor can be fragmented into singly, doubly 
charged a, b and y ions. The fragment types showed below are the most common 
fragments observed (Figure 5.9). 
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5.2.4.2 Stable isotope labelling with amino acids in cell culture (SILAC) analysis 
The SILAC method is outlined in detail in section 2.12.293-2A, -2B or -Zeo cells 
were grown in the medium containing either [13C6]-arginine or normal [12C6]- 
arginine for at least 5 passages. Lysates were prepared from each treatment and 
mixed in a 1: 1 ratio according to their protein concentrations, purified with Ni- 
NTA beads and then resolved on a 4-21% (wtlvol) SDS-PAGE gel. The entire 
lane was excised in ten sections and digested with trypsin for LC-MS/MS 
analyses. Samples were loaded, analysed and data was collected as described in 
section 2.12.5. The mass of the peptides determined in the initial MS analysis is 
shown in Figure 5.10. The peptides containing [13C6]-arginine residues are heavier 
by 6 Da than the corresponding peptides containing [12C6]-arginine residues, but 
they differ by 6 or 3 m/z (mass to charge ratio) as they are singly or doubly 
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charged. Figure 5.10 A shows a typical MS profile in which the retention time 
(RT) was 40.17 min. RT is correlating to identification of the eluting amino acid 
of a peptide or protein to a standard chromatogram of HPLC gradient. There is a 
clear peak of 626.40 m/z. The bottom panel shows an enlarged area around 626.40 
m/z. Another peak of 620.24 m/z is observed, which could be the light isotopic 
partner. These two peaks are paired differently by 6m/z, indicating they are singly 
charged. The heavy peptide is more abundant than the light one. Figure 5.10 B 
shows a different MS profile, where two peaks of 616.50 and 619.64 m/z can be 
observed; representing another pair which differ by 3m/z indicating they are 
doubly charged. Here, the light peptide is more abundant that the heavy one. 
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Figure 5-10 Mass spectrometric analysis 
The peptides containing [13C6]-Arginine residues are heavier by 6Da than the 
peptides containing [12C6]-Arginine residues. 
(A) The upper panel shows a typical MS profile, ranging from 400 to 2000 m/z, 
generated during the analysis. The retention time was 40.17 min. Between 600 
and 700m/z, there was a clear peak of 626.40 m/z marked by a red cross. The 
lower panel shows an enlarged image of the area around 626.40m/z. Another peak 
of 620.24 m/z was found, which could be the light isotopic partner. These two 
peaks differed by 6m/z, which corresponds to the singly charged ions. The heavy 
peptide was more abundant than the light one. 
(B) The upper panel shows another MS profile, ranging from 400 to 2000m/z, the 
retention time of which was 35.51 min. There were two clear peaks of 616.50 and 
619.64 m/z, respectively marked by a red cross. Lower panel shows enlarged of 
this area. Another pair is repeated here which differ by 3m/z (doubly charged), in 
this example the light peptide was more abundant that the heavy one. 
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5.2.4.3 [12C6J- and P2C61peptides elute at the same time 
Although arginine-containing peptides appeared in a light and heavy form 
separated by 6 Da, they co-elute because they are chemically indistinct. Relative 
quantification is performed from single peptide in the MS mode, relating the two 
monoisotopic peaks from peptides containing [1206]-and [13C6]-Arginine. Figure 
5.11 shows the elution profile of ions with 616 and 619 m/z (see Figure 5.10B). 
The red arrow in Figure A indicates the peak time point of 35.51min, showing the 
coelution of the peptide pairs. Figure B shows an expanded elution pattern of the 
pairs. Both of them started at 35.37 min and finished at 36.11 min. 
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Figure 5-11 [13C61- and [12C61-peptides eluted at the same time 
The elution profile of ions with of 616 m/z and 619 m/z is shown with a peak at 
35.51 minutes. The X-axis is time (min) and Y-axis is relative abundance of 
peptides. 
(A) The red arrow shows indicates the peak elution time 35.51min at which the 
light and heavy peptides eluted. 
(B) An enlarged image of the peak elution time of the peptide pairs is shown. 
Both of them started from 35.37 and finished at 36.11 minutes. 
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5.2.4.4 MS/MS analysis 
After the initial analysis of MS, the selected ions were subject to MS/MS analysis 
as a part of the automated analysis performed by the ion trap. The most abundant 
5 ions were selected and analyzed sequentially after each full MS scan. The 
fragmentation spectra were analyzed using TurboSequest as a part of the 
BioWorks 3.1 suite of data analysis programs using the NCBI non-redundant 
protein database in an attempt to determine the sequence of the peptide. Peptide 
abundance ratios from the peak intensities of the extracted ion chromatograms 
were averaged to give protein abundance ratios. Peptide ratios were also verified 
by quantification directly on the basis of the mass spectra. Figure 5.12 shows an 
example of the MS/MS analysis. 
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Figure 5-12 Evaluating the quality of the MS/MS analysis 
This figure shows MS/MS analysis of fragmented ions generated from peptides 
shown in Figure 5.10. The a, b and y ions identified in the spectra are shown in 
green, red and blue, respectively. The top panel shows that 8/11 y-ions of the light 
peptide were detected and the bottom panel shows that 9/11 y-ions of the heavy 
peptide were observed. Most b-ions and some a-ions were also seen from the two 
peptides. The difference between the detected a-ions (green) and b-ions (red) in 
the two panels is 28 units. The fragmented ions in this example are singly charged 
(blue boxes). Between heavy ions (upper panel) and light ions (lower panel) 
shows they differ by 6 m/z as expected. The y ions are always the most abundant 
ions after fragmentation. The b ion fragments with no arginine are not different 
between the two panels. 
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5.2.4.5 Protein comparison view with Mass spectrometric analysis for looking at 
difference of doublets 
5.2.4.5.1 Spectrum comparison 
To valuate the matches of heavy and light ions after fragmentation, the data was 
also analysed using the Xcalibur software package. Figure 5.13 illustrates the 
coupling of stable isotopes and mass spectrometry for both the identification of 
proteins and the quantification of their relative levels. Multiple singly and doubly 
charged peaks in MS/MS spectra from 616m/z and 619 m/z are shown. The 
corresponding fragmented light and heavy ions differ by 6 m/z units, which 
represent singly charged ions and by 3m/z units, which represent doubly charged 
ions. 
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Figure 5-13 Spectrum comparison 
MS/MS data was analysed with Xcalibur software package. The m/z of the ions 
was determined in the initial MS analysis and was used to select ions for MS/MS 
analysis. Multiple singly and doubly charged peaks in MS/MS spectra from 
616m/z and 619m/z are shown as an example. Corresponding fragmented light 
and heavy ions are shown which differ by 6 m/z units if were singly charged and 
3m/z units if doubly charged. The top panel showed the fragmented light ions and 
the bottom panel showed the fragmented heavy ions. The paired ions singly 
charged, are labelled by a red cross. The doubly charged paired ions are marked 
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5.2.4.5.2 Area comparison 
The fragmentation spectra were analyzed and quantified with the Xpress 
(ThermoFinnigan software programme). This programme calculates the ratio of 
the predicted heavy and light pairs. The data was checked manually to confirm the 
identification and to verify that an isotopic pair had been detected. The ratio of the 
paired ions is used to evaluate their abundance. Examples of Xpress data analysis 
are shown in Figure 5.14. 
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Figure 5-14 Area comparison 
On the left hand side of the each graph are examples of the selection parameters of 
ions: charge, mass, ratio of light: heavy (upper) or heavy: light (down), start and 
end time of elution. The shaded peak shows the identified ion. The farther away 
from 1 the ratio is, the more likely the protein is to interact with LMP2A or 
LMP2B. 
(A) The top panel shows the ratio of the two peptides was close to 1. This 
represents a non-specifically bound protein. 
(B) The middle panel shows the heavy peptide to be twice the abundance of the 
light peptide. 
(C) The lower panel shows the heavy peptide to be 10 times more abundant than 
the light peptide, which are therefore potential interacting proteins. 
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5.2.4.6 Quantification of protein ratios from peptide doublets in 293-2A or 293- 
2B cells 
In the MS, MS/MS analysis, the fragmentation pattern and the mass of the 
parental peptide were used to search the human and EBV databases to identify the 
peptide sequence and to assign the peptide to a protein. 
Peptide and protein identification from the MS/MS spectra was carried out as 
follows: Xcorr (XCorrection score)>2, Score>10, the first hit peptide>1. Xpress 
ratio is light: heavy. Doublets with ratio less than 0.66 were considered to be 
potential specific binding proteins. R# represents [13C6]-Arginine and R represents 
[12C6]-Arginine. MH+ represents mass of ion (M: molecule; H+, proton). 20 
doublets were found in 17 proteins in 293-2A cells (Table 5.2 A) and 27 doublets 
were found in 19 proteins in 293-2B cells (Table 5.2 B). The ions in the doublets 
containing [13C6]-Arginine residues are heavier by 6 m/z, 3m/z or 2m/z if they 
were singly, doubly or triply charged respectively. The ratio of the intensity of the 
heavy versus the light ions provides information about the strength of the protein 
interaction with LMP2A or LMP2B. Thus, the greater the extent of interaction, 
the higher its abundance in binding to LMP2A or LMP2B. Peptide pairs with little 
or no increase in intensity indicate that the protein is not different in abundance 
between the two states being compared. These proteins having an Xpress 
ratio>0.66 are likely to be nonspecifically bound proteins, so all of the doublets 
found in LMP2A cells were regarded as non-specific binding partners. There were 
5 possible binding partners of LMP2B, Ribosomal protein L27a, SFPQ protein, 
TUBB, G01211 54 kDa protein and EEF1A1 protein. The remainder were 
classified as non-specifically bound proteins. 
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Table 5-2 Quantification of protein ratios from peptide doublets in LMP2A 
and LMP2B cells 
The peptides containing [13C6]-Arginine residues are heavier by 6 Da. The ratio of 
light versus heavy ions provides information on the degree of these interactions 
with of LMP2A or LMP2B. The greater the interaction, the higher the ratio. 
Peptide pairs with a ratio close to 1 indicate that the protein is not different in 
abundance in the two states being compared and is likely to be interacting non- 
specifically. Doublets displaying a ratio less than 0.66 were considered to be 
specific interactions. In the Table, R# represents [13C6]-Arginine and R represents 
[12C6]-Arginine. MH+ represents mass of ion (M: molecule; H+, proton), and 
XCorr>2, Score>10, the first hit peptide>1. Xpress ratio is light: heavy. 
(A) 20 doublets of 17 proteins that were found in 293-2A cells compared with 
293-Zeo cells and all of them are identified as possible non-specific. 
(B) 27 doublets of 19 proteins that were found in 293-2B cells compared with 
293-Zeo cells. 5 proteins, Ribosomal protein L27a, SFPQ protein, TUBB, G01211 
54 kDa protein and EEF1A1 protein showed a ratio<0.66 and can therefore be 
regarded as specific LMP2b interactions. 
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Results Chapter 5 
5.2.4.7 Potential binding partners of LMP2A or LMP2B without finding their 
doublets 
The data by analysis identified one third of the peptides which have [13C6]- 
Arginine with high Xcorr, first hit peptide and Xpress ratio<0.66, but without 
detection of the counterpart light peptide. These data were searched manually 
again using Turbosequest and Xcalibur software package. The new criteria were: 
1) Finding light counterpart from unfiltered database. 2) Paired fragments were 
found manually by Xcalibur software. 3) Xpress ratio «0.66.4) Xpress area 
showed a neat, monopeak with ratio«0.66.5) MS/MS showed a clear 
background with good matches of y-ion and b-ion. From the new search, 10 
proteins were found as potential LMP2A binding partners and 15 proteins as 
potential LMP2B interactions (Table 5.3). 
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Table 5-3 Potential binding partners of LMP2A and LMP2B without finding 
their binding partners 
The data base was searched manually again using Turbosequest and Xcalibur 
software package according to the new criteria as described above. 10 novel 
proteins were found as potential LMP2A binding partners and 15 novel proteins 
as potential LMP2B interactors, of which particular interest is the possible 
interaction of DNA methyl transferase 1 (DNMT1) with LMP2A and OB- 
cadherin with LMP2B. 
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5.3 Discussion 
LMP2 is expressed in most EBV-associated tumours, including Hodgkin's 
lymphoma, nasopharyngeal carcinoma, and gastric carcinoma (Brooks L., et al, 
1992; Busson P, et al., 1992; Niedobitek et al., 1997; Takada K et al., 2000). 
Some proteins have been reported to interact with LMP2A in different cell 
backgrounds, but no systematic identification of LMP2 interacting proteins has 
been attempted. In this study, His-tagged LMP2A and LMP2B genes were 
expressed in HEK 293 cells and quantitative SILAC analysis with LC-MS/MS 
analysis was performed to identify potential LMP2 interacting proteins. 
SILAC has recently emerged as a valuable proteomic technique that has the 
capability to identify specific protein-protein interactions (Ibarrola et al., 2003, 
Ibarrola et al., 2004, Blagoev et al., 2003). Mann and colleagues used this 
approach in HeLa cells to examine changes associated with epidermal growth 
factor (EGF) signalling (Blagoev et al., 2003). Coupled with affinity purification 
to assess specific protein-protein interactions, their studies resulted in the 
identification and relative quantification of 228 proteins; 28 of which showed a 
significant enrichment upon stimulation by EGF with the rest being non-specific 
interactions. 
Here SILAC identified 10 potential interactors for LMP2A and 20 potential 
interactors for LMP2B. However, all of these require validation by other 
techniques such as immunoprecipitation and immunofluorescence. Of the 
potential interactors identified several are worthy of further discussion. DNA 
Methyl Transferase (DNMT) was identified as a potential LMP2A interactor. 
DNMTs include DNMT1, DNMT3a and DNMT3b. Overexpression of DNMT1 
has been detected in several human cancers (Sun et al., 1997; Saito et al., 2001; 
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Kanai et al., 2001). It was reported that DNMT1 increased cancer cell 
proliferative activity and may be associated with EBV infection and other 
etiological factors during gastric carcinogenesis (Etoh et al., 2004). EBV itself 
controls virus gene expression through the methylation of virus gene (Paulson and 
Speck, 1999). Furthermore, it has been shown that LMP1 downregulates 
expression of E-cadherin gene by activating of DNA methyltransferases (Tsai et 
al., 2002). It will be interesting to explore the potential cooperation between 
DNA methylation and signalling pathways mediated by LMP2. 
OB-cadherin was identified here as a possible LMP2B-interacting protein; this 
protein is widely distributed and functions as a cell-to-cell signalling and adhesion 
molecule, most notably in bone, where it is found on the bone cells that constantly 
remodel and maintain the structural integrity of bone (Okazaki et al., 1994; 
Lecanda et al., 2000; Kii et al, 2004). OB-cadherin is important in 
certain mechanisms of tumour spread. Many reports suggest that OB-cadherin 
plays a significant role in cancer (Pishvaian et al., 1999; Tomita et al., 2000; Nagi 
et al., 2005). Early-stage carcinomas do not express OB-cadherin, but rather 
express E-cadherin, like the epithelial cells from which they are derived. 
However, cadherin switching may occur where OB-cadherin is up-regulated as the 
tumour dedifferentiates, facilitating metastatic dissemination by promoting the 
motility of the tumour cells (Cavallaro et al., 2002; Hazan et a!., 2004; Suyama et 
al., 2002). It was reported that LMP2B may directly influence cell adhesion and 
motility in epithelial cells (Allen et al., 2005). More importantly, the array results 
(Chapter 4) show that LMP2B altered a great proportion of genes involved in 
adhesion and motility in KMH2 cells. Therefore it will be important to investigate 
whether LMP2B interaction with OB-cadherin is involved in this process. 
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SILAC combined with LC-MS/MS to identify protein interactors is a long 
process. Any steps could have an influence to the results. Several aspects affect to 
identify specific interacting proteins. Keratin contamination happens very 
frequently, which interferes with LC-MS/MS analysis to identify some important 
but less abundant peptides by occupying the most hit proteins. Purification of 
LMP2 proteins is a possible step to lose LMP2 interacting proteins. Handling the 
proteins gently to avoid disrupt LMP2's interacting proteins is the key. Getting rid 
of the non-specific proteins, which compete binding sites of the Ni-NTA beads 
increases the possibilities to identify the specific ones. 
It is concluded that the combination of LC-MS/MS and SILAC is an excellent, 
reliable method in quantitative proteomics to identify interacting proteins of 
LMP2. This study has successfully shown that the technology, SILAC can be 
applied to a model of identifying interacting proteins. Extending from this, SILAC 
can be applied to various researches for which SILAC could prove useful for 
quantitative proteomic analysis. 
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6 Conclusions and future work 
The transfection of HL cell lines is always regarded as problematic and possibly 
more so if the transgenes are toxic transmembrane proteins such as LMP2. An 
alternative way to deliver expression of LMP2 to EBV-negative HL cell lines is 
by the use of retroviral vectors carrying these viral genes. Therefore, the effect of 
LMP2A and LMP2B in HL cell background is able to be investigated. 
The expression of LMP2 in the two infected HL cell lines showed a similar 
pattern, which was low at two weeks post infection, gradually increasing and 
remaining stable at 8 weeks post-infection. Both proliferation and viability assays 
showed no significant difference with the expression of LMP2A or LMP2B in 
KMH2 and L428 cells as compared with their control neomycin-expressing 
counterparts at two weeks post-infection. At two weeks post-infection, the toxicity 
of LMP2A might predominate over its effect on proliferation, particular in the low 
serum conditions used or the expression of LMP2 may have been insufficient to 
induce the proliferation of HL cells. This result does not exclude the possibility 
that LMP2 provides a survival signal to HL cells, particularly as gene expression 
microarrays showed that the genes commonly altered by LMP2A and LMP2B are 
mainly involved in signalling transduction, proliferation and anti-apoptosis 
regulation. Therefore, it would be worthwhile to perform the proliferation and 
viability assays with the LMP2 expressing cells at 8 weeks post infection to 
further explore the growth and survival ability of LMP2. 
Analysis of the microarray data from LMP2A and LMP2B expressing KMH2 
cells identified many changes in cellular gene expression, some of which were 
examined in more detail. Semi-quantitative PCR confirmed the array result that 
IFI27, an interferon-a regulated gene implicated in cancer, was down-regulated 
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by LMP2A, but not LMP2B. The down regulation of IFI27 was also observed in 
EBV infected KMH2 cells compared with its parental counterparts and L591 cells 
compared with their EBV-negative counterparts. However, how LMP2A or EBV 
down-regulate IFI27 in HL cell lines and what the functional consequences of this 
down-regulation are need further investigation. LMP2A might maintain EBV 
latency and provide its survival signals for HRS cells through down-regulating 
IFI27. Experiments examining the signalling pathways responsible for LMP2A- 
induced down-regulation of IFI27 using LMP2A mutants and/or chemical 
inhibitors (e. g. blockade of P13-kinase) should be performed. These could be 
compared to the effects of directly reducing IFI27 expression using RNA 
interference. The expression of IFI27 in fresh HL biopsies should also be 
performed and a comparison between EBV-positive and EBV-negative HL cases 
undertaken. 
The expression level of LMP2 appeared to influence cellular gene expression. 
AICDA was down-regulated in KMH2 cells expressing lower levels of LMP2A, 
KMH2 cells infected with EBV, and EBV positive L591 cells. In contrast, late 
passage KMH2-LMP2A cells expressing higher levels of LMP2A up-regulated 
AICDA. Thus it appears that `physiological' levels of LMP2A are important in 
determining the gene expression consequence of this protein. Therefore, it will be 
necessary to confirm the RNA expression change described here at the protein 
level and to determine how this relates to the level of LMP2A expression in HRS 
cells. 
The loss of B cell lineage markers by HRS cells has been widely reported. In this 
study, many genes involved in BCR signalling that are down-regulated in HL, 
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were found to be up-regulated by LMP2A. This suggests that LMP2A utilises 
some components of the BCR pathway to maintain EBV latency, possibly to 
transform GC cells into HRS cells, but the precise details of how LMP2A uses 
BCR signalling docking proteins to play its role needs to be investigated. The use 
of LMP2A mutants with specific changes in key signalling motifs should help to 
further dissect the pathways involved in regulating specific aspects of cellular 
gene expression. 
To identify cellular proteins that interact with LMP2, His-tagged versions of 
LMP2A and LMP2B were stably expressed in HEK 293 cells. The expression of 
LMP2 in these cells was confirmed. The His-tag of LMP2B (sited at the N- 
terminus) was partially hidden in the native condition because of the confirmation 
of this transmembrane protein. In future studies the effect of a C-terminal His-tag 
should be examined. The combination of LC-MS/MS and SILAC is a reliable 
method in quantitative proteomics to identify interacting proteins of LMP2. Using 
this approach, 10 LMP2A potential binders and 20 LMP2B potential binders were 
identified. All these potential interactions require validation but of particular 
interest is the possible interaction of DNA methyl transferase 1 (DNMT1) with 
LMP2A and OB-cadherin with LMP2B. It has been reported that DNMTl can 
increase cancer cell proliferative activity and may be associated with EBV 
infection, so it will be interesting to explore the potential cooperation between 
DNA methylation and signalling pathways mediated by LMP2. Of particular 
importance is the detailed validation of the interaction between LMP2A and 
DNMT1 including an examination of specificity (using LMP2A mutants) and a 
thorough analysis of subcellular localisation of the two proteins. 
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OB-cadherin is widely distributed and functions as a cell-to-cell signalling and 
adhesion molecule, functional effects that may be induced by LMP2B. Gene 
expression arrays showed that LMP2B altered a large number of genes associated 
with adhesion and motility in HL cells, one of which (cadherinl3) is related to 
OB-cadherin. Detailed validation of this interaction, particularly as it appears to 
be occurring with a membrane spanning molecule, is necessary including co- 
localisation studies using confocal microscopy. Once confirmed, functional 
studies examining the effects of LMP2B on cadherin-mediated effects such as cell 
adhesion and motiliy could be performed. 
Overall , the studies 
described in this thesis demonstrate that LMP2A and LMP2B 
have profound effects on the behaviour of HL cells and thus are likely to 
contribute to the role of EBV in the pathogenesis of HL. In future studies it will 
be important to move away from the use of HL cell lines and develop an in vitro 
model that will allow an assessment of LMP2 function in a more appropriate 
cellular environment. We have recently validated an approach in which EBV 
genes are transfected into isolated GC B cells and any effects are subsequently 
examined using microarray analysis. It will be interesting to use this method to 
determine the effect of LMP2A and LMP2B on the primary GC B cell phenotype 
and to relate this to the data presented in this thesis. 
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8 Appendix 
8.1 Sequences of primers 
8.1.1 Primers for PCR 
LMP2A (full length): 
Forward primer: 5'-ATG ACT CAT CTC AAC ACA TAT ACG AAG AAG-3' 
Reverse primer: 5'-ATA AAA ACT GGA CCG TAT GTT CTA TTT CCA-3' 
LMP2A (N-terminus): 
Forward primer: 5'-ATG ACT CAT CTC AAC ACA TA-3' 
Reverse primer: 5'-CAT GTT AGG CAA ATT GCA AA-3' 
LMP2B (full length): 
Forward Primer: 5'- ATG TAT GAA TCC AGT ATG CCT GCC T-3' 
Reverse Primer: 5'-TTA TAC AGT GTT GCG ATA TGT CCA-3' 
















8.2 Media, solutions and reagent 
8.2.1 Solutions for small scale and large scale extraction of plasmid DNA 
Solution I (100ml) 
50mM Glucose 0.9g 
25mM TrisHCI (PH 8.0) 0.3g 
10mM EDTA (PH 8.0) 0.37g 
Autoclaved for 15 min at lOp/sg. 
Store at 4°C. 
Solution II: 
0.2N NaOH (freshly diluted from ION NaOH) 
1%SDS 
Solution III(100ml): 
60m1 5M potassium acetate 
11.5m1 Glacial acetic acid 
28.5ml H2O 
8.2.2 L-Broth Agar solution and L-Broth Agar plate 
L-Broth Agar solution: 
I Og L-Broth powder 
7.5gNutrient Agar 
500 ml distilled H2O 
Autoclaved. Add Amipicillin after it cools down (lmg/ml). 
L-Broth plate solution 
1 Og L-Broth powder 
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500 ml distilled H2O 
Autoclaved. Add Amipicillin after it cools down (lmg/ml). 
8.2.3 Solution for western blotting 
PBS-Tween 
100 Dulbecco A tablets (Oxoid Ltd) 
10 ml Tween 20 (Sigma, P7949). 





10 litre distilled H2O 
pH 7.6 
Gel Sample Buffer (GSB) 
50mM Tris solution (pH6.8) 












144g of glycine 
2 litres of methanol 
8 litres of distilled H2O 
RIPA buffer 




0.1% SDS in SDW 
5gg/ml leupeptin (Sigma, L8511) 
Aprotinin (Sigma, p5318) 
0.5mM sodium orthovanadate (Sigma, s6508) 
0.5mM sodium fluoride (Sigma, S7920) 
1mM PMSF (Sigma, P7626) added immediately proior to use. 
8M Urea Lysis Buffer 
Dissolved 480.48 urea (8M) in 1 litre dH2O 
Stripping Buffer 
100mM Tris-HC1 pH 6.8 




8.2.4 Solution for immunofluorescence staining 
4% Paraformaldehyde (PFA) 
20g PFA dissolved in 500 ml distilled H2O by stirring overnight at 42°C. 
Once dissolved, 5 Dulbecco A were added. 
20%HINGS 
Heat inactivated normal goat serum diluted to 20% in PBS. 
DABCO 
90m1 of glycerol 
2.5g of DABCO power 
10 ml PBS 
pH 8.6 
Covered in silver foil 

















8.2.6 Buffers for gene expression microarray 
12X MES Stock: 
64.61 g MES hydrate 
193.3g MES Sodium salt 
800 ml RNAse free dH2O 
Mix and adjust volume to 1000ml. Check the pH is between 6.5 and 6.7. 
Filter through a 0.2µm filter. 
2X Hybridisation Buffer (50m1): 
8.3 ml of 12X MES Stock Buffer 
17.7 ml of 5M NaCl 
4.0 ml of 0.5M EDTA 
0.1 ml of 10% Tween 20 
19.9 ml RNase free dH2O 
Store at 4°C 
2X Stain Buffer (250m1): 
41.7 ml 12X MES Stock Buffer 
92.5 ml 5M NaCI 
2.5 ml 10% Tween 20 
112.8 ml RNase free dH2O 
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Filter through a 0.2µm filter and store at 4°C in the dark. 
Non-Stringent Wash Buffer (A) (1000ml): 
300 ml 20 X SSPE 
1 ml 10% Tween 20 
698 ml dH2O 
Filter through a 0.2µm filter. 
Stringent Wash Buffer (B) (1000ml): 
83.3 ml 12X MES Stock Buffer 
5.2 ml 5M NaCI 
1 ml 10% Tween 20 
910.5 ml dH2O 
Filter through a 0.2µm filter and store at 4°C in the dark 
8.2.7 Buffer for staining 
Coomassie Brilliant Blue 
0.08% Coomassie Brilliant Blue G250 
1.6% Orthophosphoric Acid 
8% Ammonium Sulphate 
20% Methanol 
8.3 List of genes altered by LMP2A or LMP2B in KMH2 cells 
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brain-derived neurotrophic factor 
sorbin and SH3 domain containing I 
death-associated protein kinase I 
v-myb myeloblastosis viral oncogene homolog (avian)- 
like I 
carbonic anhydrase VIII 
dopachrome tautomerase (dopachrome delta-isomerase, 
tyrosine-related protein 2) 
glucosidase, beta, acid 3 (cytosolic) 
Kruppel-like factor 5 (intestinal) 
Nuclear receptor subfamily 3, group C, member I 
(glucocorticoid receptor) 
RNA binding motif, single stranded interacting protein 
reticulon 1 
ubiquitin D 
Apoptosis inhibitor 5 
Chromosome 3 open reading frame I 
Chimerin (chimaerin) 2 
cystatin 11 
G antigen 2,4,5,6,7,7B, 8 
GI to S phase transition I 
inositol(myo)-1 (or 4)-monophosphatase 2 
KIAA0367 
N-myristoyltransferase 2 
reprimo, TP53 dependant G2 arrest mediator candidate 
sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6A 
unc-13 homolog B (C. elegans) 
unc-5 homolog C (C. elegans) 
collagen, type I, alpha I 
melanoma antigen family D, I 
Rho GTPase activating protein 6 
FERM domain containing 4A 
palladin 
pleckstrin homology domain containing, family C (with 
FERM domain) member I 
scinderin 
copine IV 
fatty acid binding protein 4, adipocyte 
glycoprotein M6A 
heure binding protein 1 
PMID: 15781614 
1.7 PMID: 16181428 
PM ID: 10962554 
PM ID: 15604270 
2.8 PMID: 15504914 
PM ID: 15569975 
2.5 PMID: 16142356 
PM ID: 10378697 
2.1 PMID: 16198555 
PM ID: 12816952 
1.8 PMID: 15069192 
3 PMID: 12695295 
PM ID: 12505051 
2.7 PMID: 12077779 
PMID: 12901861 
1.8 PMID: 16046710 
PM ID: 12637494 
1.8 PMID: 15590693 
1.9 PMID: 10675610 
PM ID: 15086514 
2 PMID: 15350194 
2 PM1D: 11445583 
PMID: 11557113 
1.7 PMID: 10780674 
1.6 PMID: 15126327 
PMID: 9018111 
-2.7 PMID: 9103432 
-3.1 PMID: 10099331 
PMID: 12432251 
-2.4 PMID: 12432252 
PM ID: 15987717 
1.7 PMID: 15917414 
1.7 PMID: 14767552 
1.8 PMID: 16288218 
1.7 PMID: 16123142 
PMID: 15700311 
-4.9 PMID: 11313928 
-2.2 PMID: 10993894 
-1.6 PMID: 10233166 
PM ID: 12655055 
1.6 PMID: 11387206 
PMID: 11479215 
1.6 PMID: 15727634 
PM ID: 16107717 
1.7 PMID: 15911347 
1.5 PM ID: 10699171 
PMID: 12697302 
-2 PMID: 16086323 
PM ID: 11598191 
-1.6 PMID: 16164966 
PMID: 15716039 
1.6 PMID: 15927810 
PMID: 15686479 
2.4 PMID: 12438125 
-3.4 PMID: 10416158 
PMID: 10935488 
-1.9 PMID: 15862280 
1.7 PMID: 12359212 
PMID: 15530461 











KIAA 1202 protein 
LAGI longevity assurance homolog 6 (S. cerevisiae) 
serine (or cysteine) proteinase inhibitor, Glade E (nexin, 
plasminogen activator inhibitor type 1), member 2 
Transmembrane 7 superfamily member I (upregulated in 
kidney) 
Transformer-2 alpha 
SPANX family, member Bl/B2 
SRY (sex determining region Y)-box 9 (campomelic 
dysplasia, autosomal sex-reversal) 
-1.8 PMID: 16249884 
-1.8 PMID: 16211262 
1.6 PMID: 10449603 
1.7 PMID: 9521871 
1.6 PMID: 15210204 
3 PMID: 14734458 
PM ID: 12173687 
-2 PMID: 10412367 
SASH1 

































SAM and SH3 domain containing I 
immunoglobulin kappa constant /// immunoglobulin 
kappa variable 1-5 
Fc receptor-like and mucin-like I 
guanylate binding protein 1, interferon-inducible, 67kDa 
/// guanylate binding protein 1, interferon-inducible, 
67kDa 
guanylate binding protein 2, interferon-inducible 
interferon, alpha-inducible protein 27 
interleukin 23 receptor 
selenoprotein P, plasma, I 
activation-induced cytidine deaminase 
Fc receptor-like and mucin-like I 
immunoglobulin kappa constant /// immunoglobulin 
kappa variable 1-5 
cytochrome P450, family 4, subfamily X, polypeptide I 
dihydropyrimidinase 
phenylalanine-tRNA synthetase-like, beta subunit 
fibrous sheath interacting protein I 
microsomal glutathione S-transferase I 
napsin B aspartic peptidase pseudogene 
thyroid peroxidase 
acid phosphatase-like 2 
ARG99 protein 
cytochrome P450, family 4, subfamily Z, polypeptide I 
dopachrome tautomerase (dopachrome delta-isomerase, 
tyrosine-related protein 2) 
follistatin-like 5 
Glycerophosphodiester phosphodiesterase domain 
containing I 
G protein-coupled receptor 39 
RAB27B, member RAS oncogene family 
synaptosomal-associated protein, 25kDa 
sulfotransferase family, cytosolic, I C, member I 
sulfotransferase family, cytosolic, IC, member I 
regulator of G-protein signalling 13 
A disintegrin-like and metalloprotease (reprolysin type) 
with thrombospondin type I motif, 2 
FERM domain containing 4A 
Guanylate binding protein 5 
1.9 PMID: 16137664 
2.4 PMID: 1961033 
1.7 PMID: 16176992 
PM ID: 10087221 
1.6 PMID: 12396730 
PMID: 15717119 
1.5 PMID: 11726669 
-2.9 PMID: 15661146 
PM ID: 16210605 
1.6 PMID: 15912962 
-2.8 PMID: 8562289 
PM ID: 16380510 
8.8 PMID: 16180254 
1.7 
2.4 PMID: 12357370 
PM ID: 15797250 
-2 PMID: 15752708 
PM ID: 16191478 
-1.8 PMID: 16176880 
PM I D: 16338408 
1.7 PMID: 15000680 
PM ID: 15804423 
1.6 PMID: 15860413 
PM ID: 15796179 
1.6 PMID: 15366924 
-1.7 PMID: 14674886 
PM ID: 16007166 
-1.9 PMID: 12536361 
PM ID: 16200454 
1.8 PMID: 14585503 
PMID: 12899827 
-3.6 PMID: 14555658 
PM ID: 16243809 
-3.3 PMID: 15797250 
PMID: 15265682 
1.9 PMID: 16033338 
PM ID: 12697670 
-4.7 PMID: 12039070 
1.6 PMID: 14612981 
PM ID: 9441746 
2.5 PMID: 16284170 
5.6 PMID: 15713878 
PMID: 16314394 
1.7 PMID: 15895198 
PM ID: 15754005 
1.9 PMID: 11740338 
PM ID: 11906176 
2.1 PM1D: 15754005 
PM ID: 15047827 
1.8 PMID: 15313557 
2.2 PMID: 14505115 
-2.2 PMID: 10718198 





immunoglobulin superfamily, member 3 
inter-alpha (globulin) inhibitor H5 
1.7 PMID: 11673522 
-1.8 PMID: 14744536 
PMID: 12154058 
1.7 PMID: 16096638 
PMID: 12970751 
-1.9 PMID: 15552795 
PMID: 15659660 
1.8 PMID: 12407192 
1.7 PMID: 15311059 
PMID: 15907837 
1.6 PMID: 12185600 
PMID: 16061841 
PMID: 15645137 




-2.8 PMID: 9214392 
PMID: 12134164 
-2.1 PMID: 15340013 
PMID: 12953056 
-1.9 PMID: 11823489 
PMID: 11863369 
-2.8 PMID: 11827793 
LOXL2 lysyl oxidase-like 2 
metastasis associated lung adenocarcinoma transcript 1 
MALATI (non-coding RNA) 
TJP4 Tight junction protein 4 (peripheral) 
TRIB2 tribbles homolog 2 (Drosophila) 
WASF3 
PRL 
WAS protein family, member 3 
prolactin 
DSC1 desmocollin 1 
TIAM1 T-cell lymphoma invasion and metastasis I 
JAM3 junctional adhesion molecule 3 
COL21A1 collagen, type XXI, alpha 1 
Proliferation 
amyloid beta (A4) precursor protein (protease nexin-II, 
APP Alzheimer disease) 
FGF13 fibroblast growth factor 13 
GAGE2, 
4,5,6,7,7B G antigen 2,4,5,6,7,7B 
IL6R interleukin 6 receptor 
PRG4 proteoglycan 4 
TRIM9 tripartite motif-containing 9 
Signal transduction 
PIAS I Protein inhibitor of activated STAT, 1 
ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha 
EPS8 epidermal growth factor receptor pathway substrate 8 
TNFRSF17 tumor necrosis factor receptor superfamily, member 17 
ARHGAP18 Rho GTPase activating protein 18 
AXIN2 axin 2 (conductin, axil) 
BLNK B-cell linker 
BMPIO bone morphogenetic protein 10 
BRDGI BCR downstream signaling 1 
CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) 
EZl-2 Enhancer of zeste homolog 2 (Drosophila) 
FAT3 FAT tumor suppressor homolog 3 (Drosophila) 
GPM6A glycoprotein M6A 
GPR125 G protein-coupled receptor 125 
KCTD3 potassium channel tetramerisation domain containing 3 
KIAA1671 KIAA1671 protein 
leucine-rich repeats and immunoglobulin-like domains 1 
/// leucine-rich repeats and immunoglobulin-like 
LRIGI domains 1 
MAP3K8 Mitogen-activated protein kinase kinase kinase 8 
MEGF10 MEGF10 protein 
NYREN18 NEDD8 ultimate buster-I 
PMID: 15637681 
-2.8 PMID: 11557776 
PMID: 15814652 
-2.1 PMID: 16223856 
-2.2 PMID: 14656993 
PMID: 15982327 
2.2 PMID: 12200683 
-1.8 PMID: 15719068 




1.5 PMID: 15297606 
PMID: 16024605 
1.7 PMID: 16042555 
PMID: 14699156 
2.7 PMID: 9087167 
PMID: 16116167 
2.1 PMID: 15294946 
1.6 PMID: 15492870 
PMID: 15735151 
1.5 PMID: 15572025 
PMID: 11489945 
1.9 PMID: 15029213 
-1.7 PMID: 16049014 
PMID: 10518561 
2.2 PMID: 12540842 
2.5 PMID: 15763430 
PMID: 15817459 
PMID: 9584199 
1.9 PMID: 15882624 
1.7 PMID: 16059920 
1.6 PMID: 12359212 
1.8 PMID: 15203201 
2 PMID: 11152963 
3.2 PMID: 15289310 
2.5 PMID: 15871317 
1.7 PMID: 15833743 
1.7 PMID: 11347906 
PMID: 16171779 












































phosphatidylinositol 3,4,5-trisphosphate-dependent RAC 
exchanger) 
Protein tyrosine phosphatase, receptor type, D 
regulator of G-protein signalling I 
sortilin-related VPSIO domain containing receptor 3 
sprouty homolog 2 (Drosophila) 
SLIT-ROBO Rho GTPase activating protein 2 
Ubiquitin-fold modifier I 
WW domain binding protein 5 
Ras and Rab interactor 2 
tetraspanin 7 
SNFI -like kinase 2 
phosphatase and tensin homolog (mutated in multiple 
advanced cancers 1) /// phosphatase and tensin homolog 
(mutated in multiple advanced cancers 1) 
dystrophin (muscular dystrophy, Duchenne and Becker 
types) 
Ras association (RaIGDS/AF-6) and pleckstrin 
homology domains 1 
Calmodulin 2 (phosphorylase kinase, delta) 
estrogen-related receptor gamma 
ets variant gene 5 (ets-related molecule) 
hephaestin 
HRAS-like suppressor 3 
lecithin-cholesterol acyltransferase 
pleckstrin homology-like domain, family A, member I 
ELKI, member of ETS oncogene family 
v-myc myelocytomatosis viral oncogene homolog 1, 
lung carcinoma derived (avian) 
inhibitor of DNA binding 3, dominant negative helix- 
loop-helix protein 
ELAV (embryonic lethal, abnormal vision, Drosophila)- 
like 2 (Hu antigen B) 
glutamate-ammonia ligase (glutamine synthase) domain 
containing I 
interferon regulatory factor 2 binding protein 2 
integral membrane protein 2A 
Kruppel-like factor 13 
LIM domain binding 2 
neural precursor cell expressed, developmentally down- 
regulated 9 
nuclear factor of activated T-cells 5, tonicity-responsive 
Nuclear factor VB 
Ring finger protein 12 
transcription elongation regulator I 
Thyroid hormone receptor associated protein 2 
Vesicle docking protein p115 
zinc finger protein 91 (HPF7, HTF10) 
SRY (sex determining region Y)-box 6 
splicing factor, arginine/serine-rich 6 
chromosome 9 open reading frame 4 
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-1.7 PMID: 15750623 
PM ID: 10395944 
-2 PMID: 9531590 
1.7 PMID: 16160139 
1.6 PMID: 15009648 
PMID: 15313890 
2.3 PMID: 15342396 
-1.6 PMID: 15328020 
1.7 PMID: 15071506 
1.9 PMID: 15548568 
1.9 PMID: 15574778 
PM I D: 15965503 
2.3 PMID: 10985391 
1.7 PMID: 15067358 
PM ID: 16170333 
1.7 PMID: 16169459 
1.9 PMID: 15757977 
PM I D: 11965544 
1.6 PMID: 15609301 
PM ID: 16026476 
1.5 PMID: 11454062 
PM ID: 15878968 
-1.5 PMID: 15149736 
PM I D: 15504914 
1.8 PMID: 15082862 
PM ID: 15081 108 
1.5 PMID: 15825077 
1.5 PMID: 11973642 
1.5 PMID: 14973367 
PM ID: 11773597 
PM ID: 15037619 
1.6 PMID: 15574883 
PM I D: 16156666 
-1.8 PMID: 16239230 
1.9 PMID: 12651874 
PM ID: 16177095 
PM ID: 15121845 
-1.7 PMID: 16297338 
PM ID: 15990917 
2.2 PMID: 15060621 
PM ID: 16169192 
1.6 PMID: 15208637 
1.6 PMID: 12799427 
2.3 PMID: 11863357 
PM ID: 16303770 
1.6 PMID: 12244575 
1.7 PMID: 15380350 
1.8 PMID: 9498705 
PM ID: 12080349 
-1.6 PM1D: 15897878 
PMID: 12145335 
1.7 PMID: 15632069 
PM ID: 11882901 
1.7 PMID: 10431247 
PM ID: 11604498 
-1.6 PMID: 15456888 
PM ID: 15145061 
1.6 PMID: 14638541 
1.6 PMID: 10858540 
1.6 PMID: 11470777 
PM ID: 14993235 
1.6 PMID: 12677004 
PM ID: 12549914 
-1.8 PMID: 15604250 
3.2 PMID: 10603000 
283 
Appendix 
I'M II ): 16354715 
SOX2OT SOX2 overlapping transcript (non-coding RNA) 2.5 I'MIl) 15')10506 
Transport protein 
V( d ;; `, ' hypothetical protein MGC33987 10.3 
MOSC2 M(X'O sulphurase ('-terminal domain containing 2 -1.6 I'M 11), 121132761 
solute career family 16 (nionocartx)xyhc acid I'Mll) 15331 b4 
SLCI6A6 /// LO-C440459 transporters), member 6 1.7 PMII): 12351693 
solute carrier family I (neuronal/epithelial high affinity I'M II ) 15197647 
SLCIAI glutamate transporter, system Xag), member 1 2. l I'M 11) 161211593 
solute carrier family 7, (cationic amino acid transporter. 
I( \I I y+ system) member 11 1.7 PM I I) 161030911 
SNX7 sorting ncxin 72 IN If) 161301 12 
DNA/RNA metabolism 













































CDNA FU36544 fis, clone "1RA('H? 006378 
Proteasome (prosome, macropain) activator subunit 4 
transcription elongation factor A (Sll)-like 7 
1'M II): 10102754 
1.8 PMII): 15077182 
1.6 PMII): 15653075 
3.5 
chromosome 15 open reading frame 27 1.8 
chromosome I open reading frame 150 -1.9 
chromosome 21 open reading frame 42 -2.8 
Chromosome 2 open reading frame 3 1.6 
chromosome 6 open reading frame 118 -2.7 
chromosome 6 open reading frame 54 1.7 
chromosome 8 open reading frame 31 1.6 
chromosome 9 open reading frame 70 1.7 
cystatin 11 -2.6 
chromosome X open reading frame 33 1.8 
family with sequence similarity 45, member A 1.6 
family with sequence similarity 46, member C 2.1 
Weakly similar to zinc finger protein 195 1.6 
KIAA0776 1.6 
KIAA1815 1.6 
similar to KIAA0386 1.6 
neuron navigator 2 1.7 
zinc finger and BTB domain containing 8 1.6 
zinc finger protein 227 1.8 
zinc finger protein 567 1.7 
Zinc finger protein 638 1.7 
zinc finger protein 652 1.6 
hypothetical protein DKFZp434JOI 13 -1.7 
F-box protein 22 1.5 
hypothetical protein FU21986 -2.3 
hypothetical protein FU21986 -2.2 
hypothetical protein FU22457 -1.6 
Hypothetical protein FU31810 2.5 
ketch-like 13 (Drosophila) 3.7 
hypothetical LOC 151261 1.9 
hypothetical protein LOC284757 1.9 
hypothetical protein LOC284757 1.9 
hypothetical LOCS53137 -2 
Hypothetical protein MGC22265 /// Similar to 
bAl 10H4.2 (similar to membrane protein) 1.7 
hypothetical protein FU37659 1.7 
L0C440460 1.6 
SET and MYND domain containing 2 1.7 
Transmembrane and coiled-coil domains 3 -1.5 
tribbles homolog 2 (Drosophila) 2.2 
U2AF homology motif (l%HM) kinasc 1 -1.7 
WD repeat domain 72 2.6 
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Table 8.2: Classification of cellular genes up- and down-regulated by LMP2B 









































dopachrome tautomerase (dopachrome delta-isomerase, 
tyrosine-related protein 2) 
glucosidase, beta, acid 3 (cytosolic) 
prostaglandin-endoperoxide synthase I (prostaglandin 




death-associated protein kinase I 
transcription elongation factor A (Sll)-like 7 
pleckstrin homology domain containing, family C (with 
FERM domain) member I 
kelch-like 13 (Drosophila) 
serine (or cysteine) proteinase inhibitor, Glade E (nexin, 
plasminogen activator inhibitor type 1), member 2 
testis specific A2 homolog (mouse) 
Leucine-rich repeats and immunoglobulin-like domains 2 
SPANX family, member BI /// SPANX family, member 
B2 
activation-induced cytidine deaminase /// activation- 
induced cytidine deaminase 
NADPH oxidase I 
cytochrome P450, family 4, subfamily Z, polypeptide I 
follistatin-like 5 
sulfotransferase family, cytosolic, IC, member I 
cytochrome P450, family 4, subfamily Z, polypeptide I 
carboxylesterase-like urinary excreted protein 
CD24 antigen (small cell lung carcinoma cluster 4 
antigen) 
Guanylate binding protein 5 
otoraplin 
sperm protein associated with the nucleus, X-linked, 
family member A1B1 /A2/C/B2 
opioid binding protein/cell adhesion molecule-like 
cadherin 13, H-cadherin (heart) 
inhibin, beta E 
laminin, alpha 3 
Runt-related transcription factor 1; translocated to, I 
(cyclin D-related) 
Growth arrest-specific 6 
2.8 PMID: 12695295 
2.8 PMID: 12505051 
PM ID: 12077779 
2.1 PMID: 11195467 
PM ID: 16201851 
1.9 PMID: 15086514 
PM ID: 15350194 
1.8 PM1D: 12203114 
2.5 PMID: 11445583 
2.0 PMID: 15569975 
PMID: 16142356 
4.4 
1.8 PM1D: 15716039 
PMID: 15927810 
5.7 PM1D: 15870933 
1.9 PMID: 10449603 
1.6 PMID: 15215198 
1.7 PMID: 15145052 
2.4 PMID: 12393489 
2.2 PMID: 16380510 
PM ID: 16180254 
1.7 PMID: 10485709 
PM ID: 15780757 
-3.3 PMID: 16243809 
PM ID: 15797250 
-2.8 PMID: 12697670 
PM ID: 12039070 
2.5 PMID: 11906176 
PM ID: 15754005 
1.5 PMID: 15059886 
PM ID: 16243809 
1.8 PMID: 16029166 
PM ID: 12401131 
1.3 PMID: 16322224 
PM ID: 10446804 
1.8 PMID: 15311059 
1.6 PMID: 12592021 
PMID: 11813878 
2.5 PMID: 14734458 
1.6 PMID: 16115914 
PMID: 14596858 
2.5 PMID: 16013438 
PM ID: 14729458 
2.1 PMID: 15601830 
PM ID: 14641267 
1.8 PMID: 7533763 
PMID: 15953081 
1.6 PMID: 15728845 
PMID: 15331666 
1.7 PMID: 15605394 
PM ID: 14667825 
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ti()RBSI sorbin and SH3 domain containing I 
CA2 carbonic anhydrase 11 
CNKSR3 CNKSR family member 3 
CTH cystathionase (cystathionine gamma-lyase) 
EFEMPI EGF-containing fibulin-like extracellular matrix protein I 
RAB39B RAB39B, member RAS oncogene family 
SPRY2 sprouty homolog 2 (Drosophila) 
WBPý WW domain binding protein 5 
I SP. A 7 tetraspanin 7 
Transcripition factors 
2.3 PMID: 15604270 
PM ID: 15504914 
2.0 PMID: 10860835 
PM ID: 11382925 
2.4 PMID: 15908431 
PM ID: 15383320 
1.9 PMID: 11711533 
1.8 PMID: 11683410 
2.0 PMID: 12438742 
2.8 PMID: 11053437 
PMID: 15313890 
2.0 PM ID: 15548568 
2.0 PMID: 15735753 
PM ID: 15342396 
1D132 LIM domain binding2 1.8 PMID: 15380350 




solute carrier family 7, (cationic amino acid transporter, 2.0 PMID: 16103098 
y+ system) member 11 
CXorf26 chromosome X open reading frame 26 1.2 
GPR50 G protein-coupled receptor 50 1.7 PM ID: 9933574 
MGC16121 zinc finger protein 19 (KOX 12) /// zinc finger protein 23 1.6 
(KOX 16) 
/\f 227 zinc finger protein 227 1.7 
Unknown 
\1(1( 3? xx7 hypothetical protein MGC33887 10.1 
IT-13 1N 10 Hypothetical protein FLJ31810 2.7 
MGC16121 hypothetical protein MGC16121 1.6 
MGC39325 hypothetical protein MGC39325 1.9 
* The genes highlighted by red are altered by both LMP2A and LMP2B 
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